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Abstract
Mild traumatic brain injury (mTBI) or concussion is the most common form of TBI, and 
although a single concussion rarely results in long-term neurological dysfunction, repeated mild 
traumatic brain injury (r-mTBI) is a recognized risk factor for later development of 
neurodegenerative disease. However, the mechanisms contributing to neurodegeneration 
following TBI remain obscure. Animal models provide a means to examine the factors and 
mechanisms involved in TBI in experiments that cannot be conducted using human participants.
The purpose of this thesis was to develop and fully characterize a reproducible, non- 
invasive mTBI model that will facilitate the study of repetitive brain injury. In the present study, 
male wild type mice received a midline concussive blow via an electromagnetic impactor, tuned 
to produce an injury without fracturing the skull. The injured mice were used to examine the 
chronic neurobehavioral, neuropathological and biochemical outcomes following single and r- 
mTBI up to 18 months following injury. Importantly, our findings recapitulate many aspects of 
human long term TBI sequelae, in particular persistent neuroinflammation, white matter injury, 
and axonal pathology in the corpus callosum. Our results provide the first evidence that, whilst 
a single concussion produces transient neurobehavioral changes and pathology which remains 
static in the period following injury, r-mTBI produces behavioral and pathological changes 
which continue to evolve many months post injury.
There have been a number of clinical studies implicating tau in TBI pathology. As such, 
we investigated the relationship between tau pathologies after trauma in a transgenic mouse 
model expressing all 6 isoforms of human tau protein on a null murine background (hTau). Our 
results revealed that that single and r-mTBI induced a modest cortical increase in the soluble 
fraction of three different p-tau epitopes at 24 h post last injury. Moreover, this increase was 
not associated with worse behavioral performance when compared to wild type animals. 
Therefore, tau hyperphosphorylation appears to have a contributory, but not primary, role in 
the acute phase post-injury. Additional prospective studies in both humans and animal models 
are required to characterize the contribution of tau to TBI sequelae.
The experimental data presented here suggest that inflammation and axonal injury (as 
seen in both wild-type and hTau models) appear to play a role in the events following single or 
repetitive mTBI and strongly correlates with the behavioral changes post-injury. The 
relationship between a history of mTBI and neuroinflammation are likely to be complex and 
warrant further work to elucidate their association with neurodegenerative disease. This work 
represents the development of a novel model, and the demonstration of its relevance to 
human TBI. This model can now be used for further exploration of TBI-related effects and for 
evaluation of potential therapeutic and diagnostic approaches, as is discussed throughout the 
thesis.
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Chapter 1
1. General introduction:
Traumatic Brain Injury (TBI) is defined by the Centers for Disease Control and Prevention 
(CDC) as an external force (arising from blunt or penetrating trauma or from 
acceleration/deceleration forces) that significantly disrupts brain function. Changes in brain 
function can include any of the following: a period of loss or alteration in consciousness (e.g., 
confusion, disorientation); loss of memory (amnesia) of events immediately before or after the 
injury; neurological deficits (e.g., weakness, loss of balance, change in vision); or intracranial 
lesions. The presence and duration of these features are used to define the severity of the 
injury that has occurred and are now recognized to persist or emerge weeks, months or even 
years after the event.
Over the past decade, the scientific literature on TBI and mild trauma has increased 
considerably. For example, using the search engine PubMed (National Library of Medicine) for 
the term "traumatic brain injury" there were 27,566 articles published-between the years of 
2003-2012, compared to 14,123 for the years 1993-2002. During this time, a number of 
models, theories and hypotheses regarding the injury mechanisms and consequences have 
been presented in the TBI field. Despite major advances in this field of medicine, TBI and mild 
traumatic brain injury (mTBI), also referred as concussion, are puzzling neurological disorders 
and one of the least understood injuries facing the scientific community. The need for 
multidisciplinary research on mTBI is evident from the emerging understanding of the 
complexity of TBI pathogenesis. As such, scientists have to collaborate with many different 
research fields, such as traumatology, neurosurgery, internal medicine, neurology, psychiatry
and/or psychology in order to obtain as complete a picture as possible of TBI sequelae, and 
hopefully identify paths toward treatment.
1.1. Traumatic brain injury in humans:
Sports related concussions have attracted public and political attention in recent years in 
part because of increased media attention regarding the adverse health consequences 
(neurodegenerative diseases, behavioral problems) and suicides in high profile individuals that 
has then drawn attention to the frequency and outcome of mTBI that professional athletes 
sustain1'8. The clinical significance for further research on mTBI stems from the fact that the 
main cause of death in athletes is from blows to the brain9. Concussion symptoms may appear 
mild, but these effects can lead to significant, life-long impairment affecting an individual's 
ability to function physically, cognitively, and psychologically. Therefore, athletes who 
prematurely return to play are highly susceptible to future trauma and often experience more 
severe brain injuries with subsequent concussions. Athletes with a history of an mTBI who 
return to competition upon symptom resolution are still at risk for the cumulative effects of 
concussion as measured by increased symptomatology or slowed recovery on 
neuropsychological tests10'14.
1.2. Classification of traumatic brain injury:
Traumatic brain injury classifications can be clinical, mechanistic, or pathological. 
Pathological classifications separate diffuse from focal injury with histological assessments or 
through brain imaging techniques (computed tomography (CT) and diffusion tensor imaging
2
(DTI)). Mechanical classifications describe the type of impact: penetrating, blast, impact, inertia 
loading. Clinically there are four main types of brain injury: mild (no loss of consciousness and 
a lack of skull fractures), moderate (loss of consciousness of a few minutes or presence of skull 
fractures), severe (coma with or without skull fractures) and penetrating TBI in which the dura 
mater, the outer layer of the meninges, is penetrated. About 75% of all TBI's are classified as 
mild with the remaining 25% described as moderate or The Glasgow Coma Scale (GCS) is the 
most commonly used system to asses TBI severity15 (Table 1.1). The scale was published in 
1974 by Graham Teasdale and Bryan J. Jennett, Professors of Neurosurgery at the University of 
Glasgow's Institute of Neurological Sciences at the Southern General Hospital. Determining the 
severity of injury consists of grading the patient's level of consciousness. The grade is based on 
verbal, motor, and eye-opening reactions to stimuli. The patient score can fluctuate between 3 
(indicating deep unconsciousness (e.g. coma) and 15 (fully conscious), severe. Several 
techniques are used to determine severity and classification of the injury.
3
Eye opening (E) Spontaneous 4
To speech 3
To pain 2
N il 1
Best motor response (M) Obeys 6
Localizes 5
Withdrawn 4
Abnormal flexion 3
Extensor response 2
N il 1
Verbal response (V) Oriented 5
Confused conversation 4
Inappropriate words 3
Incomprehensible sounds 2
N il 1
Coma score (E + M  + V)==3-15
Table.1.1: Glasgow Coma Scale.
1.3. Concussions:
Concussion or mTBI (from the Latin concutere ("to shake violently") or concussus ("action of 
striking together")) is a form of TBI incurred through head impact or change of acceleration, or 
both, accompanied by some alteration or limited loss of consciousness with no gross pathology. 
Concussions are also the mildest and most common form of traumatic brain injury. Although 
the incidences of these injuries are high, concussions have been called a "silent epidemic" 
because the symptoms are so subtle that the majority of people who have experienced a 
concussion do not seek medical attention16,17. As a result, the consequences of concussions 
have long being underestimated. Time to recovery varies depending on the severity of the
injury but most people recover within days and weeks after the original injury while a small 
fraction experience post concussive syndrome18'19 (PCS).
The consequences of multiple concussion/repetitive-mTBI were first described by an English 
pathologist, Harrison S. Martland who in 1928 noted chronic motor and neuropsychiatric 
symptoms in former boxers20. A decade later, further case reports indicated that repetitive 
mTBI (r-mTBI) might result in an early form of TBI-induced dementia termed "dementia 
pugilistica"21 (DP). Up until 2002 when Dr. Bennet Omalu first described chronic traumatic 
encephalopathy (CTE) in former American football players, DP/CTE was recognized as a peculiar 
condition confined to boxers22. With the appreciation that the pathology was not restricted to 
boxing, or pugilism, the term CTE was introduced to better reflect the wide range of mTBI 
exposure situations. Recent media attention sparking considerable public awareness with 
stories of the consequences of r-mTBI in high profile athletes (particularly in the United States) 
as well as the incidence of mTBI in the military, has prompted the scientific community to focus 
on the consequences of mild injury (especially repeated mTBI).
1.3.1. Symptoms and pathology:
Signs and symptoms of concussion can be ascribed to multiple taxa, both physiological 
and neurological. Headache is the most common while others, such as nausea, difficulty 
balancing, dizziness, insomnia, fatigue, memory loss, depression, anxiety, irritability, 
impulsivity, poor concentration and personality changes, may be consequent to cerebral 
damage, endocrine or autonomic nervous system dysfunction23"25. In addition, visual and 
auditory symptoms include seeing bright lights, light sensitivity, blurred vision, double vision,
and tinnitus23,24. Unlike moderate or severe head injury, the neurological disturbance 
associated with a concussion often occurs without identifiable brain damage. There is no 
obvious pathology, and regular imaging techniques such as CT and magnetic resonance imaging 
(MRI) used in cases of moderate and severe head injury reveal no signs of structural changes. 
Moreover, as concussion is not associated with acute mortality, it is difficult to obtain post 
mortem tissue for pathological analysis.
Due to these limitations, researchers have developed new techniques to improve the 
diagnosis of concussions. Among these, DTI is a magnetic resonance imaging technique that 
measures the directional diffusion of water in neural tracts, which is often abnormal after mTBI. 
For example, a decrease in fractional anisotropy (FA) in the corpus callosum correlates with 
axonal degradation and discontinuities with excess water between tracts or in perivascular 
spaces26,27. However, the relationship between these injuries and behavioral changes remains 
variable across individuals and is poorly understood. The inflammatory response following the 
concussion could also be assessed in vivo using the positron emission tomography (PET) ligand 
[11C](R)PK11195 (PK)28. This last study suggests that at chronic time points, microglial 
activation correlates with the degree of cognitive impairment, and thus warrants further 
longitudinal studies as a potential biomarker to assess the severity of the injury and the 
potential outcome. However, the abnormality may also be associated with other preexisting 
conditions such as psychiatric illness, neurodegenerative disease, history of injuries, and 
alcohol/drug abuse.
1.3.2. Repeated concussion:
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The acute and chronic biomechanics and pathophysiology of concussion are still not well 
understood and can lead to significant sequelae from either single or multiple concussions29. 
The combination of post concussive symptoms and a second impact may be cumulative and 
thus it is important to know when professional athletes may return to play. Indeed, previous 
reports and studies have shown that professional athletes exposed to concussion rates 
exceeding that occurring in the general population may develop ongoing impairment and later 
degenerative condition such as CTE30'32. This problem is also of great interest to victims of car 
crashes or physical abuse in the civilian population, and to combat veterans as many military 
personnel sustain more than one combat concussive injury during their service33'34.
Pathological studies of postmortem brain tissue taken from both former athletes and veterans 
who had sustained repeated concussions displayed CTE symptoms with evidence of white 
matter injury, neuroinflammation, brain atrophy, and amyloid and tau deposition4'8'35'36.
Animal studies have demonstrated that the duration of the disturbed cellular and physiological 
metabolism after the first injury reflects the time-course of vulnerability to future mTBI making 
the brain vulnerable to further injuries37'38. In mice, repeated mTBI results in progressive white 
matter injury, axonal injury, chronic inflammation and behavioral dysfunction29'39'41. Repetitive 
but not single mTBI (s-mTBI) in a transgenic mouse model of Alzheimer's disease (Tg2576) was 
attributed to acceleration of brain amyloid beta accumulation and oxidative stress which 
support the hypothesis that r-mTBI could work synergistically to promote the onset of 
neurological disease42. A relevant laboratory model is thus needed to explore the pathogenesis 
and mechanisms of human mTBI. To this end, my doctorate research has involved the 
development and characterization of a novel experimental model of mild TBI to facilitate
identification of the mechanisms underlying the neurological and behavioral dysfunctions 
resulting from single concussion and repeated concussions.
1.3.3. Tau pathology and repetitive mTBI:
The tau protein is an intracellular, microtubule-associated protein (MAP) that is highly 
enriched in axons43. The major function of tau is to bind to tubulin, the main component of 
microtubules (MTs), which results in the stabilization of MT polymers and the cell structure. 
However, a growing body of evidence suggests that tau could be a multifunctional protein 
interacting with signaling networks, and as a regulator of the intracellular trafficking of 
organelles and molecules involved at the pre and postsynaptic level44'45. Tau has also a 
pathogenic role in neurodegenerative disorders exhibiting extensive accumulation of 
neurofibrillary tangles (NFTs), neuropil threads, and glial tangles in conditions collectively 
termed tauopathies46'47. These include Alzheimer's disease (AD); frontotemporal lobar 
degeneration with tau inclusions (FTLD-tau) such as Pick's disease, progressive supranuclear 
palsy (PSP); agyrophillic grain disease (AGD); amyotrophic lateral sclerosis (ALS); some forms of 
Parkinson's disease and CTE3,48'51. In CTE, the modified tau protein (phosphorylated, truncated, 
hyperphosphorylated, aggregated, polymerized) accumulates and aggregates in the human 
brain52. These structures are aggregates of filamentous polymers called paired helical filaments 
(PHF), where the main component is tau in its phosphorylated form43,47. Many of these 
pathogenic forms of tau resemble some of the pathologic changes seen with AD, including 
abundant widespread tau deposits. The relationship between mTBI and tau pathologies 
remains unclear, but has received considerable focus owing to the increased interest in CTE,
highlighted above, and the apparently critical involvement of tau in CTE pathology. The role 
and functions of tau after mTBI will be addressed and discussed in further detail in chapter 4.
1.4. Animal models of head trauma:
Although there is substantial similarity between the brains of humans and other 
mammals, it is important to realize that no single laboratory animal model can fully reproduce 
the clinical mechanisms encountered by the human brain following injury. Of the species 
available to use, mice and rats allow efficient analyses of the pathological and behavioral 
consequences associated with TBI. The most notable differences between rodent and human 
models is the craniospinal angle, white to grey matter ratio, and brain geometry53'55. That said, 
the development of an animal model that replicates certain pathological components or phases 
of clinical trauma is essential to understanding the mechanisms involved in human brain injury 
and to developing appropriate treatment strategies. Over the past decades, investigators have 
attempted to establish and characterize clinically relevant laboratory models of human TBI. 
Although large animal models such as swine and non-human primates have been used 
successfully to investigate specific aspects of TBI56'62, many investigators have accepted rodent 
models as the most suitable and ethical choice to study brain trauma. Their relatively small size 
and cost allows repetitive measurements for a wide range of physiological and behavioral 
measurements, and also enables the consequences of TBI to potentially be readily examined 
over the lifespan of the animal. Another benefit of rodent models is the ability to examine the 
consequences of TBI in a very controlled situation, before attempting translation to the human 
setting, with animals receiving a specific, homogenous, replicable injury with age, sex, and
genetic background all controlled. Furthermore, mice are the most common specie for the use 
of transgenic technology and thus scientists can use a wide panel of rodent strains that have 
been genetically modified by either inserting new genetic information/mutation or simply 
knocking out the activity of a gene. The use of genetically engineered animals offers the 
advantage of investigating of the effects of specific gene modulation that may influence 
response to TBI (such as Apolipoprotein E (APOE)) that would not be easily feasible in higher 
animal models such as in primates.
Accordingly, numerous rodent models have been developed that mimic different 
aspects of the complex spectrum of human TBI. Of these, the most commonly used are the 
weight-drop, fluid percussion injury (FPI), and the controlled cortical impact model (CCI) (see 
1.3.2 below). The following sections will summarize the different animal models that were 
available when I started this project and how researchers modified them to study mTBI.
1.4.1. Mild TBI models:
Several models of TBI have been adapted to mimic the clinical consequences of r- 
mTBI40'63'64. While the definition of mTBI in human is straight forward as previously described 
(section 1.2.), the criteria for evaluating mTBI in animals models remain to be harmonized. 
Indeed, the current literature may be confusing as many researchers use the term mTBI to 
define the milder version of their experimental model. In fact, these injuries are simply a milder 
version of a severe TBI and consequently do not reflects the clinical characteristic of human 
mTBI. Series of criteria can be established according to human mTBI definition and translated 
into animals models. For example, measurable outcomes such as mild cognitive deficits,
impaired motor coordination, loss of consciousness (right reflex for animals), and white matter 
injury with DTI can be evaluated in both animals and humans. It is vital to choose experimental 
model that replicate certain pathological components of mild clinical trauma. For our study, 
these requirements were as follow: 1) a short period of post traumatic apnea less than 30 sec, 
2) a short period of righting reflex less than 6 min, 3) no skull fractures, 4) no major 
hemorrhage, 5) mild cognitive deficits and 6) axonal injury associated with neuroinflammation. 
The absence of skull fracture and hemorrhage are a characteristic of human mTBI and can be 
easily assessed in rodent to differentiate mild to moderate TBI. The righting reflex, a 
mesencephalic reflex is recognized an animal analog to loss of consciousness and is now 
accepted as a good indicator similar to the loss of consciousness in human. In our laboratory, a 
right reflex suppression less than 6 min was considered as mild injury while any right reflex 
superior to 6 min were considered as moderate TBI. Using a FPI or CCI which require longer 
duration of anesthesia, righting reflex suppression less than 15 min is considered as a mTBI, 15- 
20 min as moderate and superior of 20 min as severe.
1.4.2. Weight-drop:
Well known in the TBI field, the weight drop injury model uses gravitational forces to 
produce either a focal65'67 or diffuse injury68. The impact can be delivered either on the 
exposed skull69, or directly on the dura 70 of the anesthetized animal (Fig.1.1). In Feeney's 
weight drop, the impact is delivered to the intact dura, which cause a severe focal injury similar 
to CCI. The original Mammarou's weight drop model is classified as a moderate to severe TBI 
and results with high mortality rate, widespread damages of neurons, axons, dendrites, and
extensive axonal injury in the corpus callosum and the long tracts of the brain stem66. Because 
diffuse axonal injury is often observed in the clinical situation, this makes the weight-drop 
injury model an appropriate tool in studying neuronal and axonal changes in TBI. Since then, 
Marmarou's model has been modified to allow repeated head impact in lightly anesthetized 
mice and to produce different grade of diffuse brain injury with varying weights and drop 
heights68. This method has been recently used by Kane et al71 and Mannix et all72 to study 
repeated mTBI, a form of CHI commonly occurring in contact sports, physical abuse and among 
the military population. In Kane's model, repeated mTBI caused shortterm behavioral 
impairments, mild astrocytic reactivity and increased phospho-tau without microglial 
activation71. More importantly, Mannix et al suggests that the cognitive effects of r-mTBI are 
cumulative and reports persistent cognitive deficits associated with increased astrocytosis but 
not tau phosphorylation or amyloid beta or plaques72. A drawback of this model is the high 
variability of the injury severity and a high mortality rate due to apnea and skull fractures.
A-Marmarou's weight-drop B-Feeney's weight-drop
Plexiglas tubing
Weight
Brass weight
Animal mounted in 
stereotactic device
Steel helmet over 
exposed skull
Footplate over the 
exposed dura
Figure.1.1: Features of weight drop apparatus. (A) In the Marmarou model, the device uses a brass 
weight to induce closed head injury (CHI). A metal disk is placed over the skull to prevent bone fracture. 
The In Feeney's model (B), a free weight is released directly onto the exposed dura. Reprinted by
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permission from Macmillan Publishers Ltd: Nature Reviews, Xiongl, Ye., et al. "Animal models of 
traumatic brain injury." 14(2): 128-142, copyright 2013.
1.4.3. Fluid percussion injury:
Fluid percussion injury is another widely used model to study TBI, especially in the rat. 
The FPI model induces brain injury by rapidly injecting fluid volumes onto the intact dural 
surface of the brain through a craniectomy56'57,62'73'76 (Fig.1.2). With graded levels of injury 
severity achieved by adjusting the force of the fluid pressure pulse, FPI can produce different 
severity of brain injury (mild, moderate and severe). In general, this type of injury has been 
used to replicate moderate to severe clinical TBI and produces a combination of focal cortical 
contusion and diffuse subcortical injury regardless of the injury location77, centrally around the 
midline78, or laterally to the sagittal suture79. Recently, mild lateral FPI have been adapted 
from its more severe setting by decreasing the pressure of the fluid applied to the brain to 
better reflect a clinically relevant mTBI. A single mild lateral FPI in rats and mice induced 
transient behavioral and neuropathological changes80'82, whereas 3 or 5 mild lateral FPI caused 
cortical neuronal loss and cumulative behavioral deficits83. The main weakness of this model is 
that it requires long anesthesia to trepan and inflict the injury and not representative in terms 
of mechanism of injury to human mTBI. The inflicted injury is also variable between 
laboratories due to the fact that some investigators will induce the trauma either centrally or 
laterally. In addition, this model also does not allow the investigator to perform behavioral 
analyses immediately post injury due to the side effects of the long anesthesia while 
performing the surgery.
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Figure.1.2: Features of a fluid percussion injury apparatus. The fluid percussion injury device uses rapid 
injection of a fluid pulse into the epidural space. Reprinted by permission from Macmillan Publishers 
Ltd: Nature Reviews, Xiongl, Ye., et al. "Animal models of traumatic brain injury." 14(2): 128-142, 
copyright 2013.
1.4.4. Controlled cortical impact:
The controlled cortical impact model introduced in the late 1980's 84 utilizes a 
pneumatic pistol to deform the exposed dura and provide a controlled impact and quantifiable 
biomechanical parameters (Fig.1.3). The advantage of this model is that it uses a graded and 
reproducible brain injury through a predefined dural compression depth and dwell time. Similar 
to the FPI, this model was developed to study moderate to severe TBI, but can be adjusted by 
varying the amount of brain deformation and the velocity of the impactor. In rodents, CCI 
always results in a focal brain injury with cortical contusion, hemorrhage and BBB disruption 85. 
The delayed progression of brain damage is accompanied by neuronal cell death, inflammatory 
events, microglial activation, astrogliosis, axonal damage and cognitive deficits55,86'88. The
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mildest form of CCI uses a velocity of 2.8m/sec and 0.2 mm brain impact depth. With a single 
mTBI this model caused a mild extend of cell death accompanied by extensive dendrite 
degeneration and synapse reduction in the cortex89. Similar to the FPI model, the major 
drawback of this injury is that it requires long anesthesia and a craniectomy that may 
compensate for intracranial pressure (ICP) increase.
Controlled Cortical Impact Injury
Piston High air 
pressure
Sagittal View Caudal View
'A
Low air pressure
Figure.1.3: Drawing of the mouse controlled cortical impact injury apparatus showing the impactor and 
part of its mounting system, the craniectomy location, and the orientation of the impactor tip to ensure 
perpendicularity to the exposed dura and to the surface of the brain. The model uses an air or 
electromagnetic driven piston to penetrate the brain at a known distance and velocity. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews, Xiongl, Ye., et al. "Animal models of 
traumatic brain injury." 14(2): 128-142, copyright 2013 and from Journal of Neuroscience Methods, 
160(2): 187-196, Onyszchuk, G., B. Al-Hafez, et al, A mouse model of sensorimotor controlled cortical 
impact: Characterization using longitudinal magnetic resonance imaging, behavioral assessments and 
histology, Pages No., 187-196, Copyright 2007, with permission from Elsevier.
Overall, CCI and FPI were widely used and are well characterized model but are also the 
least useful as they do not replicate the mechanisms of mTBI in human due to the extensive 
surgical preparation. For that reason, a closed version of the CCI model was also developed 
allowing a direct blow to the skull without surgical intervention and minimizing the confounding 
effects of prolonged anesthesia on TBI outcome. Closed-head injury is not only a type of mTBI
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in which the skull and dura mater remain intact but also allows multiple mTBI on the same 
animal90'91.
The closed version of the CCI model in mice and the weight drop model are more 
analogy in terms of mechanism of injury and are also amenable multiple injury. In terms of 
reproducibility, the CCI apparatus incorporates an electromagnetic (EM) coil-based delivery 
device, which delivers consistent strike velocities while, at the same time, reducing rebound 
hits that can occur with other brain injury methods (e.g. the weight drop model).
1.4.5. Blast injury:
Due to the emergence of blast induced neurotrauma (BINT) and its particular relevance 
to the military, a considerable number of animal models have been proposed to be suitable for 
blast research. Open field exposure [as compared to confined space] to blast provides data for 
effects of blast that may be most relevant to human military situations but require large 
amounts of explosives and the experiments are hard to replicate92,93. Thus, blast tube models 
are more commonly used to study the effect of the blast wave on small animals (Fig.1.4). As it 
is the case with other mTBI models, there are considerable variations within the available BINT 
models and a disagreement about what is meant by mild blast injury. For example, Elder et al 
reported a significant increase in post-traumatic stress disorder (PTSD) symptoms in absence of 
histopathological changes or mortality rate94. In contrast, Kochanek's mild BINT model 
produced 25% mortality rate from apnea and histopathological changes95. In a more recent 
model of repetitive mild BINT, Gama Sosa and colleagues95 reports intreventricular
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hemorrhages with tears at 24h post injury. Other models of BINT showed prolonged behavioral 
and motor abnormalities, increase tau phosphorylation, axonal injury, chronic 
neuroinflammation and neurodegeneration with or w ithout macroscopic tissue damage35,96'97. 
The consequences of BINT remain to be standardized across each laboratory model. Because 
this type of injury is specific to  the m ilitary population and misrepresent the majority of mTBI, 
we decided to not pursue our studies with this model.
Blast wave
Detonation
A-Blast TBI
B-Representation of the shock tube system
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Figure.1.4: (A) Drawing of a blast tube apparatus. Blast brain injury can be caused by the primary injury 
related to the blast. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews, Xiongl, 
Ye., et al. "Animal models of traumatic brain injury." 14(2): 128-142, copyright 2013. (B) Schematic 
representation of the shock tube system. The system allows direct measurement of the various shock
17
loading characteristics, including static pressure, total pressure, and overpressure impulse. The driver 
section is pressurized with helium gas until the pressure differential between the driver and driven 
sections exceeds the material failure threshold of the diaphragm. The threshold to initiate the rupture 
can be changed by selecting various combinations of Kapton and polyethylene sheets. Reprinted from 
Neurobiology of Disease, 41(2): 538-51, Cernak, I., A.C. Merkle, et al, The pathobiology of blast injuries 
and blast-induced neurotrauma as identified using a new experimental model of injury in mice, Pages 
No., 538-51, Copyright 2011, with permission from Elsevier.
1.5. Hypothesis:
The models of head injury described above establish and imitate certain aspects of the 
biomechanics and pathobiology of human TBI. They have enabled an understanding of the 
primary damage occurring at the time of injury and identification of complex mechanisms of 
secondary injury. The primary damage mainly includes anatomical lesions such as contusion, 
laceration, or hemorrhage with secondary injury including swelling and edema. However, these 
models are not best suited to model mTBI which is estimated to account for 80-95% of all 
human cases of TBI98 and they do not easily allow analysis of repetitive injury. To this end, my 
project aimed to develop a clinically relevant laboratory model of closed head concussion, and 
to characterize the neurobehavioral and neuropathological consequences of both single mTBI 
and r-mTBI over time. Specifically, I propose to test the following hypotheses in the following 
chapters:
1. Chapter 2: After a single mTBI, a state of transient brain vulnerability exists during which the 
occurrence of repetitive concussion lead to greater behavioral dysfunction and pathological 
abnormalities. Such study is achievable by the development of an animal model CHI model 
is more representative of mild TBI/concussive conditions (e.g. minimally invasive, short
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period of right reflex, no skull fracture or hemorrhage) and is amenable to the study of 
more than two repeated concussions.
2. Chapter 3: i) r-mTBI is associated with long term deficits in cognitive and increased 
inflammation and axonal degeneration, ii) the effect of a single mTBI is transient iii) r-mTBI 
increases tau hyper-phosphorylation at 12 months post mTBI.
3. Chapter 4: r-mTBI is associated with increased of amyloid-p (Ap) deposition and tau 
accumulation with worse behavioral performance. In order to address this question, our 
hTau transgenic mouse model was used.
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1.6. Synopsis:
In tandem with the development of a reproducible, clinically relevant laboratory model 
of mTBI, these studies were designed to expand on previous literature by describing the 
progression of symptoms following both single and r-mTBI. Behavioral assays were conducted 
in parallel with histopathological analyses to understand the potential association between 
neurobehavioral deficits and its associated pathology at acute and chronic time points following 
the injury (ies). In the following chapter (Chapter 2), the development of the model and the 
acute effects of single and r-mTBI were investigated to determine the neurobehavioral and 
neuropathological changes associated with the injury, and thereby further assess the validity of 
our model. Chapter 3 focuses on the chronic structural and functional changes after mTBI. The 
chronic neurobehavioral outcomes were evaluated at 6,12 and 18 months post­
injury/anesthesia using the Barnes maze. At 6 and 12 months post-mTBI the evolution of the 
same neuropathological changes observed at early time points was reassessed. Given the 
increasing interest in the role of tau in mTBI (as outlined above) we then used our validated 
model of mTBI in mice genetically modified to express the different human forms of tau (the 
human tau (hTau) transgenic mouse), to facilitate investigation of the role of tau in human TBI 
(Chapter 4). Chapter 5 summarizes the current studies that were aimed at characterizing and 
identifying the longterm neuropathological and neurobehavioral consequences of single and r- 
mTBI and also discuss ongoing research and future directions.
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Chapter 2
2. Development, optimization and characterization of a novel mouse model of concussive 
brain injury:
2.1. Introduction:
There is growing recognition that for both repetitive and single moderate to severe injuries, 
the adverse effects of traumatic brain injury (TBI) may continue for many years after the 
original event, with trauma representing the strongest environmental risk factor for developing 
neurodegenerative disorders, including Alzheimer's disease (AD)1*4. Studying mild brain injury 
(mTBI) in humans is challenging, as it is restricted to cognitive assessment and brain imaging to 
evaluate such injuries, thus there is a dire need in the field of TBI research for better animal 
models in order to elucidate the pathobiology that follows post single and repetitive mTBI (s- 
mTBI and r-mTBI). Although the full complexity of human brain injury cannot be completely 
addressed in laboratory models, they offer the ability to investigate molecular and 
neurophysiological changes from minutes to days following nonfatal injury.
While in vitro TBI models are a strong tool to test detailed aspects of biological mechanism,
they generally have not been exploited for discriminating between the different types of TBI
(e.g. mild, moderate or severe), long term studies (effect of aging), and for treatment
strategies. However, they have been of special interest to elucidate specific mechanisms
outside a complex biological environment such as the brain. Such models use a pulse wave or a
vacuum pulse to stretch neuronal and glial cells5,6. For example Tang et al used a model of
dynamic stretch injury of cortical axons to determine the potential mechanisms between
microtubule damage, partial transport interruption and axonal varicosities in traumatic axonal
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injury7. Because the objective of this work is to understand the long term effect of single and 
repetitive mTBI, an in vivo model will provide critical insights into the evolution of mTBI 
pathobiology.
Different animal models that have been studied to characterize the consequences of TBI 
include pigs8"10 and primates11, but primarily these studies have been performed using 
rodents12"19. Our choice of a murine model was driven by the future potential to study this 
mTBI model in mice genetically modified at loci of relevance to TBI such as Apolipoprotein E 
(APOE) or Tau. The CHI model used in this study is more representative of mTBI/concussive 
conditions than invasive brain injury models such as fluid percussion injury (FPI) or controlled 
cortical impact (CCI) that require a craniectomy, which itself can confer profound 
proinflammatory and behavioral damages20. It is also amenable to the study of repeated 
concussions and, in terms of reproducibility, incorporates an electromagnetic (EM) coil-based 
delivery device, which delivers consistent strike velocities21'22. To date, published mouse 
models of CHI have typically investigated the effect of a single mTBI or two mTBIs with an inter­
injury interval of 24 h14,18,19,23. A single mTBI has been shown to cause subtle and transient 
behavioral and immunohistochemical abnormalities, whereas two such injuries 24 h apart 
worsened the outcome14'15'18'19. Unfortunately, little is known about the cumulative 
consequence of more than two brain injuries at multiple time intervals, as investigations of this 
nature are scarce and have predominantly employed the weight drop model12'13'24'25. In this 
study, we addressed this void by examining mice subjected to one mTBI (s-mTBI) or a total of 
five mTBIs (r-mTBI). Moreover, our interconcussive interval was 48 h, a temporal window
during which the mouse brain is known to be vulnerable to subsequent injuries15 which mimics 
human situations (combat or sports) where additional injuries are sustained prior to full 
recovery from the previous injury. The purpose of these studies was to develop a reliable and 
robust mouse model of mTBI/concussion to investigate the neurobehavioral and 
neuropathological consequences of single and repetitive injury, and provide a platform for 
investigation of the long-term consequences of mTBI, particularly r-mTBI.
2.2. Materials and Methods:
2.2.1. Animals:
Male, C57BL/6J mice (10 weeks, 24-30g, Jackson Laboratories, Bar Harbor, ME) were 
singly housed under standard laboratory conditions (23°C ±1C, 50% ±5% humidity, and 12 h 
light/dark cycle) with free access to food and water throughout the study. Mice were allowed 
to adapt to the vivarium for 1 week prior to experimental procedures. All procedures involving 
mice were performed under Institutional Animal Care and Use Committee approval and in 
accordance with the National Institute of Health Guide for the Care and Use of Laboratory 
Animals.
2.2.2. Optimization of the closed head injury model:
A separate group of 28 animals was used for survival studies and optimization of the 
mTBI model. All of these mice were euthanized 24h after the single or last injury/anesthesia for 
pathological analyses.
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Group I (n=6): 3 animals with s-mTBI (injury parameter at 5 m/sec, strike depth of 1.3 mm) and 
3 control/sham injury animals (3 min anesthesia).
Group II (n=6): 3 animals with s-mTBI (injury parameter at 5 m/sec, strike depth of 1.8 mm) and 
3 controls (3 min anesthesia).
Group III (n=6): 3 animals with s-mTBI (injury parameter at 3 m/sec, strike depth of 1.0 mm) and 
3 controls (3 min anesthesia). This group was sacrificed 24H post injury and was solely used for 
pathology.
Group IV (n=10): 5 animals with r-mTBI (injury parameter at 5 m/sec, strike depth of 1.0 mm) 
over a period of lOh (1 injury every 2h) and 5 control animals (3 min anesthesia every 2 hours).
In addition to these 4 groups, there have been different survival studies to address 
other injury parameters such as the dwell time (impact duration), frequency of the injury and 
the stereotaxic positioning of the probe on the skull.
2.2.3. Injury groups and schedules for the novel mTBI model:
For the behavioral analyses, a total of 48 mice were randomly assigned to one of four 
groups: single injury, single sham (anesthesia alone), repetitive injury (total of five hits with an 
interconcussion interval of 48 h), and repetitive sham (five anesthesias, 48 h apart); (Table.2.1). 
The behavior analysis began 24 h after the sole/last mTBI/anesthesia for each group (Fig.2.1). 
Behavior outcomes were assessed by an experimenter blinded to group assignment. For 
histological examination, a total of 35 mice were randomly assigned to one of five treatment
groups: single injury, single sham, repetitive injury, repetitive sham (all euthanized at 24 h post 
sole/ last mTBI/anesthesia), and single injury euthanized at 10 days post mTBI (s-mTBI-lOD). 
The s-mTBI-lOD treatment group was included to enable comparison of the consequences of 
one hit versus five hits at the same time point after the first injury. The mice used for behavior 
analysis were aged to be further assessed at 6,12, and 18 months post injury as presented in 
the following chapter (Chapter 3). Separate cohorts of mice were used for histological analysis 
at 6,12 months' time points.
Study Injury status n Survival tim e
i Behavior s-sham 12 > 1 year
s-mTBI 12 > 1 year
r-sham 12 > 1 year
r-mTBI 12 > 1 year
i Histology s-sham 7 24H
s-mTBI 7 24H
s-mTBI 7 10 Days
r-sham 7 10 Days
r-mTBI 7 10 Days
Table.2.1: Summary of the injury groups at acute time points.
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2.2.4. Injury protocol:
Mice were anesthetized with 1.5 L/min of oxygen and 3% isoflurane and, after its head 
was shaved, each mouse was transferred into a stereotaxic frame (Just For Mice Stereotaxic, 
Stoelting, Wood Dale, IL) mounted with an EM controlled impact device (Impact One™ 
Stereotaxic Impactor, Richmond, IL), (Fig.2.2). The animals were placed on a heating pad to 
maintain their body temperature at 37°C and noninvasive rubber pads were adjusted in height 
to level the skull. The head holders were positioned such that lateral movements would not 
occur when the head was impacted. A 5 mm blunt metal impactor tip was retracted and 
positioned above the sagittal suture midway before each impact (Fig. 2.3). The injury was 
triggered using the myNeuroLab controller at a strike velocity of 5 m/sec, strike depth of 1.0 
mm, and dwell time of 200 ms; these parameters selected after pilot experiments revealed that 
a strike velocity > 5 m/sec and/or strike depth > 1.0 mm resulted in skull fracturing. Based on
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the manufacturer's instructions, the force applied to the mouse head at the time of impact is 
72N under these conditions. At the end of the procedure, the animal was removed from the 
stereotaxic table and allowed to recover on a heating pad and, upon becoming ambulatory, was 
returned to its home cage. No pre-operative or post-operative analgesic administration in 
addition of the anesthesia was given to the mice. Post-surgery, animals were given soft food 
and closely monitored for 48 h, and then daily for the following 5 days. For the r-mTBI group, 
additional injuries were administered at days 3, 5, 7, and 9 after the original injury. Sham 
injured animals underwent the same procedures and anesthesia duration on each occasion, but 
did not receive a hit, in order to control for the effects of repeated anesthesia.
Neuro
Figure.2.2: Photograph of the EM controlled impact device for mTBI mounted on the Just For 
Mice™ Stereotaxic table (a), a 5 mm diameter impactor tip (b) and myNeuroLab controller (c).
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Figure.2.3: Stereotaxic location of the 5 mm impactor tip on the head surface. Three-dimensional view
(A) (image adapted with permission from Stephen Larson http://wholebraincatalog.org), sagittal view
(B), and coronal view (C) (Images adapted from Franklin et al., 2001)26.
2.2.5. Assessment of righting reflex and traumatic apnea:
Immediately after term ination of anesthesia of both impacted and sham groups, each 
animal was placed on its back and the latency period to return to  an upright position was 
recorded. Apnea duration was visually measured after each injury as the time to return to
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spontaneous breathing. The time taken by injured and sham animals to return to an upright 
position and the traumatic respiration depression following each injury was recorded as an 
indicator of restoration of neurological function.
2.2.6. Assessment of motor function:
The rotarod apparatus (Ugo Basile, Varese, Italy) was used to assess motor performance 
following the injury paradigm, with performance evaluated by measuring the latency to remain 
on an elevated rotating accelerating rod (3 cm in diameter). Three acclimation trials were 
performed at a fixed speed of 5 revolutions per minute (RPM) with a 3 min duration. Rotarod 
pre-training (to establish a performance baseline) was conducted at linear accelerating speed of 
5-50 RPM for three trials per day for 3 consecutive days. Each trial lasted a maximum of 5 min 
with a 3 min rest interval to avoid fatigue. Rotarod testing started 24 h following the sole/last 
mTBI or anesthesia. For each trial, latency to fall was recorded by an experimenter blinded to 
group assignment. The trial was also terminated if the animal spun around the rod through 
three complete revolutions. Testing occurred on days 1, 3, 5, and 7 after the sole/last 
mTBI/anesthesia.
2.2.7. Assessment of cognitive function:
Two different cognitive-behavioral tests were available to assess spatial memory and 
learning in rodents. The Morris water maze (MWM), originally designed for rats, uses a pool of 
water containing an escape platform hidden a few millimeters below the water surface. Visual cues, 
such as pictures and colored stickers are placed around the pool in sight of the animal to orient 
themselves. Since its conception the MW M has been widely used in behavioral neuroscience
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and optimized to fit neurobehavioral tests in mice. The Barnes Maze (BM) is similar to the 
Morris water navigation task, but does not utilize a strong aversive stimulus (stress induced by 
swimming such as in the MW M). If stress is the main driver of MWM performance as suggested 
by Harrison and colleagues27, then it may mask spatial memory impairments resulting from 
mTBI. After the final day of rotarod testing, cognitive function was evaluated using the BM over 
the MWM. Ethovision XT (Noldus, Wageningen, Netherlands) was used to track and record the 
movement of each animal. Mice were given 90 sec to locate and enter the target box, and they 
were required to remain in the target box for 30 sec prior to retrieval, regardless of success.
For a period of 6 days, four trials were given per day, with mice starting from one of four 
cardinal points on each trial. On the 7th day, a single probe trial lasting 60 sec was performed 
with the mouse starting from the center of the maze and the target box removed. An 
Ethovision XT system was used to continually record the position of the mouse and measure 
the distance from the target box 30 times per second for the duration of each trial. The sum of 
that value was expressed as cumulative distance from target hole. Escape latency was 
measured as the time taken for the mouse to enter the box.
2.2.8. Tissue processing:
All mice were euthanized 24 h after their last injury/sham injury except for one group 
that was euthanized 10 days after a single mTBI. All mice were anesthetized with isoflurane 
perfused transcardially with heparinized PBS, pH 7.4 followed by PBS containing 4% 
paraformaldehyde. After perfusion, the brains were postfixed in a solution of 4% 
paraformaldehyde at 4°C for 48 h. The intact brains were then blocked and processed in
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paraffin using Tissue-Tek VIP (Sakura, USA). The processing schedule was 1.5 h in each graded 
ethanol bath (70%, 80%, 95% and three 100%), followed by three xylene baths of 2 h each, and 
finally four paraffin baths at 60 °C of 2h each. Sagittal (n = 4 brains/group) and coronal (n = 3 
brains/group) 6 pm sections were cut with a microtome (2030 Biocut, Reichert/Leica, Germany) 
and mounted on positively charged glass slides (Fisher, Superfrost Plus).
2.2.9. Histology:
Prior to staining, sections were deparaffinized in xylene, and rehydrated in an ethanol to 
water gradient. For each group, sets of sagittal (lateral 0.2-0.4 mm) and coronal (-1.5 and - 3.0 
mm relative to bregma) sections were cut. Each slide was visualized with a bright field 
microscope (Leica, Germany) and digital images were scanned without zoom and with a 
resolution of 16896 x 26624 pixels for further analysis with a NanoZoomer (Hamamatsu, Japan). 
The slides were viewed using Slidepath Digital Image Hub software. As a negative control, one 
section was incubated with all reagents except the primary antibody. Tissue sections were 
subjected to antigen retrieval with either heated tris-ethylenediaminetetraacetic acid (EDTA) 
buffer (pH 8.0) or modified citrate buffer (Dako, Glostrup, Denmark, S1699) under pressure. 
Endogenous peroxidase activity was quenched with a 15 min H20 2 treatment (3% in water).
Each section was rinsed and incubated with the appropriate blocking buffer (ABC Elite kit, MOM  
kit, Vector Laboratories, CA) for 20 min, before applying the appropriate primary antibody 
overnight at 4°C. Then, the diluted biotinylated secondary antibody from the ABC Elite Kit was 
applied on each glass slide. Antibodies were detected using the avidin-peroxidase complex, and 
labeling was revealed after incubating the sections in 3,3'-diaminobenzidine (DAB) peroxidase
solution (0.05% DAB - 0.015% H2O2 in 0.01M PBS, pH 7.2) for 6 -7  min and counterstained with 
hematoxylin.
2.2.9.1. Haemotoxylin and Eosin staining
A series of sections, mounted on glass slides, were dried for 30 min at 60°C before being 
stained with Haemotoxylin and Eosin (H&E). Each slide was re-hydrated with Histo-clear (10 
min), and alcohol (100% x2 and 95% x2 30 sec each). Following a 30 sec rinse in running tap 
water, sections were transferred in a solution of Mayer's Haematoxylin for 5 min. Sections 
were then rinsed a second time followed by a 5 to 10 sec dipping in 1% acid alcohol to 
differentiate the nuclei. Sections were rinsed again in running tap water followed by a 
differentiation step in Scott tap water substitute until sections turned blue. After another wash 
in tap water, the slides were finally immersed in a solution of eosin for 1 minute. The slides 
were dehydrated with ethanol (95% x2 30 sec each, then 100%x2 30 sec each) followed by two 
baths of xylene for 3 minutes each. Mounting medium was applied to coverslip and sections 
were viewed by light microscope.
2.2.9.2. Luxol fast blue staining
A series of sections, mounted on glass slides, were dried for 30 min at 60°C before being 
stained with luxol fast blue (LFB) and cresyl violet. Each slide was re-hydrated with Histo-clear 
(10 min), and alcohol (100% x2 and 95% x2 30 sec each). Following a 30 sec rinse in running tap 
water, sections were transferred in a solution of LFB for 4 h in an oven at 60°C. The excess of 
stain was then removed with a bath of 95% ethanol. Following a 2 minutes wash in running tap 
water, the sections were dipped (5-15 sec) in a differentiator bath of 0.05% aqueous lithium
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carbonate until the grey matter could be distinguished from white matter. This step was 
repeated until the nuclei were discolored and sections were then rinsed in running tap water 
for one minute and transferred to 0.1% cresyl violet solution for 5 minutes. Sections were 
differentiated in 95% acidic alcohol and rinsed in fresh 95% alcohol followed by dehydration 
and mounting.
2.2.9.3. Amyloid precursor protein:
A series of sections, mounted on glass slides, were dried for 30 min at 60°C before being 
stained with amyloid precursor protein (APP) primary antibody (1:40,000 in super sensitive 
wash buffer, Biogenex, Fremont, CA; monoclonal antibody to the N-terminus, Millipore,
Billerica, MA, MAB348.) by overnight incubation at 4°C. Tissue sections were subjected to 
antigen retrieval with heated tris-ethylenediaminetetraacetic acid (EDTA) buffer (pH 8.0). After 
three washes (10 min each) in PBS, sections were then incubated as described in the MOM kit 
(Vector Laboratories). After applying the Avidin/Biotin HRP complex for 30 min, each slide was 
stained for 7 min with the Vector DAB kit (Vector Laboratories).
2.2.9.4. Glial fibrillary acidic protein:
A series of sections, mounted on glass slides, were dried for 30 min at 60°C before being 
stained with GFAP antibody (GFAP, 1:20,000 in super sensitive wash buffer, Biogenex, Fremont, 
CA; Dako, Glostrup, Denmark, Z0334) by overnight incubation at 4°C. After three washes (10 
min each) in PBS, sections were then incubated as described in the ABC kit (Vector 
Laboratories). After applying the Avidin/Biotin HRP complex for 30 min, each slide was stained 
for 7 min with the Vector DAB kit (Vector Laboratories).
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2.2.9.5. Ionized calcium binding adaptor molecule 1:
A series of sections, mounted on glass slides, were dried for 30 min at 60°C before being 
stained with lba-1 antibody (Anti-lbal, 1:5000 in super sensitive wash buffer, Biogenex,
Fremont, CA; Abeam, Cambridge, MA, ab5076) by overnight incubation at 4°C. Tissue sections 
were subjected to antigen retrieval with a solution of citrate buffer (Dako, Glostrup, Denmark, 
S1699) under pressure. After three washes (10 min each) in PBS, sections were then incubated 
as described in the ABC kit (Vector Laboratories). After applying the Avidin/Biotin HRP complex 
for 30min, each slide was stained for 7 min with the Vector DAB kit (Vector Laboratories).
2.2.10. Immunohistochemical quantification:
For each animal, sets of sagittal (n = 4) and coronal (n = 3) sections were stained and 
analyzed by an observer blinded to experimental conditions using ImageJ software (US National 
Institutes of Health, Bethesda, MD). Using this software, images were separated into individual 
color channels (hematoxylin counter stain and DAB chromagen) using the color deconvolution 
algorithm28. While a semi-automated program allowed the threshold setting to be applied as a 
constant to all images, this was not done due to immunostaining intensity variation between 
batches of immunostaining. Therefore, each slide had unique parameters set to determine the 
optimal segmentation (threshold setting) based on the intensity of immunostaining for each 
antibody. Immunoreactive profiles discriminated in this manner were used to determine the 
ratio between the area of the counted object (the immunostained area) to the defined field 
(areas of interest). Two non-overlapping areas of 200 pm2 in the CA1 region (Fig.2.4A) and two 
non-overlapping areas of 150 pm2 in the body of the corpus callosum (CC) were selected within
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which the area of GFAP immunoreactivity was calculated and expressed as a percentage of the 
field of view. Two non-overlapping areas of 200 pm2 in the cortex underlying the impact site 
and three non-overlapping areas of 100 pm2 in the body of the CC were selected within which 
the area of anti-lbal immunoreactivity was calculated and expressed as a percentage of the 
field of view. APP-immunohistochemistry was quantified in discrete areas, namely the CC and 
the brainstem (BS) (lateral 0.2-0.4 mm). The numbers of APP-positive profiles were counted in 
three non-overlapping areas of 100 pm2 within the body of the CC (Fig.2.4B), and two non­
overlapping areas of 200 pm2 within the BS. Immunoreactive axonal profile counts from the 
four sections from each animal (n = 4) were then averaged, and all were combined for each 
group to determine a mean value. Overt cell death was determined by assessing the density of 
degenerating neurons (acidophilic with shrunken perikarya and pyknotic nuclei) per pm2 in H&E 
stained sections (lateral 0.2-0.4 mm). The percentage of degenerating neurons in CA1 regions 
in the ipsilateral and contralateral hippocampus was then averaged across four sections to 
evaluate histological changes in each group.
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Figure.2.4: Examples of quantitative assessment techniques used to calculate the area of GFAP 
immunoreactivity in the hippocampus (A) and the number of numbers of APP-positive profiles in the 
corpus callosum (B).
2.2.11. Statistical analysis:
All data were analyzed using JMP 8.0 (SAS, Cary, NC). Data were tested for normality 
using the Shapiro-Wilk W test; when not normally distributed, the data were transformed using
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square root or natural log transformation. If the data were still not normal after 
transformation, they were analyzed using nonparametric methods. Normally distributed data 
were analyzed using parametric methods such as analysis of variance (ANOVA) followed by 
Tukey's post-hoc correction for multiple comparisons. Repeated measures ANOVA were used 
to compare performance between cohorts for both rotarod and BM experiments. Only p values 
< 0.05 were considered to be statistically significant (indicated by an asterisk in the figures).
2.3. Results:
2.3.1. Optimization of the closed head injury model:
Using the cohort of mice for survival studies and optimization of my CHI model, I found 
that an impact with a depth greater than 1 mm, and faster than 5m/sec, although non-lethal, 
increased the amount of skull fractures. As illustrated in Figure 2.6, the extent of injury was 
significantly worse when the mice were injured 5 times in a 10 hours period rather than a 
period of 9 days. 30% of the mice who received 5 hits over a 10 hours period showed mild 
hemorrhage at various locations such as the cortical layer (Fig.2.5A), olfactory bulb (Fig.2.5B), 
cerebellum (Fig.2-6C), and brainstem. After these observations, I determined the standardized 
setting to induce an mTBI to be at a strike velocity of 5m/sec at 1 mm depth with a 48 h injury 
interval for the r-mTBI.
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Figure.2.5: Histological images of H&E stained sagittal sections following 5 r-mTBI within 10 h and 
sacrificed 24 h post last injury. Repetitive-mTBI caused hemorrhages (pointed by arrows) on the cortical 
surface at the injury site (A), on the surface of the olfactory bulb (B) and within the brain stem (C) at 24h 
post injury. No damage was observed in the pyramidal cell layer of the hippocampus (D).
2.3.2. Acute neurological response:
Having optimized the conditions for mTBI, single or r-mTBI paradigm or anesthesia 
control was administered to the study cohort (see section 2.2.3 above). Following CHI, all 
injured animals demonstrated a period of apnea ranging from 3 to 30 sec followed by a 
prolonged period of unresponsiveness (3-6 min), (Fig.2.6A). There were no significant 
differences among impact apneas across injury groups, although the time of apnea did 
decrease with each mTBI in the r-mTBI group (repeated measures ANOVA). However, we 
observed significant differences in righting between sham and injured groups (***p  < 0.0001) 
(Fig.2.6B). Similar to apnea, the righting reflex recovery duration slightly decreased with each 
mTBI, although this was not significant (repeated measures ANOVA), (Fig.2.6B). Therefore, 
regardless of the number of injuries, the traumatic apnea and the time required for recovery of 
the righting reflex was similar, and did not increase with increasing number of injuries.
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Figure.2.6: Length of traumatic apnea (A) and latency of right reflex (B) were recorded following each 
anesthesia (n=12 per group). The main effect of injury on traumatic apnea and recovery of the righting 
reflex was significant (***p < 0.0001). The within group effect of days was not significant for either 
group. Values are presented as mean ± SEM.
2.3.3. Sensorimotor function:
Motor function was evaluated 24 h following the sole/last mTBI/anesthesia. Overall, all 
animals exhibited a decreased rotarod performance when compared to their last day of pre­
training (Fig.2.7). By the last day of rotarod, the s-mTBI and r-mTBI fall latency was shorter than 
that of their sham controls, 9% and 19% less, respectively (s-mTBI, p = 0.005; r-mTBI, p < 0.001; 
repeated measures ANOVA). Mice with a single mTBI improved over the testing period from 90 
± 13% of pre-injury level on day 1 to 95 ± 12% on day 7 (interaction "Injury and test day"; p < 
0.05; repeated measures ANOVA). In contrast, the r-mTBI mice did not return to an uninjured 
baseline level; 84 ± 9% of pre-injury level on day 1 to 82 ± 15% on day 7 (interaction "Injury and 
test day"; p > 0.05; repeated measures ANOVA). Rotarod testing was also conducted at 24 and 
30 days after the final injury, but by this extended time point the performance of singly or
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repetitively injured animals was not different from that of controls, demonstrating the transient 
nature of the motor deficits.
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Figure.2.7: Effect of mild traumatic brain injury on rotarod performance. Values were recorded on 7 
separate days with three 5 min accelerating trials. Results are the mean ± SEM of the time animals 
remained on the rotarod before falling. There was a gradation of impairment with multiply injured 
animals remaining less time on the rod between days 1 and 7 after sole/last mTBI or anesthesia (s-mTBI 
vs. s-sham [**p = 0.005]; r-mTBI vs. r-sham [**p < 0.001]; [n = 12 per group]).
2.3.4. Cognitive deficits after single and repetitive injury:
Acquisition deficits were observed in brain-injured mice relative to their sham controls 
(Fig.2.8A and B). Again, we found that the repetitively injured animals were performing worse 
than the singly injured mice. Although both sham and injured mice were able to find the 
correct hole by the last day of the acquisition period, both singly and repetitively injured mice 
had a greater cumulative distance from the hole than their sham controls (52% and 73% 
further, respectively) (s-mTBI, p < 0.005; r-mTBI, p < 0.0001; repeated measures ANOVA). Their 
ability to find a previously learned location of the escape hole was also assessed and all groups
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showed improvement in escape latency, but with the r-mTBI group performing worse than 
controls and the s-mTBI group. Only day 6 from this dataset passed normality testing, and 
analyzing that day alone, the r-mTBI group was found to be significantly different from the 
other three groups ( p < 0.0001). The velocity across each group was similar, (s-sham, 6.3 ± 
0.34 cm/s; r-sham, 6.6 ± 0.60 cm/s; s-mTBI, 5.9 ± 0.34 cm/s; r-mTBI, 6.4 ± 0.31 cm/s) indicating 
that differences in BM performance were not a function of motor deficits.
The probe trial analysis of the average time to reach the target zone, (defined by the 
target escape hole and its adjacent north and south holes) revealed that the r-mTBI mice 
performed the worst, requiring on average 15 sec to reach the target zone, followed by the s- 
mTBI (8.3 sec), the r-sham (4.8 sec), and the s-sham (2.9 sec). For both injury groups, the time 
to reach the target or adjacent holes was significantly longer than for their sham controls (p < 
0.02 for both injury groups; ANOVA) (Fig.2.8C). As with the acquisition trials, the average 
velocity was not significantly different across all four groups (p > 0.05).
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Figure.2.8: Evaluation of learning (acquisition) and spatial memory retention (probe) using the Barnes 
maze on days 8-14 after sole/ last mild traumatic brain injury (mTBI). Mice were tested in the Barnes 
maze for their ability to locate a black box at the target hole. During the acquisition testing, both injured 
groups traveled a greater cumulative distance before escaping to the target hole compared with their 
respective anesthesia controls, with the r-mTBI groups versus the r-sham group showing a greater 
significant difference than the s-mTBI groups versus the s-sham group (**s-mTBI, p < 0.005; r-mTBI,
***p  < 0.0001) (A). The mean time to escape to the target hole was longer for the r-mTBI group. On
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day 6 of the acquisition trial, the r-mTBI group spent significantly more time escaping to the target hole 
than did their sham control, r-sham (***p < 0.0001) (B). For the probe trial (1 day following the 6 days of 
acquisition testing), the target box was removed and mice were placed in the middle of the table for a 
single, 60 sec trial. Although both mTBI groups had a greater latency to reach the target zone than their 
respective shams (*p < 0.02), there was a clear trend for the r-mTBI mice to take longer to reach the 
target zone (C). The mean velocity for acquisition phase and probe test was similar across all groups. 
Data are presented as mean ± SEM.
2.3.5. Pathology of single and repetitive injury:
Macroscopic examination of fixed brains revealed focal architectural disturbance with 
evidence of hemorrhage (<lm m 2) in the inferior surface of the cerebellum in all animals 
subjected to r-mTBI. These were also evident, but to a lesser extent, in every singly injured 
mouse at 10 days after injury. Otherwise, there were no focal macroscopic lesions in any of the 
animals subjected to injury. Specifically, there were no skull fractures, cerebral hemorrhages, or 
contusions identified using this injury model. Further, examining sections stained for H&E or 
LFB/CV revealed no evidence of focal structural pathology in the cortex, hippocampus, or hilus 
of the dentate gyrus (Fig.2.9), with quantification of hippocampal neurons demonstrating no 
overt cell loss in either the ipsi- or contralateral hippocampi of the injured groups. Animals 
subjected to s-mTBI displayed no evidence of cerebellar injury at 24 h post- injury (Fig.2.9F). 
However, at 10 days after single injury, a focal, superficial region of architectural disruption 
associated with a glial response was observed in the inferior surface of the cerebellum 
(Fig.2.91). In the r-mTBI group, this lesion was extensive and extended into underlying white 
matter (Fig.2.90).
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Figure.2.9: Luxol fast blue/cresyl violet staining revealed no overt abnormalities in the cerebral cortex of 
the injured or non-injured mice. Coronal sections of mouse brain at =1.9 mm posterior to bregma (A, D, 
G, J, M). The red box indicates the region of interest, which is shown at a higher magnification (B, E, H,
K, N). Sagittal sections of the cerebellum (0.26 mm lateral to midline) (C, F, I, L, 0). A focal region of
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architectural disturbance in the inferior surface of the cerebellum was observed in the r-mTBI group (0), 
which was less extensive in the s-mTBI-lOD group (I).
2.3.6. Amyloid precursor protein immunostaining:
Numerous APP-immunoreactive axonal profiles were identified in sections from injured 
animals (Fig.2.10A and B). These APP immunoreactive axonal profiles were observed as either 
granular or more elongated, fusiform swellings in the white matter of the parasagittal cortex, 
the CC, and the spinal trigeminal tracts of the BS. Unique to the r-mTBI group, there was also 
evidence of cytoplasmic staining in neurons of the primary and secondary motor cortex 
(Fig.2.10C). APP-immunoreactive axonal profiles were observed 24 h post-injury in the CC of 
the s-mTBI (Fig.2.11G) and r-mTBI groups (Fig.2.11S) but not in their controls (Fig.2.11C-0).
The numbers of APP-immunoreactive profiles in the CC of the s-mTBI was greater than in the r- 
mTBI group (s-mTBI group 14.4 ± 2.26 vs. r-mTBI 6.0 ± 0.8 axonal profiles/100 pm2; p < 0.001; 
Fig.2.12A). Axonal damage in the BS was minimal in the s-mTBI, whereas greater numbers of 
punctate immunoreactive swellings were present in the r-mTBI group (s-mTBI 0.4 ± 0.2 vs. r- 
mTBI 5.2 ± 1 axonal profiles/200 pm2; p < 0.001; Fig.2.12B). By 10 days post-mTBI, no 
immunoreactive profiles were observed after s-mTBI (Fig.2.11J and K).
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Figure.2.10: Photomicrographs of sagittal sections stained with APP. Immunoreactive axonal profiles 
were observed as either granular (A) or more elongated, fusiform (B) swellings in both s-mTBI and r- 
mTBI groups (only the r-mTBI group is displayed). APP immunoreactive neurons were only present in 
the r-mTBI group, and occasionally observed in the cortex underneath the impact site (C). No APP 
staining was observed in the sham animals (D). Tissue sections were counterstained with hematoxylin 
Scale bar, 100 pm.
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Figure.2.11: Amyloid precursor protein immunohistochemistry of sagittal sections of mouse brain at 
=0.4 mm lateral to the midline in the brainstem (B, F, J, N, R), in the corpus callosum (C, G, K, 0, S), and 
coronal sections =2.1 mm posterior to bregma (D, H, L, P, T). Colored boxes indicate areas of interest 
shown at higher magnification in the right hand panels. Tissue staining from s-sham (A-D), s-mTBI-lOD 
(l-L), and r-sham animals (M-P) was negative for APP immunostaining. Immunoreactive axonal profiles 
were observed the brainstem in an area underlying the cerebellum in the r-mTBI (R), whereas few such 
profiles were detected in the s-mTBI group (F). Extensive accumulation of APP was observed as discrete 
axonal profiles in the corpus callosum of the s-mTBI (G, H), and less in the r-mTBI animals (p < 0.001) (S, 
T). Tissue sections were counterstained with hematoxylin.
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Figure.2.12: Average counts of APP-immunoreactive axonal profiles per pm2 in the corpus callosum (A) 
and in the brainstem (B) (n = 4). Fewer axonal profiles were observed in the corpus callosum of the r- 
mTBI group than in the s-mTBI group (**p < 0.001). APP immunoreactive axonal profiles in the 
brainstem were observed in the r-mTBI group, whereas only a few were detected in the s-mTBI group 
(**p < 0.001). Tissue staining from s-sham and s-mTBI-lOD animals was negative for APP 
immunostaining. Data are presented as mean ± SEM.
2.3.7. Glial fibrillary acidic protein immunostaining:
For mice subjected to r-mTBI, immunostaining for GFAP revealed evidence of a mild reactive 
astrogliosis in regions of the cortex underlying the impact site (Fig.2.13R), the CC (Fig.2.13S), 
and the hippocampus (Fig.2.13T). In contrast, no gliosis was observed in the cortex at the 
impact site in shams (Fig.2.13B) or 24 h after a single injury (Fig.2.13F). In the CC, the r-mTBI 
(Fig.2.13S) and s-mTBI-lOD (Fig.2.13K) groups showed a notable increase in the area of GFAP 
immunoreactivity compared with their respective sham controls, with the magnitude of this 
increase greater in the r-mTBI than in the s-mTBI-lOD group (s-sham 0% vs. s-mTBI-lOD 1.8 ± 
0.7%; p < 0.0001; r-sham 0.6.1 ± 0.2% vs. r-mTBI 5.0 ± 0.7%; p < 0.0001; Fig.2.14A). In the CA1 
region, there was no evidence of increased immunoreactivity in mice subjected to s-sham 
(Fig.2.13D), or in the singly injured animals at either time point (Fig.2.14H-L), (s-shaml.5 ± 0.2% 
vs. s-mTBI 1.2 ± 0.2%, vs. s-mTBI-lOD 1.9 ± 0.3%; p > 0.05). By contrast, increased GFAP
immunoreactivity was observed in the CA1 region of the r-mTBI group (Fig.2.13T) compared 
w ith its sham (Fig.2.139P), (r-mTBI 5.7 ± 0.4% vs. r-sham 3.8 ± 0.5%; Fig.2.14B; p < 0.005). 
Interestingly, we also observed an increase in GFAP-immunoreactivity in the CA1 region of the 
r-sham animals (Fig.2.13P) when compared with the s-mTBI (Fig.2.13H) and the s-sham animals 
(Fig.2.13D, p < 0.01).
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Figure.2.13: Glial fibrillary acid protein immunohistochemistry of sagittal sections of the mouse brain at 
± 0.4 mm lateral to midline in the cortex (B, F, J, N, R), corpus callosum (C, G, K, O, S), and the CA1 sub 
region of the hippocampus (D, H, L, P, T). Colored boxes indicate areas of interest shown at higher 
magnification in the right panels. There were no changes in the s-mTBI group (E-H) compared with their 
respective sham group (A-D) at 24 h post-injury. An increase in the area of GFAP staining was observed 
in the corpus callosum at 10 days post s-mTBI (K). An increased area of GFAP immunoreactivity was 
observed in the CA1 region of the r-sham group (P). GFAP immunohistochemistry shows extensive
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staining in the r-mTBI at 24 h after final injury in the cortex, corpus callosum, and hippocampus (R-T). 
Tissue sections were counterstained with hematoxylin.
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Figure.2.14: Quantitative analysis of GFAP staining intensity in two 150 pm2 areas of the corpus 
callosum (A) and two 200 pm2 areas of the CA1 region (B) (n = 4). Data are presented as mean ± SEM, 
(*p < 0.05; **p < 0.001; ***p  < 0.0001).
2.3.8. Ionized calcium binding adaptor molecule 1 immunostaining:
In the sham animals, none of the regions of interest showed cells with structural 
characteristics of activated microglia (hypertrophic and bushy morphology); (Fig.2.15A-C; J-L). 
In the singly injury animals, microglial activation in the BS and in the cortex was not noticeable 
at either 24 h or 10 days post injury (Fig.2.15D-l). However, in the CC, the s-mTBI and the s- 
mTBI-lOD showed a notable increase in Ibal-immunoreactivity (s-sham 1.34 ± 0.2% vs. s-mTBI 
2.5 ± 0.3%, vs. s-mTBI-lOD 2.9 ± 0.9%; p < 0.005; Fig.llE-H and Fig.2.16A). For mice subjected 
to r-mTBI, immunostaining for anti-lba-1 revealed clusters of activated microglia in the BS (Fig. 
12.15M), the CC (r-sham 1.5 ± 0.3% vs. s-mTBI 8.5 ± 0.8%; p < 0.0001; Fig.2.16N), and microglia 
with a bushy morphology in the region of the cortex underlying the impact site (r-sham 0.3 ± 
0.09% vs. r-mTBI 4.0 ± 1.1%; p < 0.0001; Fig.2.160).
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Figure.2.15: Immunohistochemical labeling for microglia with anti-lbal. Sagittal sections of the mouse 
brain at ~ 0.4 mm lateral to midline in the brainstem (A, D, G, J, M), in the corpus callosum (B, E, H, K, N), 
and in the cortex (C, F, I, L, 0). There was no microglial activation in the sham (A-C) and r-sham (J-L) 
groups. An increased area of anti-lbal immunoreactivity was observed in the corpus callosum at 24 h 
(E) and 10 days (H) post s-mTBI. Anti-lbal immunohistochemistry indicates multifocal microglial
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activation after r-mTBI in the brainstem (M), corpus callosum (N), and cortex (0). Tissue sections were 
counterstained with hematoxylin.
A B
s-sham s-mTBI s-mTBI-lOD r-sham r-mTBI s-sham s-mTBI s-mTBI-lOD r-sham r-mTBI
Figure.2.16: Quantitative analysis of anti-lbal staining intensity in three 100 pm2 areas of the corpus 
callosum (A) and two 200 pm2 areas of the cortex (B) (n = 4). Data are presented as mean ± SEM, (**p <
0.001; ***p  < 0.0001).
In summary, our results demonstrate that animals exposed to s-mTBI have short-term 
behavioral abnormalities that manifest as transient deficits in motor function and spatial 
memory, which are accompanied by reactive astrocytosis and sparse APP-immunoreactive 
axonal pathology in the CC. By contrast, animals subjected to r-mTBI with an inter-injury 
interval of 48 h demonstrated greater cognitive impairment, microglial activation, more 
widespread and marked reactive astrocytosis, multifocal axonal pathology, and focal injury in 
the cerebellum (Table 2.2).
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s-sham s-mTBI s-mTBI-lOD r-sham r-mTBI
i Cortex - A
- - G G G G
- - - M M
Corpus - A A A  - - AA
callosum - - GG G G G G
M M M  M M  M M M M
I CA1 - . - - ' -
G G G G G G G G
M M M M M
Brain stem A - - A A
- - - M
Table.2.2: Summary of the location and relative intensity of immunohistochemical data for APP (A), 
GFAP (G) and anti-lbal (M). Present (X), moderate staining (XX), and intense staining (XXX).
2.4. Discussion:
Following the development and optimization of mTBI in a non-invasive CHI model, the 
influence of single and r-mTBI on cognitive performance and the resulting neuropathology was 
assessed in mice. Results from our study indicated that a single injury a 5m/sec velocity strike 
and 1mm impact depth, or r-mTBI with the same parameter but spaced every 48h met mild 
injury criteria (i.e. 0% mortality, no hemorrhage, short period of traumatic apnea, and no skull 
fracture).
We achieved our goal by successfully developing and characterizing a new mouse model of 
CHI produced by using an EM controlled impact device. The purpose in developing this model 
was to establish an easily implemented, robust, and highly replicable animal model to address 
the consequences of mTBI and understand the cumulative and chronic effects of repetitive mild
injury. Moreover, to our knowledge, this is the first study of its kind to examine the 
consequences of more than two repetitive hits at an interconcussive interval of 48 h.
Rodent models of CHI that predominate the field use either an electromagnetic impactor or 
the weight drop model to model r-mTBI. Since the publication of our model, two other 
independent groups have confirmed and replicated our observations using similar settings on 
the same injury device (EM controlled impactor). In these studies, r-mTBI caused exacerbated 
acute spatial learning, memory deficits, inflammation, and axonal injury when compared to 
single mTBI18,29. The study of Hylin and colleague29 uses the same impactor tip (5 mm in diameter) 
driven at a velocity of 5.0 m/sec to a depth of 1.0 mm. At these settings, they delivered 2 impacts 
within 24h or 4 impacts within 24 h. In a second study, Shitaka and colleague18, used the same injury 
apparatus but incorporated a larger rubber tip (9 mm in diameter) delivering 2 impacts within 24 h at 
5.0 m/sec to a deeper depth: 3.3 mm. Likewise, studies using a weight drop model report that 4 to 5 
injuries within 24 h produced acute deficits in spatial memory13,30. Overall, while differences exist across 
laboratories in term of the injury setting, there is a consensus on the consequences of r-mTBI. This is of 
specific importance for the continuing development and the translation of animal models to clinical 
settings.
Consistent with other mouse models of r-mTBI and evidence from athletes who have 
experienced repeated mild concussive injuries, our model shows acute postural equilibrium 
impairment post-injury as assessed by the rotarod motor task24,31. Whereas the performance 
of the s-mTBI group improved overtime, the r-mTBI group was unable to recover their 
sensorimotor function up to 7 days post-injury, which was the latest day tested in this study.
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Over this time period, each injury group performed worse than their respective shams with a 
rank order of performance of r-mTBI < s-mTBI < r-sham = s-sham. When tested for cognitive 
performance in the BM, both injury groups showed cognitive impairment consistent with 
findings in previous animal models of brain injury13,17,18'32'34. There was a worsening trend for r- 
mTBI compared with s-mTBI during the acquisition trials as well as on time to zone in the probe 
trial, and on the final day of acquisition training the r-mTBI group performed significantly worse 
than the other three groups.
From a neuropathological perspective, the only macroscopic abnormality observed was a 
focal contusion injury on the inferior surface of the cerebellum away from the site of injury in 
the r-mTBI and s-mTBI-lOD groups. In addition, we observed an evolving cerebellar injury in 
the s-mTBI-lOD group that is likely the result of secondary injury processes that develop over a 
period of days after the initial trauma. Aside from this observation, there was no evidence of 
structural damage to the brain based on routine morphological assessment with H&E and 
LFB/CV staining, including no signs of neuronal loss.
Axonal injury can be detected by immunohistochemistry for the APP, a member of the 
homologous type-1 transmembrane protein35. APP is found in neurons and conveyed along the 
axon by fast anterograde transport36,37. In case of axonal damage or transection, the transport 
is interrupted and APP has been shown to accumulate in the damage areas indicative of 
dysfunction or in the proximal axonal ends if transected38. As a consequence, so-called 
APP-positive varicose followed by spheroids (bulbs) are formed. APP has been hypothesized to 
function as a receptor in intracellular axonal transport and may interact with kinesin and the
microtubule cytoskeleton enabling the transport of cargo to the synaptic terminal39. Several 
studies have also hypothesized the role of this protein to be involved in tissue maintenance40, 
brain development41 and in response to injury42.
In this study, axonal injury following trauma results in swollen and tortuous axons that can 
be detected by the accumulation of APP as early as 35 min after brain injury43, and in our 
model, a single impact resulted in APP-immunoreactive axons localized to the CC, evident at 24 
h after injury. By 10 days postinjury (s-mTBI-lOD) there was no evidence for APP 
immunoreactivity, consistent with the current literature for animal models in that strong APP 
staining is present at 24 h post-injury8'17'44, which diminishes by 14 days post-injury33,43. In the 
r-mTBI group, more widespread damage was observed, with immunoreactive axons also 
evident in the spinal trigeminal tracts of the BS and beneath the impact site in the form of APP 
immunoreactive neuronal perikaryas.
However, in the r-mTBI group, the APP immunoreactive axonal swellings were less frequent 
and less robustly stained in the CC than those observed at 24 h after s-mTBI. These 
observations may be consistent with a deleterious effect of repetitive versus single injury on 
the ability of the brain to efficiently catabolize and clear APP, facilitating amyloidogenic 
processing and contributing to later evolution of amyloid plaque pathology3'45. More work is 
required to explain why no increase in APP immunoreactivity was observed in r-mTBI versus s- 
mTBI. Nevertheless, the comparison of r-mTBI with s-mTBI-lOD (where both groups are 
matched for time since the first/single injury) clearly demonstrates that repetitive injury
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sustains an APP immunoreactive axonal profile over the 10-day period following the initial 
injury.
As stated above, the cohort of r-mTBI also showed multifocal injury in various brain regions 
but the extent of axonal damage represented by the number of APP immunoreactive profiles 
were significantly reduced when compared to the s-mTBI group. This apparent decrease in the 
density of APP-immunoractive profiles may arise for a number of reasons. These include 
cleavage enzymes, inflammatory response, or/and axoplasmic leakage after axonal rupture.
For example, axonal swellings may either dissipate as axonal homeostasis is restored and/or 
cleared by enhanced activation of macrophage/microglial cells and increased astrocytosis. It 
was also reported that following experimental head injury in rodents, resident microglia and 
macrophages are recruited in both focal and diffuse TBI46'48. After injury, the axonal 
membranes break apart stimulating cytokine/chemokine release by neurons followed by 
degradation of the myelin sheath and macrophage infiltration49,50. Then, macrophages clear 
APP and the cell debris significantly decreasing the amount of APP by the time of the fifth 
injury. Ultimately, these disconnected axons are cleared by microglia and macrophage which in 
turn triggers Wallerian degeneration within days after injury51. As expected, our data show co 
localization of astrogliosis and APP profiles which is correlated with a lower magnitude of APP 
staining in the corpus callosum in the r-mTBI group as well as 10 days post s-mTBI. Further 
studies are required to determine if the decrease of APP pathology could be the consequence 
of reactive astrocytes and/or microglial activation.
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A simpler mechanism may also explain the decrease in APP immunostaining in the r-mTBI.
By 10 days post initial injury, the axons could be significantly damaged by both primary and 
secondary injuries impairing axonal transport, and thus be perceived as a decreased APP 
accumulation. APP staining was strongly visible at 24H after injury, and then disappeared by 10 
days. Consistent with the literature, in rodent, APP is evident between 6 and 24 h before 
gradually decreasing and completely disappearing by 14 days. Identifying the impact of axonal 
injury is an important determinant of sensorimotor, behavioral and cognitive impairments after 
mTBI. Damage to white matter tracts by the primary injury cannot solely explain cognitive 
problems52. This is likely because the cognitive memory, executive function and processing 
speed largely rely on the coherent activity of the brain network.
In addition to the white matter damage, the r-mTBI group was associated with a notable 
reactive astrocytosis, with a distinct pattern of GFAP-positive reactive astrocytes localized to 
the medium and deep layers of the cortex beneath the impact site. As observed in the s-mTBI- 
10D group, our model produced a measurable reactive astrocytosis at 10 days after initial mTBI. 
These results are consistent with other studies that showed astrocytosis peaking between 10 
and 14 days following concussion in rodents33,53'54. This increase in gliosis is also believed to 
coincide with macrophage accumulation, which has also been shown to peak at 10 days post­
injury. Our data demonstrate that repetitive, noninvasive mTBI in the mouse resulted in a 
graded injury response, with the extent of reactive astrocytosis increased in animals exposed to 
repetitive impacts. Whereas a single impact produced moderate reactive astrocytosis at 10 
days post-injury and was isolated to the CC, five impacts over 9 days showed increased staining
in the CC as well as cortical and hippocampal involvement. As well as axonal injury and 
astrogliosis, microgliosis was also detected in the CC of injured animals as early as 24 h and up 
to at least 10 days post-mTBI, whereas the r-mTBI group revealed clusters of activated microglia 
in multiple brain regions (CC, BS, and cortex). The time course of microglial activation observed 
in this study was similar to that noted in previous reports18'55'57. Depending mainly upon injury 
severity and the duration of the ensuing inflammatory cascade, microgliosis can be either 
beneficial or detrimental with respect to tissue preservation58. Known as the first line of 
defense in both focal and diffuse TBI59, microglial activation has been reported to play a 
beneficial role by secreting brain-derived neurotrophic growth factors and insulin-like growth 
factor60'62. They have also been shown to have a detrimental role at an acute time point by 
secreting inflammatory cytokines such as interleukin (IL)-lp and tumor necrosis factor (TNF)- 
a63,64. Moreover, in several TBI models, minocycline, which has anti-inflammatory properties, 
has been shown to reduce histopathological consequences after mTBI in mice65,66. Of particular 
interest is a recent study by Siopi and collaborators which demonstrated that reducing 
neuroinflammation post-injury attenuated memory impairment in a mouse model of CHI67,68, 
however more work is required to address the impact of microglial activation on cognitive 
function after TBI.
The main limitation of this model is a function of interspecies physiological differences. The 
murine skull has a greater deformability than that of the rat, and its relatively small mass 
compared to that of humans complicates biomechanical studies, as it cannot simulate a true 
human rotational/angular injury induced by the brain inertia69,70. Consequently, the lack of
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head movement is a common issue of brain concussion in sub-primate animals, as this is 
inconsistent with human brain concussion. Nonetheless, the key elements of brain trauma 
neuropathology remain similar across species. For example, the pathological consequences of 
axonal injury (axonal varicosities, axonal bulbs) have been observed in humans, pigs, rats, and 
mice3,8'18'33. The other advantages of mouse models (genetic manipulability, ease of protocol 
implementation, and cost) make this an appropriate platform in which to identify molecular 
consequences of repetitive versus single injury for exploration in higher mammals.
In conclusion, we have developed a simple and reproducible mouse model of mTBI, 
which induces pathological and behavioral features comparable to those observed in the 
human condition. Moreover, by recapitulating the pathological alterations observed in human 
TBI patients, this model is also suitable for studying various mechanisms of post-traumatic 
injury such as axonal injury, cell death, or apoptosis. Our intent was that future application of 
this model of mTBI could be used to investigate the long term consequences of r-mTBI (see 
Chapter 3), the influence of different numbers of injuries and different inter-injury intervals, 
and the impact of r-mTBI in mice genetically modified at loci of relevance to human TBI such as 
Tau (see Chapter 4) or APOE, aspects currently lacking in the literature. An increased 
understanding of mTBI and its cumulative effects will enable identification of molecular targets 
specific to mTBI and ultimately the development of novel, effective therapeutics, which are 
desperately needed. Furthermore, the acute phase following traumatic brain injury is 
associated with a complex and mixed neuroinflammatory response involving polymorphs, 
microglia and T lymphocytes amongst others59,71. Whilst this acute phase response has long
been recognized as contributing to immediate pathology, more recently attention has been 
drawn to the role persistent inflammation beyond this acute phase response might have in 
respect of longer-term neurodegenerative consequences. The next chapter lays out the 
foundation for prospective longitudinal studies in mTBI by characterizing the chronic 
pathological and behavioral outcomes following s-mTBI and r-mTBI in this mouse model of 
mTBI. We believe this work promises to be instrumental to the field of TBI research, we will be 
the first to provide an extensive timeline of TBI sequelae after s-mTBI and r-mTBI, as well as 
potential pre-clinical platform in which to investigate therapeutic opportunities in TBI and wider 
neurodegenerative diseases.
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Chapter 3
3. Chronic evaluation of neurobehavioral and neuropathological changes in the novel mouse 
model of mTBI
3.1. Introduction:
As already described, epidemiological studies indicate that repetitive traumatic brain 
injury (TBI) is associated with increased risk of neurodegenerative diseases1'5. Chronic 
neuropathological studies on autopsied human TBI tissue have demonstrated a variety of 
pathologies typically described in neurodegenerative disorders, suggesting that a history of 
repetitive mild TBI (r-mTBI) could act as a substrate for future dementia6. Descriptions thus far 
include pathologies in amyloid beta (A|3)7'10, tau9'11, TAR DNA binding protein 43 (TDP-43)9'10,12, 
and neuroinflammation10'13'14. Historical data on 'dementia pugilistica'15, together with recent 
descriptions of the pathology of athletes10 ' 11 ' 16 ' 18 and military personnel9,13 ,19 exposed to r- 
mTBI, which includes the features now often described as chronic traumatic encephalopathy 
(CTE) support an association between TBI and neurodegeneration.
In humans, as observed in our mouse model, the acute phase following TBI is associated 
with a complex and mixed neuroinflammatory response involving activation of resident 
microglia and astrocytes that express inflammatory mediators locally20,21. Whilst this acute 
phase response has long been recognized as contributing to immediate pathology, more 
recently attention has been drawn to the role persistent inflammation might have in relation to 
longer term neurodegenerative consequences22. In support of this, autopsy-derived tissues 
from athletes10 ,13 ,14 demonstrate persistent neuroinflammation many years after TBI.
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Increasingly, neuroinflammation is proposed as contributing to development of 
neurodegenerative diseases23, perhaps representing an early event in their pathogenesis.
My development and acute phase characterization of a novel mTBI mouse model, 
described in Chapter 224, laid the foundation for evaluation of the long term consequences of 
mTBI, in particular r-mTBI, using the same paradigm. This, we anticipated, would be of most 
significance to the translation of our preclinical efforts to human populations. It has recently 
been suggested that CHI animal models may more closely approximate clinical mTBI than fluid 
percussion or cortical impact models25. To date, few CHI models have examined the long term 
consequences of r-mTBI26' 27 with neuropathological changes and neurobehavioral deficits being 
reported up to 3 months post injury in mice. To our knowledge the only study with a time point 
of analysis greater than 3 months post injury comes from the work of Mannix and colleagues 
who reported neurobehavioral deficits at 1 2  months post injury in mice, with little 
accompanying neuropathology28,29.
In our model we observe behavioral deficits at up to 18 months post-injury in 
repetitively versus singly injured mice that is accompanied by characteristic neuropathological 
features including progressive neuroinflammation supporting the potential for this model to 
serve as a pre-clinical platform in which to investigate therapeutic opportunities in TBI.
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3.2. Materials and Methods: 
3.2.1. Animals:
Male, C57BL/6J mice (aged 9-15 months, 32-42g, Jackson Laboratories, Bar Harbor ME) 
were housed singly under standard laboratory conditions (23°C ± 1°C, 50±5% humidity, and 12- 
hour light/dark cycle) with free access to food and water throughout the study. All procedures 
were carried out under Institutional Animal Care and Use Committee approval and in 
accordance with the National Institute of Health Guide for the Care and Use of Laboratory 
Animals.
3.2.2. Injury groups and schedule:
For the behavioral analyses we evaluated the same groups of mice on which we 
previously published (Chapter 2) the results from an acute time point post injury24 (Fig.3.1). A 
total of 48 mice were randomly assigned to one of four groups: single injury, single sham, 
repetitive injury (total of 5 hits with an inter-concussion interval of 48 h), and repetitive sham (5 
anesthesias, 48 h apart). For this current study these mice were tested again at 6  (n=12 per 
group), 12 (n=12 per group) and 18 (n=9 per group) months after mTBI/anesthesia. This cohort 
of mice was not euthanized at the 18 month timepoint, as we are aging them for a later final 
timepoint of analyses, and therefore we do not have histological data for the 18 month time 
point. Separate cohorts of mice for the histological examination and biochemical analyses were 
randomly assigned to each of the 4 treatment groups as follows: 6  months post injury histology 
cohort (n=5/treatment group), biochemistry cohort (n=4/treatment group); 12 months post 
injury histology cohort (n=4/treatment group), biochemistry cohort (n=4/treatment group).
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Figure.3.1: Outline of experimental schedule.
3.2.3. Injury protocol:
The mTBI was administered to mice as described in Chapter 2.
3.2.4. Assessment of cognitive function:
Cognitive function was evaluated at 6 and 12 months post-injury/anesthesia using the 
Barnes maze (BM) as described previously in Chapter 2. The experiments were run blindly to 
grouping, and the Ethovision XT system (Noldus, Wageningen, NL) was used to  track and record 
the movement of each animal. In addition, at the 12 months post injury time point, follow ing 
the probe trial (day 8), we performed a reverse behavioral test in which the escape box was 
switched to the opposite side of the table to test the ability of mice to learn a new spatial 
contingency. Mice were pre-trained for 4 consecutive days to learn the location of the new 
hole and tested again with a single probe trial as described above.
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3.2.5. Assessment of Anxiety:
Anxiety-like behavior was assessed using an elevated-plus maze which relies on the 
animal preference for dark enclosed arms over bright open arms30. This task assesses the 
willingness of the mouse to explore the open arms of the maze which are fully exposed and at 
an elevated height. Time spent in the open arm is decreased in mice that exhibit anxiety-like 
behaviors. The maze consisted of a plexiglass plus-shaped platform elevated 50 cm from the 
floor with 4 arms intersecting at a 90° angle, creating 4 individual arms each 55 cm long and 5 
cm wide31. Closed and open arms were orthogonal to each other; the two closed arms were 
shielded by 25 cm high side and end walls, whereas the two open arms had no walls. The 
experimental procedure was initiated by the placement of the mouse into the center zone 
(intersection point) of the maze, facing one of the open arms. The mouse was allowed to 
explore the maze for a 5-minute period while an overhead video camera recorded the 
movements of each mouse. Another student blind to grouping of the mice scored the number 
of entries in each of the arms. All four paws of the mouse had to enter an arm for it to be 
considered an entry, as the percentage score for the time spent in the open arm was calculated 
as follows: (time spent in the open arms/ [time spent in the open arms + time spent in closed 
arms]) x 1 0 0 .
3.2.6. Histology:
At 6  and 12 months post-mTBI mice assigned to histological studies were anesthetized 
with isoflurane and perfused transcardially with phosphate-buffered saline (PBS), pH 7.4 
followed by PBS containing 4% paraformaldehyde. After perfusion, the brains were postfixed in 
a solution of 4% paraformaldehyde at 4°C for 48 h. Immunohistochemistry for GFAP, Ibal and
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APP was carried out as described in Chapter 2. Sets of adjacent sections were stained with a 
panel o f antibodies (Table.3.1) for immunohistochemical analyses. Each slide was visualized 
with a bright field microscope (BX60), and digital images were visualized and acquired using an 
Olympus MagnaFire SP camera.
Protein Target Antibody Epitope IHC-Dilution Source Assay
Amyloid Precursor Protein 22C11 aa* 66-81 1:40,000 Millipore ih c t
Glial Fibrillary Acidic Protein GFAP GFAP 1:20,000 Millipore IHC
Anti lba-1 lba-1 lba-1 1:5,000 Dako IHC
Total-tau DA31 aa 150-190 N/A Dr. P. Davies ELISA*
Phospho-tau CP13 pS202 1:400 Dr. P. Davies ELISA/I HC
Phospho-tau PHF1 pS396/404 1:400 Dr. P. Davies ELISA/I HC
Phospho-tau RZ3 pT231 1:400 Dr. P. Davies ELISA/I HC
Phospho-tau M C I Conformational 1:200 Dr. P. Davies IHC
Beta Amyloid (A(3) 4G8 a a l7 -2 4 1:750 Covance IHC
*aa, amino acid; T1HC, Immunohistochemistry; *ELISA, Enzyme-Linked Immuno-Sorbent Assay 
Table.3.1: Summary of antibodies used in chapter 3.
3.2.7. Immunohistochemical quantification:
All quantifications were done as previously described in Chapter 2. For each animal,
(n=5 per group at 6 months post mTBI; n=4 per group at 12 months post mTBI), sagittal sections 
were stained and analyzed by another student blinded to  experimental conditions using ImageJ 
software (US National Institutes of Health, Bethesda, MD, USA). The atrophy of the corpus 
callosum was calculated using ImageJ. The "freehand" selection tool was selected to outline the 
surface area of the body of the corpus callosum as illustrated in Figure3.2. For each 
experimental group, 14 sagittal brain sections of same area located between the splenium and 
the body of the corpus callosum was measured and averaged. The scale was set based on the
88
known distance revealed by the scale of a lOx magnification photomicrograph. For our 
measurements, 100 pixels represented 100 pm.
Splenium
Genu
Figure.3.2: Sagittal view of a lOx photomicrograph stained with LFB/CV. Example of an outline 
highlighted in red used to calculate the surface area for each brain section. Scale bar represents 100pm.
3.2.8. Quantitative assessment of soluble Ap40/ phosphorylated and total tau protein:
Analyses of soluble A(340, phosphorylated tau and total tau protein were carried out on 
the left hemisected brain obtained from PBS-perfused mice at 6 and 12 months post s/r-mTBI 
(n=4/group) or s/r-sham exposure (n=4/group). Snap-frozen hemisected cortices and 
hippocampi were sonicated in 0.5 ml and 0.3 ml of chilled M-PER buffer solution (Thermo Fisher 
Scientific, Waltham, MA) supplemented with protease and phosphatase inhibitor cocktail 
(Roche, Indianapolis, IN). For tau biochemistry, tissue homogenates were coded and sent to 
Peter Davies' group at Albert Einstein College of Medicine, for blinded quantitative
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assessments. Sample preparation for the Low-Tau level sandwich ELISA and quantitation of 
murine-specific tau protein was performed as previously described32. Antibodies to detect 
total and phospho tau (p-tau) (Table.3.1) were used as capture antibodies in the Low-Tau, 
Sandwich ELISA. Soluble Ap4 0  was assessed using a sandwich ELISA (WAKO, Richmond, VA) as 
per the manufacturer's directions. Total protein content was determined by the bicinchonic 
acid (BCA) method (Thermo Scientific, Waltham, MA) and data were expressed as pmol/g 
protein (A(340) and ngtau/mg protein (tau and phosphorylated tau).
3.2.9. Statistics:
All behavioral and pathological data were analyzed using JMP 8.0 (SAS, Cary, NC). Scores 
were analyzed separately for groups of animals assigned to survival groups for each time points 
post-injury. Data were tested for normality using the Shapiro-Wilk W Test; when not normally 
distributed, the data were transformed using square root or natural log transformation. If the 
data were still not normal after transformation, they were analyzed using non-parametric 
methods were used for analysis. Repeated-measures ANOVA was used to compare 
performance during the 6  days of acquisition of the Barnes maze between the matching injury 
groups when the data were normally distributed. Potential sphericity violations were corrected 
by adjusting degrees of freedom for all repeated-measures effects by using the Greenhouse- 
Geisser estimate for epsilon. Probe dataset and quantitative histologic parameters were 
analyzed with one-way ANOVA, with a Tukey's post-hoc correction for multiple comparisons, 
unless indicated. ELISA data were plotted and analyzed using Graph-Pad Prism (Prism 6.01, 
GraphPad Software Inc, La Jolla, CA). One way ANOVA followed by Tukey's post-hoc test was
used for comparison of soluble tau and Ap4 0  levels between the four groups. Only p values < 
0.05 were considered to be statistically significant and are indicated by an asterisk in the 
figures. Error bars represent the standard error of the mean (SEM).
3.3. Results:
3.3.1. Barnes Maze: acquisition:
At all-time points, both of the injured groups demonstrated a longer cumulative 
distance to the target in the Barnes maze than their respective sham groups (Fig.3.3A-C), (r- 
mTBI vs. r-sham, p < 0.0001; s-mTBI vs. s-sham, p < 0.0001 repeated-measures ANOVA). At 12 
and 18 months post injury (Fig.3.3B and C) the deficit in performance of the r-mTBI group 
became even more apparent in comparison to the s-mTBI group (r-mTBI vs. s-mTBI, p < 0.005; 
repeated-measures ANOVA). The mean cumulative distance over the 6  days acquisition period 
in the s-mTBI mice was 17%, 36% and 30% longer, respectively, than the s-sham mice at 6 ,1 2  
and 18 months post injury. At the same time point the r-mTBI had a greater and progressive 
separation on cumulative distance travelled (34%, 49% and 55% respectively) when compared 
to the r-sham. Specifically at 18 months post injury, the r-mTBI group not only travelled longer 
distances than any other group (r-mTBI vs. s-mTBI, p < 0.005; r-mTBI vs. s-sham, r-sham p < 
0.0001 repeated-measures ANOVA), but was also the only group to show a lack of learning 
throughout the acquisition trial (Fig.3.3C). There was no difference between the s-sham and r- 
sham groups at anytime point (p > 0.05 repeated-measures ANOVA).
The dataset for latency to escape was not normally distributed and thus did not satisfy
the assumptions required for a repeated-measure ANOVA. The Wilcoxon signed rank test was
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used to test for the daily correlation between each group. No difference in escape latency 
performance was observed at 6  months post injury between the s-mTBI and s-sham (day 6  of 
acquisition; p > 0.05) (Fig.3.3D). However, when tested at 12 and 18 months post injury, the s- 
mTBI group showed a progressive decline in escape latency performance. At 6  months post 
injury, the mean escape latency of the s-mTBI mice improved from 89.18±0.9 s on the first day 
of acquisition and 52.4 ± 4.0 s on their last day of acquisition. By 12 months post injury, they 
spent on average 75.8 ± 2.6 s on the first day of acquisition and 59.9±4.4 s by their last 
acquisition day. There was no improvement observed at 18 months post injury (77.3 ± 2.7 s on 
day 1 to 73.1 ± 4.4 s on day 6 ). In contrast, even at the 6  month time point the r-mTBI mice 
exhibited less improvement over the 6  days than the other groups (Fig.3.3D; days 1 and 6  of 
acquisition; r-mTBI, 87.94±0.9 s to 69.17±1.0 s; r-sham 88.4±l.ls  to 45.1±4.5 s; p<0.0002); this 
lack of improvement during acquisition persisted at 12 months, (79.5 ± 2.1 s to 6 6 . 6  ± 4.1 s) and 
18 months (79.7 ± 2.8 s to 78.2 ± 4.2 s) post injury. The average velocity was similar across all 
groups and all time points with a trend for the r-mTBI to be faster than the three other groups 
(p > 0.05; data not shown).
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Figure.3.3: Evaluation of learning (acquisition) using the Barnes maze at 6 ,12 and 18 months post mTBI. 
Mice were tested in the Barnes maze for their ability to locate a black box at the target hole. During the 
acquisition testing at 6  and 1 2  months, both injured groups traveled a greater cumulative distance 
before escaping to the target hole compared to their respective anesthesia controls (s-sham vs. s-mTBI; 
r-sham vs. r-mTBI ***p  < 0.0001) (A-C), with a trend for the r-mTBI travelling a greater distance than the 
three other groups. At 12 and 18 months post injury the performance of the r-mTBI group was worse 
than the s-mTBI (s-mTBI vs. r-mTBI, **p < 0.005) (B, C). On day 6  of the acquisition trial at 6  months post 
injury, the r-mTBI group spent significantly more time escaping to the target hole when compared to the 
r-sham (red asterisks; ***p  < 0.0001) (D). On day 6  of the acquisition trial at 12 months post injury, the 
s-mTBI group spent significantly more time escaping to the target hole when compared to the s-sham 
(black asterisk; *p < 0.05) (E). At 18 months post injury, both injured group spent significantly more time 
escaping to the target hole when compared to their sham control at every single day of training (***p < 
0.0001) (F). The mean velocity for the acquisition phase was similar across all groups (data not shown). 
Data are presented as mean ± SEM; n=12 per group at 6  and 12 months and n=9 per group at 18 months 
post injury.
3.3.2. Barnes Maze: probe:
Probe test performance was markedly impaired in the r-mTBI mice compared to other 
groups at each time point (Fig.3.4), requiring on average 12s, 11s and 27s to reach the target
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zone at 6  (p < 0.01), 12 (p < 0.05), and 18 months (p = 0.055) respectively (ANOVA). At each 
time point the s-mTBI, s-sham and r-sham groups had similar performance to each other, which 
progressively declined as they aged (Fig.3.4A-C). Similar to the acquisition trials, the average 
velocity was not different across all groups (p>0.05; data not shown).
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Figure.3.4: Evaluation of spatial memory retention (probe) using the Barnes maze at 6 ,12 and 18 
months post mTBI. For the probe trial (1 day following the 6  days of acquisition testing), the target box 
was removed and mice were placed in the middle of the table for a single, 60-sec trial. Probe test 
performance was markedly impaired in the r-mTBI mice across each time point (A*p < 0.01 at 6  months, 
B *p < 0.05 at 12 months, and C p = 0.05 at 18 months; as determined by ANOVA). The mean velocity 
for acquisition phase and probe test was similar across all groups (data not shown). Data are presented 
as mean ± SEM; n=12 per group at 6  and 12 months and n=9 per group at 18 months post injury.
3.3.3. Reversal Barnes maze and elevated plus maze at 12 months post mTBI:
Following probe testing at 12 months post injury, reversal testing in the Barnes maze 
was carried out to examine the ability of mice to learn a new location of the target hole. For 
the r-mTBI group the mean distance travelled to the hidden box was longer compared to the 
three other groups (r-mTBI vs. r-sham, p < 0.02; s-mTBI vs. r-mTBI, p < 0.0001; s-mTBI vs. s- 
sham, p > 0.05; repeated-measures ANOVA) (Fig.3.5A). Similarly, the mean escape latency of 
the s-mTBI mice was not different to their respective shams with performance improving over 
the four trials from 78.1 ± 3.7 to 50.4 ± 4.8 s, compared to 81.8 ± 3.8 s to 57.5 ± 5.6 s in s-sham 
animals (Fig.3.5B). In contrast, the r-mTBI group had a higher mean escape latency than the r-
sham group in their ability to learn the new target location (r-mTBI, 87.8 ± 1.1 s to 67.2 ± 4.6 s;
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s-sham, 82.9 ± 2.3 s to 51.7 ± 5.3 s; p < 0.004 at day 4; The Wilcoxon signed rank test) (Fig.3.5B).
Probe testing revealed no difference between any of the groups (Fig.3.5C; p > 0.05). The day 
following reversal testing, the anxiety of each animal was tested with the elevated-plus maze 
(Fig.3.6). Both sham groups (s-sham, 10.19 ± 2 % ;  r-sham, 9.70 ± 2.7 %) spent a smaller percent 
of time in the open arm than the s-mTBI (s-mTBI, 14.9 ± 3.3 %) or the r-mTBI (r-mTBI, 13.4 ± 4.7 
%; p > 0.05).
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Figure.3.5: Reversal represents learning to find the box when moved to the opposite quadrant. During 
reversal training, search time decreased in all groups as indicated by a significant effect of trial (***p  < 
0.0001; AB). The r-mTBI group performance was impaired during reversal acquisition (cumulative 
distance, *p < 0.05; A; escape latency, **p < 0.001 at day 4; B), while no deficits were observed between 
the s-mTBI and s-sham group (p > 0.05). There was no group differences in probe trials (p > 0.05; C).
The mean velocity for acquisition phase and probe test was similar across all groups (data not shown). 
Data are presented as mean ± SEM; n=12 per group.
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Figure.3.6: Anxiety-like behavior measuring the willingness of the animal to explore exposed arm at a 
specific height was assessed using an elevated-plus maze. There was a trend for both injured groups to 
spend more time in the open arms compared to the sham groups, (p > 0.05). Data are presented as 
mean ± SEM; n=12 per group.
3.3.4. White matter integrity:
Changes in the white matter integrity and thickness of the corpus callosum were 
assessed in sections stained for LFB/CV. Following s-mTBI there was a 12% (+/- 9.2 pirn; p < 
0 .0 0 0 1 ) reduction in thickness of the body of the corpus callosum at 6  months compared to s- 
sham (Fig.3.7A-B). This reduction in thickness remained static at 12 months, where the body of 
the callosum showed a 10% (+/- 4.6 pm; p < 0.0001) reduction in thickness compared to sham 
animals (Fig.3.7C-D). The repetitively injury animals also showed a thinning of the body of the 
CC at 6  months, with a decrease of 21% (+/- 7.8 pm; p < 0.0001) compared to the r-sham group 
(Fig.3.7E-F). In contrast to the s-mTBI, there was continued loss of callosal white matter 
between the 6  and 12 month time points where by 12 months post injury the r-mTBI showed a 
further reduction of 5% (p < 0.002) in callosal thickness compared to the 6  month r-mTBI
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animals, representing a 26% reduction in CC thickness compared to  (Fig.3.6G-H) (+/- 4.0 pm; p < 
0.0001) to the r-sham.
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Figure.3.7: Sagittal sections of the mouse brain stained with LFB/CV. LFB/CV staining indicated changes 
in white matter integrity in the injured animals at both 6 and 12 months post injury (B, D, F, H). At 6 
months, the thickness of the corpus callosum was decreased on average by 9% after s-mTBI, and by 11% 
in the r-mTBI (I). By 12 months post injury the average decrease of thickness in the corpus callosum of 
the s-mTBI was similar to the 6 month timepoint with a 4% decrease, while the r-mTBI showed a 
progressive reduction by approximately 20% (J). Data are presented as mean ± SEM,*p<0.05,
***p<0.0001.
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3.3.5. Amyloid precursor protein immunostaining:
APP-immunoreactive profiles were scattered diffusely throughout the corpus callosum 
in both injury groups at 6  and 12 months post injury. Typically these were observed as sparse 
rounded to granular immunoreactive axonal profiles (Fig.3.8B, D). In contrast, save for sparse, 
single APP-immunoreactive profiles, sham animals showed no evidence of axonal pathology.
The number of APP-immunoreactive profiles in the body of the CC of the r-mTBI group was 
greater than the s-mTBI group at 6  months post mTBI (s-mTBI group 1.2 ± 0.2 vs. r-mTBI 3.6 ± 
0.1 axonal profiles/body of CC p < 0.001) and 12 months post mTBI (s-mTBI group 3.3 ± 0.5 vs. r- 
mTBI 9.3 ± 0.8 axonal profiles/body of CC, p < 0.0001) (Fig.3.8l-J). Notably, the degree of axonal 
pathology increased from 6  to 12 months for both the s-mTBI (p < 0.05) and r-mTBI groups (p < 
0.001).
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Figure.3.8: Axonal injury within the corpus callosum at 6 and 12 months post mTBI. APP immunoreactive 
profiles, predominantly observed as axonal bulbs, were seen after s-mTBI and r-mTBI at both time 
points (B, D, F, H). Tissue staining from sham animals was negative for APP immunostaining. For each 
image, magnifications of the boxed insets are areas pointed by an arrow. Tissue sections were counter­
stained with hematoxylin. Quantitative analysis of APP-immunoreactive profile quantified from the 
caudal to the dorsal area of the body of the CC at 6 and 12 months post mTBI; n=5 and n=4 respectively. 
The numbers of APP-immunoreactive profiles in the body of the CC of the r-mTBI group was greater 
than the s-mTBI group at 6 months post mTBI (s-mTBI group 1.2 ± 0.2 vs. r-mTBI 3.6 ± 0.1 axonal 
profiles/body of CC p < 0.001) and 12 months post mTBI (s-mTBI group 3.3 ± 0.5 vs. r-mTBI 9.3 ± 0.8 
axonal profiles/body of CC, p < 0.0001) (I - J). Notably, the extent of axonal pathology progressively 
worsened from 6 to 12 months for both the s-mTBI (p < 0.05) and r-mTBI groups (p < 0.001). Data are 
presented as mean ± SEM, (**p < 0.005).
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3.3.6. Gial fibrillary acidic protein immunostaining:
For all groups, the cortical region underlying the impact site (somatosensory and 
primary motor cortices), the CC, and the hippocampal regions were assessed in sections stained 
for GFAP. No astrocytes with morphological appearances of reactive glia, manifest as GFAP- 
immunoreactive astrocytes with thickened cell processes and hypertrophied cell soma, were 
observed in the cortex or in hippocampal sector CA1 at 6  or 12 months following s-mTBI 
(Fig.3.8A-D) or in the single or repetitive anesthesia controls (Fig.3.9E, G), nor was any 
quantitative difference detected in area of immunopositivity in these regions. Similarly, there 
was no measurable increase in GFAP immunoreactivity at 6  months in the r-mTBI group in 
hippocampal sector CA1 (Fig.3.9G). However, increased GFAP-immunoreactivity was observed 
in this region at 12 months following r-mTBI (r-mTBI 4.2 ± 0.7% vs. r-sham 2.5 ± 0.9%; p < 0.005) 
(Fig.3.9H-J).
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Figure.3.9: GFAP immunohistochemistry of the mouse brain at approximately 0.4 mm lateral to midline 
in the CA1 subregion of the hippocampus. There were no changes between sham (A, C) and injured (B, 
D) animals at 6 months post injury. A decrease of GFAP immunoreactivity was observed at 12 months 
post injury in all groups. An increased area of GFAP immunoreactivity was observed in the r-mTBI (H) 
when compared to the r-sham (G) at 12 months post injury. Tissue sections were counter-stained with 
hematoxylin. Quantitative analysis of GFAP staining in two area of 200 pm2 areas of CA1 subregion of 
the hippocampus at 6 months (I) and 12 months (J); n=5 and n=4 respectively. Data are presented as 
mean ± SEM, (**p < 0.005).
As regards the corpus callosum, the r-mTBI group showed increased GFAP 
immunoreactivity at 6 (Fig.3.10D) and 12 months (Fig.3.10H) in the body of the corpus callosum 
when compared to their shams (Fig.3.10C-G), (6 months: r-sham 3.8 ± 0.6% vs. r-mTBI 7.95 ±
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1.2%; p < 0.01; 12 months: r-sham 6.25±0.4% vs. r-mTBI 15.4±1.9%; p < 0.0001) (Fig.3-101). Of 
note, while there was no measurable increase in GFAP immunoreactivity at 6 months in the s- 
mTBI group (Fig.3-910F), there was an increase in immunoreactivity at 12 months post injury 
compared to its sham (Fig.3-10E), (Fig.3-101; 12 months: s-sham 3.0 ± 0.4% vs. s-mTBI 6.6 ±
0.8%; p < 0.0001).
s-sham s-m TBI r-s h a m r-m T B I
I/) s'
JC■M
c
o
E
VO
„ * «.
A “
6* • *•
r * *% O' . • *• •
■ • 1 . . '* - -
' 50nm
 ^ -A, . ■ ‘ • s
B ■ '
V '  N 
* * *.*- . '  ' »
.. \ . ’ * . •. i y
» v ' \  f t' > .• ^ -;v ■
«■ ‘ ' » •• *v v ...
** aa; » i 
: ..v r:<• • r • < < .
-. S V <t .
. . 4 .
D . . . '  , v  ^  *
* , ** v*'*' ' %*.s *’ * ♦ . • *•* ’ V
 ^ \ £  - - v ; •*
;■ . *• *' f
;  v  r  ,• %
\ ' 1
~ - ** j
\  /  / - t  .V 0 m '
•> ** \ ** . • - #
4 . - 1 ** * ;*
«V • >r'\ • * \  ^ N
F  ' T.
* / * ! '  ‘ ' '  : " : 1
• ? ’ ;  T* *A. .
\  ‘ \  * ./! V  < */•• 8 * - V.* fi..•V  •.. *\V -s
G. , *j *. . . .
• *• • * .
‘ r • •• •»4 r* V.1  ^ .•«
*" 41 •
4i~ . .
* * * . v  ^ ' *-A* . . > ‘ '' •. ” ‘ ’
- . r - ' r
^  / V .
* . *2i
20
ouai
S 15
1 “
•I 10
6 months post mTBI
20
uu«
0 .5  15
<  £  u-O &
o 1 10re u <D re
12 months post mTBI
i-------------
* * *
1 i
T T
m
s-sham s-mTBI r-sham r-mTBI s-sham s-mTBI r-sham r-mTBI
Figure.3.10: GFAP immunohistochemistry of sagittal sections of the mouse brain at approximately 0.4 
mm lateral to midline in the corpus callosum. Healthy astrocytes were observed in sham animals at 
both time points (A, C, E, G). At 6 months post injury, the s-mTBI animals exhibited normal GFAP
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inmmunoreactivity (B). By 12 months post injury the s-mTBI group showed mild reactive astrogliosis 
with variable degrees of thickened cell processes and hypertrophied cell soma (F). These changes were 
observed in the r-mTBI group as early as 6 months post mTBI (D). By 12 months post injury, severe 
reactive astrogliosis with disruption of individual domains was observed in the r-mTBI group (H). Tissue 
sections were counter-stained with hematoxylin. Quantitative analysis of GFAP staining in three 100 
pm2 fields of the CC at 6 months (I) and 12 months (J); n=5 and n=4 respectively. Data are presented as 
mean ± SEM, (*p < 0.05; ***p  < 0.0001).
3.3.7. Ionized calcium binding adaptor molecule 1 immunostaining:
The pattern and distribution of activated microglia revealed that staining for lba-1 was 
similar to GFAP. For all groups, there was no appreciable evidence of microglial activation in 
the retrosplenial, sensorifrontal and motor cortex at 6 orl2  months post injury (Fig.3.11A-H). In 
the corpus callosum, the s-mTBI showed a notable increase in anti-lbal reactivity at 12 months 
(Fig.3.12F-H; s-sham 4.8 ± 0.4% vs. s-mTBI 6.8 ± 0.5%; p < 0.0001). For mice subjected to r- 
mTBI, immunostaining for lba-1 revealed a markedly increased expression at both 6 and 12 
months (Fig.3.12D-H) when compared to their sham groups (Fig.3-6C-G), (6 months: r-sham 
4.45 ± 0.6% vs. r-mTBI 11.6 ± 0.8%; p < 0.01; 12 months: r-sham 4.3 ± 0.6% vs. r-mTBI 11.9 ±
0.6%; p < 0.0001).
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Figure.3.11: Immunohistochemical labeling for microglia with lba-1. Sagittal sections of the mouse brain 
approximately 0.4 mm lateral to midline in layer lll/IV of the cortex. There was no difference in the 
expression of lba-1 with respect to the sham animals at 6 months (A-D), and 12 months (E-H) post injury. 
Tissue sections were counter-stained with hematoxylin. Quantitative analysis of lba-1 staining in four 
150 |im2fields between layer III and V of the cortex at 6 months (I) and 12 months (J); n=5 and n=4 
respectively. Data are presented as mean ± SEM, (p > 0.005).
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Figure.3.12: Immunohistochemical labeling for microglia with anti-lbal. Sagittal sections of the mouse 
brain approximately 0.4 mm lateral to midline in the corpus callosum, lba-1 immunoreactivity was two­
fold greater in the CC following r-mTBI (D) when compared to the s-mTBI (B) and three fold greater 
when compared to sham controls (A, C). At 6 months post injury, lba-1 immunoreactivity was markedly 
increased in both injured groups (F, H) at 12 months post mTBI when compared to sham animals (E, G). 
Tissue sections were counter-stained with hematoxylin. Quantitative analysis of lba-1 staining in three 
100 pm2 fields in the corpus callosum at 6 months (I) and 12 months (J); n=5 and n=4 respectively. Data 
are presented as mean ± SEM, (*p < 0.05; ***  p < 0.0001).
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3.3.8. Amyloid and tau biochemistry:
To investigate any pathological effect of TBI on tau in this model, we used our recently 
developed Low-Tau ELISAs that quantitatively assess different epitopes of tau relevant to 
various tauopathies: DA31 (total tau; amino acids 150-190), CP13 (pSer-202), RZ3 (pThr-231), 
and PHF1 (pSer-396/404), To corroborate the biochemical findings, we also carried out 
immunohistochemical analyses using CP13, RZ3, PHF1 and MCI, an antibody that recognizes 
only tau in a pathological conformation.
In all experimental groups, at both 6 and 12 months post mTBI/anesthesia, there was no 
TBI-dependent increase in cortical or hippocampal soluble total or p-tau (Fig.3.13, Fig.3.14, 
Fig.3.15, p>0.05). An age-dependent increase in soluble p-tau was observed between 6 and 12 
months in the hippocampi and cortices of all experimental groups (p<0.0001). In addition, p-tau 
was also quantitated as a ratio of phosphorylated tau protein to total tau protein. Again there 
was no injury effect on these ratios at either time points and in either brain region (cortex; 
Fig.3.14B, E, H; hippocampus; Fig.3.15B, E, H).
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Figure.3.13: DA31 (Total tau) ELISAs measuring the soluble tau level of each group at 6 and 12 months 
post mTBI/anesthesia. One way ANOVA was used to calculate significance of tau in the cortex (A) and in
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the hippocampus (B) between the four groups for each time point. Each data point indicates an 
individual animal (n=4 per group). No difference was observed between each groups; p>0.05.
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Figure.3.14: Biochemical (ELISA) and IHC assessment of different soluble p-tau species in the neocortex 
at 6 andl2 months post injury. There was no TBI-dependent increase in cortical soluble p-tau pSer-202 
(CP13), pThr-231 (RZ3) and pSer-396/404 (PHF1) at 6 or 12 months post mTBI (A, D, G) (p>0.05; one-way 
ANOVA,). An age-dependent increase for each soluble p-tau was observed between 6 and 12 months 
post mTBI in the cortices of all groups (p<0.0001; one-way ANOVA followed by Tukey's post hoc t-test). 
Each data point indicates an individual animal (B, E, H) (n=4 per group). Similar to the quantitative 
analysis of each p-tau epitopes, there was no increase of p-tau when quantitated as a ratio of p-tau 
protein to total tau protein. P-tau immunohistochemistry of mouse brain at approximately 0.5 mm 
lateral to midline in the superficial layers of the cerebral cortex (C, F, I). All experimental groups 
exhibited somatodendritic localization accumulation of CP13 and RZ3 immunoreactivity in neurons of
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the superficial layer of the cerebral cortex (C, F). No PHF1 immunoreactivity was observed in injured or 
sham animals at 6 and 12 months post injury (I). Qualitative assessment of tau immunohistochemistry 
revealed no change between sham and injured animals at 6 and 12 months post injury in all groups. 
Tissue sections were counter-stained with hematoxylin.
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Figure.3.15: Biochemical (ELISA) and IHC assessment of different soluble p-tau species in the 
hippocampus at 6 andl2 months post injury. There was no TBI-dependent increase in hippocampal 
soluble p-tau pSer-202 (CP13), pThr-231 (RZ3) and pSer-396/404 (PHF1) at 6 or 12 months post mTBI (A, 
D, G) (p>0.05; one-way ANOVA). Each data point indicates an individual animal (n=4 per group). An age- 
dependent increase in soluble p-tau was observed between 6 and 12 months post mTBI in the 
hippocampus of all groups (p<0.0001; one-way ANOVA followed by Tukey's post hoc t-test). Similar to 
the quantitative analysis of each individual p-tau epitope, there was no increase in p-tau when 
quantitated as a ratio of p-tau protein to total tau protein (B, E, H). P-tau immunohistochemistry of 
mouse brain at approximately 0.5 mm lateral to midline in the CA1 region of the hippocampus. All
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experimental groups exhibited somatodendritic accumulation of CP13 and RZ3 immunoreactivity in the 
pyramidal cell layer of the hippocampus (C, F, I). There were no change between sham and injured 
animals at 6 and 12 months post injury in all groups. Tissue sections were counter-stained with 
hematoxylin.
Immunohistochemical analyses revealed no injury effects in the localization or 
accumulation for the p-tau epitopes CP13 and RZ3. All experimental groups exhibited 
somatodendritic accumulation of CP13 and RZ3 immunoreactivity in neurons of the superficial 
layer of the cerebral cortex (Fig.3.14C, F, I), CA1 (Fig.3.15C, F, I). The same brain regions were 
devoid of PHF1 (Fig.3.14,151) and M CI (Fig.3.16) positive neurons regardless of the injury 
status.
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Fig.3.16: MCl-positive cells, an early pathological tau conformation produced by the 
intramolecular association between the extreme N-terminus and the third microtubule repeat domain 
of tau observed in positive control (top right corner inset) were not detected in both the neocortex and 
the hippocampus at 6 and 12 months post injury/anesthesia in all groups; n=5 and n=4 respectively. 
Tissue sections were counter-stained with hematoxylin.
109
ELISA analysis o f soluble m urine A(340 showed no TBI or age-dependent increases
(Fig.3.17A, C). A(3 deposition w ith 4G8 (Fig.3.17B, D) was not detected in the cerebral cortex or 
in the hippocampus of any group at 6 and 12 months post injury.
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Figure.3.17: Quantification (ELISAs) of soluble A340 and its associated IHC staining in the cortex and 
hippocampus at 6 andl2 months post injury. Analysis of soluble murine Ap40 showed no TBI or age- 
dependent increases (A, C). A3 deposition with 4G8 was not detected in the cerebral cortex and 
hippocampus in any group at 6 and 12 months post injury (B, D). Top right inset represent a positive 
control animal for 4G8.
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3.4. Discussion:
With this extension of our original work on the acute phase characteristics of single and 
r-mTBI in our mouse model (Chapter 2) we have now demonstrated that there are measurable 
behavioral and neuropathological consequences which persist and evolve for some 
considerable time after injury, particularly following repetitive injury. This is manifest as 
continued and developing behavioral deficits up to 18 months following injury and as evolving 
neuropathological changes up to 12 months from the initial injury, characterized by persistent 
neuroinflammation associated with ongoing white matter degradation independent of A(340 or 
tau accumulation. Importantly, the findings provide evidence that our mouse model 
recapitulates many aspects of TBI described in human studies4'9'10,18'33,34.
The neurobehavioral analyses were carried out in the same cohort of mice that were 
previously evaluated at an acute (24 h) time point after injury (Chapter 2) in which both s-mTBI 
and r-mTBI injury resulted in cognitive deficits. From the current data we demonstrate that for 
the probe trial (cognitive performance) the single injury animals have recovered to the same 
level of performance as their sham animals by 6 months post injury, remaining at comparable 
levels at subsequent 12 and 18 month evaluations. These findings are consistent with 
observations in the human population in which those suffering from mild head injury often 
return to their pre-concussive status within one week35'37. In contrast, following repetitive 
injury, where animals are subjected to a total of 5 mild TBI with an inter-concussion interval of 
48 h, the acute cognitive deficit persisted at six months and, indeed, continued to evolve 
through the 12 and 18 month time points. Altogether, these data provide evidence that 
cognitive impairments following a single mTBI may be transient, while cognitive deficits
1 1 1
following repetitive injury not only persist but continue to evolve up to 18 months after injury. 
Moreover, with regard to repetitive injury, Guskiewicz and colleagues5 suggest that the effects 
of a concussion far outlast the acute phase. Indeed, the prevalence of mild cognitive 
impairment and significant memory problems is 5-times greater in former athletes who 
suffered multiple concussions compared with retirees without a history of concussion5.
At all-time points examined, the behavioral performance of repetitively-injured animals 
was diminished when compared to the other groups. The main difference between both injury 
groups at 18 months was in the average distance travelled to reach the target hole. Animals 
from the r-mTBI group were unable to learn and were continually distant from the target, 
reinforcing the fact that repetitive insults worsen cognitive performance at chronic time points 
post injury. Overall, these results are consistent with observations in human patients, where 
residual impairments in learning strategy and/or a lack of executive function have also been 
reported post injury38'40.
Interestingly, in the elevated plus maze, there was a trend for the injured mice to spend 
more time in the open arm than the sham controls, demonstrating a mild behavioral 
disinhibition. This trend is also consistent with human studies where disinhibition has been 
reported as a consequence of mTBI10,41'43.
Accompanying these neurobehavioral deficits, we observed comparable concordant 
neuropathologies in the various injury models. In particular, the single injury animals displayed 
evident pathology, manifest as a degree of neuroinflammation and white matter loss (corpus 
callosum thinning), which peaked at six months and remained static at the 12 month 
evaluation. This suggests that the pathological disturbance following a single mTBI may be
1 1 2
transient in nature, potentially due to the action of intrinsic mechanisms that restore axonal 
membrane and reorganize the fiber tracts. Indeed, activated microglia can promote neural 
plasticity44'46 and repair47. Similar to microglia, activated astrocytes have also been involved in 
facilitating repair48 in the mature brain via the release of neurotrophic factors49 such as brain- 
derived neurotrophic factor (BDNF). In contrast, not only did the repetitively injured mice show 
greater pathological changes at all-time points when compared to the single injury animals, 
there was also evidence of a continued progression of neuropathology up to 12 months post 
injury. White matter degradation appeared to continue some considerable months from the 
original injuries, with evidence of further callosal thinning between 6 and 12 months 
corresponding to evidence of ongoing axonal degradation manifest as APP-immunoreactive 
axonal profiles. The sequence of these chronic changes remain unclear, however, secondary 
mechanisms initiated after trauma such as chronic microglial activation and reactive astrogliosis 
may contribute to the ongoing axonal pathology and eventually lead to the progressive loss of 
axons following r-mTBI. Post-traumatic neuroinflammatory responses possess both beneficial 
and detrimental effects, and these likely differ in the acute and delayed phases after mTBI45,50.
Imaging studies have demonstrated white matter integrity is correlated with executive 
function, attention and memory34,51'53. Given that the most significant pathological changes 
were observed in the corpus callosum rather than the hippocampus, it appears likely that the 
white matter pathology is responsible for the neurobehavioral deficits. Behavioral performance 
depends on a broad array of circuits/brain systems including afferent (sensory) pathways, and 
sensorimotor integration in which the corpus callosum is involved. The pattern of white matter 
injury could very well be the underlying cause of these widespread deficits, although it is
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impossible to ascertain the specificity of any particular lesion/mechanism to any one deficit.
For example, a multitude of diverse secondary injury mechanisms could cause the neurological 
deficits observed months to years after r-mTBI. Among these, oxidative stress54, lipid 
peroxidation54, mitochondrial dysfunction54, cytoskeletal degradation55'57, depolarization and 
disturbances of ionic homeostasis58 have long been implicated in the pathophysiology of TBI. 
These events release toxic and pro-inflammatory chemokines, cytokines, prostaglandins and 
oxidative metabolites which in turn could contribute to the ongoing neuroinflammation. Of 
note, the crosstalk between proinflammatory cytokines and glutamates receptors, a process 
defined as "immunoexcitotoxicity" may also play a central role in the prolonged progression of 
neurodegenerative changes after r-mTBI22. This correlates with the impairments in strategy 
learning which are frequently observed in human subjects in the absence of overt lesions in 
grey matter following TBI59'61.
The results of this study also support the contention that r-mTBI may also prevent 
normal microglial switching from an activated to resting state, which was specific to the 
subcortical white matter regions, particularly the corpus callosum. As time elapses post injury, 
our results indicate that the level on inflammation observed at acute time point post injury 
remains elevated in corpus callosum while it recovered in the cortical grey matter.
Although inflammation is a consistent pathological feature in our model, there may be 
other pathologies that contribute to the observed cognitive deficits, such as dendritic62,63 
and/or synaptic loss63,64. As such, additional biochemical, electrophysiological and pathological 
examinations are warranted.
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The chronic inflammation we observe is in line with autopsy reports from former 
athletes with history of r- mTBI10,13,14. Given the proposed pathophysiological role for chronic 
neuroinflammation in neurodegenerative disease23, our data suggest that the progressive 
neuroinflammation in the r-mTBI model may be a key contributor to the neurobehavioral 
deficits. Our data also suggest that the cognitive deficits observed occurred independently of 
AP4 0 or tau accumulation. Recently, Mannix and colleagues used a weight drop model to 
deliver r-mTBI to wild type mice and to APOE transgenic mice expressing the human E4 allele 
(which confers risk for development of Alzheimer's disease, and also risk of poor outcome after 
TBI). They reported no change in tau phosphorylation and A(340 accumulation at 6  months post 
injury28. Consistent with that study, we observed no evidence for involvement of tau or 
amyloid beta pathology in this model at the 6  and 12 month timepoints. Use of genetically 
modified animals, expressing human forms of these proteins, may be necessary in order to 
mimic these pathological features, but in our wild type mouse model these results further 
underscore the significance of the neuroinflammatory processes as contributory toward the 
neurobehavioral dysfunction we observe.
Despite the limitations when translating from laboratory TBI models to human 
populations25,65, in this model we describe components that are clinically relevant. The white 
matter degradation, axonal injury and neuroinflammation we observed in the corpus callosum 
in our injury groups at 6  and 1 2  months post injury are now recognized to be important aspects 
of human long term TBI sequelae, observed after both repetitive mTBI4 '6 ,10 ' 34 and single 
moderate to severe injury66"69. This may suggest that the neurodegenerative consequences of a
115
single moderate to severe injury and of r-mTBI are on the same spectrum, with a phenotype 
influenced by severity and frequency of TBI, but this has yet to be demonstrated.
The acute cognitive deficits and accompanying neuropathology reported in Chapter 2 
are thus demonstrated to persist and progress at extended time points in repetitively injured 
mice. Our demonstration of cognitive deficits at 18 months post injury, and progressive 
neuropathological changes at 12 months post injury, emphasize the relevance of our model for 
translational studies to elucidate the pathophysiology of these TBI-associated neurobehavioral 
and neuropathological changes. Together these acute and chronic evaluations support our 
contention that this model is a relevant preclinical model for human mTBI, and will serve as a 
valuable tool with which to explore TBI sequelae at the molecular level which in turn should 
identify therapeutic targets. For example, since glial activation endure over time, it seems that 
controlling it could be beneficial and may lead to behavioral improvements. Moreover, as 
originally intended, the development of this mTBI paradigm in a mouse model facilitates the 
investigation of the role of genes and proteins known or hypothesized to be of significance in 
human TBI; the influence of one such protein "tau" is investigated in the work described in the 
following Chapter.
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Chapter 4
4. Exploration of the effects of single and repetitive mTBI on tau phosphorylation in hTau 
transgenic animals
4.1. Introduction:
With TBI affecting approximately 20% of the 2.3 million deployed U.S. military personnel1 
and the unprecedented wave of suicide and death among NFL players has drawn public concern 
on mTBI. The constant media focus on veterans and athletes struggling with the consequences 
of TBI has raised concerns among parents as to their children's safety if they participate in high- 
TBI-risk sports such as American football or ice hockey. The potential medical consequences of 
r-mTBI have been known for some time, but were previously restricted mostly to the aftermath 
of boxing, and the neurobehavioral disorder termed "dementia pugilistica"2. Recently, this term 
was replaced by chronic traumatic encephalopathy (CTE) to describe the negative pathological 
sequelae resulting from a wider range of exposure situations3,4 (football, wrestling, hockey, and 
rugby). CTE is a progressive neurodegeneration characterized by prominent neuropsychiatric 
features and a neuropathological profile that includes: brain atrophy, cavum septum 
pellucidum, amyloid-(3, TDP-43 and a widespread evidence for hyperphosphorylated tau (p-tau) 
and neurofibrillary tangles5 (Fig.4.1).
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Figure.4.1: Gross pathology of chronic traumatic encephalopathy.
Left Panel: The coronal section of normal brain (top left), showing the expected size and relationship of 
the cerebral cortex and ventricles. The brain from a retired professional football player (bottom left), 
showing the characteristic gross pathology of CTE with severe dilatation of ventricles II (1) and III (2), 
cavum septum pellucidum (3), marked atrophy of the medial temporal lobe structures (4), and shrinkage 
of the mammillary bodies (5).Microscopic pathology of chronic traumatic encephalopathy.
Right Panel: (Top) Phosphorylated tau (AT8) immunostained coronal hemisections of a normal brain 
(left) and a brain from a retired professional football player with CTE (right). The brain with CTE, showing 
severe neurofibrillary degeneration of the amygdala (a), entorhinal cortex (ec), temporal cortex, insular 
cortex (ins), nucleus basalis of Meynert (nbM), and frontal cortex. The cortical changes are most severe 
at the depths of the sulci. Right Panels (Bottom): (C) Tau neurofibrillary tangles (NFT) are often 
prominent at depths of the sulci (AT8 immunostain, original magnification 60). (D) Subpial tau 
immunoreactive tangles are found in both neurons and astrocytes (double immunostained section for 
GFAP [red] and AT8 [brown], showing colocalization of tau and GFAP; original magnification 350). (E) 
Extremely dense NFTs are found in the medial temporal lobe structures, including CA1 of the 
hippocampus, shown here. Senile plaques are absent (AT8 immunostain, original magnification 150). (F) 
NFTs and astrocytic tangles tend to be centered around small blood vessels and in subpial patches (AT8 
immunostain, original magnification 150). (G) NFTs characteristically involve cortical layers II and III (AT8 
immunostain, original magnification 150). (H) NFT in a Betz cell of primary motor cortex (AT8 
immunostain, original magnification 350). (I) Perivascular tau immunoreactive NFTs are a characteristic 
feature of CTE (original magnification 150). Reprinted from PM&R, Volume 3, Issue 10, Supplement 2,
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Robert A. Stern, David 0. Riley, Daniel H. Daneshvar, Christopher J. Nowinski, Robert C. Cantu, Ann C. 
McKee, Long-term consequences of repetitive brain trauma: chronic traumatic encephalopathy, Pages 
No. S460-S467, Copyright 2011, with permission from Elsevier.
Recent autopsy reports reveal similar pathologies found years after single blast injury1 
and in a few cases at acute time points post r-mTBI5,6. CTE can only be definitively diagnosed 
post-mortem, and because the symptoms begin insidiously and are clinically confounded with 
other neurodegenerative diseases with aging, the incidence of CTE is likely underestimated. 
Because the pathological presentation of CTE depicts abnormal accumulation of tau protein, 
this illness has been classified as a tauopathy1,4,5,7. Tauopathies are characterized by tau 
aberrations: abnormal and hyperphosphorylation8, misfolding6, and aggregation9. The best 
known tauopathy is Alzheimer disease, others include progressive supranuclear palsy, Pick's 
Disease, frontotemporal dementia and Parkinsonism linked to chromosome 17 (human location 
of the tau gene), among others10.
To study the specific contribution of tau pathology to the pathogenesis of CTE, we used our 
head injury model to compare and characterize the consequences of single and r-mTBI in 
genetically modified mice that express the 6 human tau isoforms. Tau has already being 
extensively characterized owing to its critical involvement in AD and other neurodegenerative 
disorders10'12. We do not know to what extent the pathobiology of tau in TBI may relate to the 
pathobiology of tau in AD or other tauopathies, but we assume that it will derive from a 
disruption of normal tau function so a brief overview of tau biology is outlined below.
In this chapter we will test the following hypotheses:
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1. Single or r-mTBI is associated with an acute increase of A(3 deposition and p-tau 
accumulation in hTau transgenic animals.
2. The increase of p-tau and A(3 deposition is associated with worse behavioral 
performance compared to the wild type animals.
To this end, we will use our previously characterized CHI model and repeat the same 
experimental procedures including behavioral, pathological, and biochemical analyses in hTau 
transgenic mice.
4.1.1. Tau Background:
The microtubule-associated protein tau (MAPT) was identified as a microtubule- 
assembly factor in 1975 in Marc Kirschner's laboratory13. Tau proteins are expressed in the 
peripheral and central nervous system (CNS) but are also present at a lower level in kidney, lung 
and testis14. In the CNS, Tau proteins are mostly found in the distal portions of axons where 
they provide stability and flexibility to the microtubule15. Tau also plays a physiological role in 
dendritic function in postsynaptic targeting of the Src kinase Fyn in dendrites16 and by 
promoting morphological differentiation of oligodendrocytes17. Tau has also been shown to 
have a role in axonal transport18'20, to be an enzyme inhibitor21,22 and to bind to mitochondria 
leading to cell death23.
4.1.2. Tau isoforms in humans:
In the human CNS a total of 6 Tau isoforms are produced by alternative mRNA splicing
of the MAPT gene on chromosome 17q21.319 (Fig.4.1). These isoforms are named according to
whether 3 or 4 microtubule binding repeat (MTBs) sequences are expressed and by the
presence or absence of two exons at the N-Terminus (termed N) (Fig.4.2). The exclusion of exon
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10 leads to the production of tau isoform with three repeats (3R), and its inclusion leads to tau
isoforms with four repeats (4R). Tau isoforms can include no N-terminal exons (ON), tau exon 2 
(IN), or tau exons 2 and 3 (2N), resulting in six human tau isoforms as represented in Figure 4.1. 
Alternative mRNA splicing of MAPT is similar across brain regions and equal amounts of 3R and 
4R tau are found in the cortex of healthy adults24. Expression of these isoforms is 
developmentally regulated, the shortest isoform (3R0N) is highly expressed in the brain during 
development and rapidly decreases after birth25.
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Figure.4.2: Structural domains of the 6 tau isoforms (amino acids 352-441) expressed in the adult 
human brain after alternative mRNA splicing of Exon 2 (dark blue), Exon 3 (light blue) and Exon 10 (light 
grey)26. The isoforms can differ from each other in the number of microtubule bindings domains (MTBs) 
(three or four repeats located in the C-terminal), and are referred to as 3R or 4R tau isoforms, 
respectively. Each repeat is 31 or 32 amino acids in length. They can also differ in the presence or 
absence of either one or two 29 amino acid long, highly acidic inserts (shown in blue) at the N-terminal
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portion of the protein (the projection domain). Between the projection domain and the MTBs lies a 
basic proline-rich region (shown in red). The exons and introns are not drawn to scale.
4.1.3. Tau isoforms in animal models:
Since various animal models have been established to investigate the physiological role 
of tau, it is important to consider the differences between the adult profiles of tau isoforms in 
both humans and animals. To date, in all vertebrates examined, tau is produced by similar 
developmentally regulated alternative mRNA splicing, but the number of expressed tau 
isoforms in adult brain varies between species. In contrast with humans, most adult wild type 
rodents almost exclusively express isoforms with four repeats (Fig.4.3). In the rat, the protein 
expression of 4R isoforms is ninefold higher than 3R isoforms27, and mice also express 
predominantly 4R isoforms28. Goedert and colleagues showed that isoforms with up to 5 MTBs 
repeats are expressed in the brains of adult chickens29. Invertebrates such as Caenorhabditis 
elegans and Drosophila melanogaster are also well established model organisms that have been 
used successfully to explore many aspects of human neurodegenerative diseases, including 
tauopathies30'32. However, unless genetically altered, their genomes each encode only one tau 
isoform32'34. The species divergences and the complex nature of tau regulation in normal brains 
and in brains exhibiting tauopathy makes modeling of tau pathogenesis difficult.
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Figure.4.3: Relative distribution of 3R and 4R tau isoforms in adult human, mouse and rat brain. In 
healthy adult human brain, the ratio of expression level of 4R to 3R is approximately 1. While all 6 
human isoforms are produced in the hTau transgenic mouse, only 20% of the total Tau is 4R (80% are 
3R; 2:8). In the wild-type mouse, tau exists almost exclusively in the 4R form, while isoforms in the adult 
rat consist of a 4R:3R ratio of approximately 9:1.
4.1.4. Tau structure:
From a structural standpoint, tau can be subdivided into three regions (Fig.4.2). The N- 
terminal domain is associated with the cell membrane and regulates the spacing between the 
microtubules35'37. Between the C and N-terminal domain, a basic proline-rich region includes 
many phosphorylation sites26'37. The C-terminal region contains the positively-charged 
microtubule domains that interact with the negatively-charged microtubule38'39. The ability of 
tau to bind to the microtubule depends on the MTBs, with 4 MTBs isoforms demonstrating 
greater microtubule stabilization than isoforms with three repeat domains40. Interestingly, the 
region between repeats 1 and 2 is unique to 4R tau and is responsible for a 40-fold difference in 
the binding affinities between 3R and 4R tau41,42.
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4.1.5. Tau Phosphorylation and Tauopathies:
In many cases, tau phosphorylation under physiological conditions regulates the binding 
of tau to microtubules, or to other structures such as the membrane43 or the actin 
cytoskeleton44. In tauopathies such as AD, Pick's disease, progressive supranuclear palsy (PSP), 
and CTE, tau is hyperphosphorylated and, as a result, is unable to interact with 
microtubules10'45'48 (Fig.4.4). The microtubule (MT) binding ability of tau is regulated primarily 
by serine/threonine-directed phosphorylation, which can effectively modulate the binding 
affinity of tau for MTs, although other post translational modifications such as glycosylation, 
ubiquitinylation, deamidation, oxidation, and nitration have been described48. The 
hyperphosphorylation of tau is the most studied modification and seems to be an early and 
crucial event to precede filament assembly. Other causes of abnormal disengagement of tau 
from the MTs include imbalance in the activity levels or regulation of tau kinases and 
phosphatases, and mutation of the MAPT gene that directly affect the MTB domain10,49 (e.g. 
inclusion or exclusion of exon 10). Under these pathological conditions, the equilibrium of tau 
binding to the MTs is perturbed, which results in an increase in the levels of unbound tau. 
Abnormally phosphorylated tau protein becomes dissociated from neuronal microtubules and 
accumulates and aggregates in an insoluble form. These aggregates are made of 
hyperphosphorylated tau and are also referred to as paired helical filaments (PHFs). These 
PHFs will form elongated inclusions or eventually develop in neurofibrillary tangles (NFTs). 
Similar to AD, CTE can be classified in phases defined by Braak staging. Braak stages I and II are 
used when NFTs are confined mainly to the transentorhinal region of the brain, stages III and IV 
indicate involvement of limbic regions such as the hippocampus, and stages V and VI are when
there is extensive neocortical involvement50. Mutations in the tau gene, which give rise to 
frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), alter the 
proportion of tau isoforms or the ability of tau to bind microtubules and to promote 
microtubule assembly51,52. Although phosphorylation of tau is a major early characteristic of 
tau aggregation, dysregulation of the MAPT gene splicing is enough to cause 
neurodegeneration by altering the tau isoform ratio12. For example, all six tau isoforms are 
usually present in equimolar concentration in AD patients, whereas a shift toward an increase 
of 4R isoforms is observed in patients with PSP or argyrophilic grain dementia (AGD). In 
contrast, a shift toward an increase of 3R is associated with Pick's disease. Together these 
apparent differences in tau pathogenic mechanisms in different diseases underscore the 
significance of tau homeostasis and the complexity of tau pathogenesis. Interestingly Tau 
hyperphosphorylation may not necessarily always be detrimental as the process happens 
reversibly in state of hibernation53, hypothermia54 and during the period of development55.
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Figure.4.4: Intracellular neuronal aggregates in tauopathies. Microtubules are strong cylindrical 
polymers composed of a- and (3-tubulin that provide structural support to neurons (A). Phosphorylation 
(by kinases such as GSK3-(3; CDK5 and ERK2) at a number of serine/threonine sites flanking the 
microtubule-binding repeats, as well as sites in the repeat region, attenuates tau binding, which results 
in destabilization of microtubules (B). Abnormally phosphorylated tau protein becomes dissociated from 
neuronal microtubules and accumulates as PHFs (C). Proteolytic processing leads to the formation of tau 
oligomers and NFTs (D). Tau in these aggregates is heavily phosphorylated at several sites and 
crosslinked by disulphide bonds. The decrease in the association of tau with microtubules and other 
physiologically relevant proteins, together with the formation of PHFs, is thought to contribute to 
neuronal dysfunction and eventually cell death. Modified by permission from Macmillan Publishers Ltd: 
Nature Reviews, Mazanets M.P, Fisher P.M. "Untangling tau hyperphosphorylation in drug design for 
neurodegenerative diseases".6(6):464, copyright 2007.
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4.1.6. Tau and TBI:
Since traumatic brain injury has long been recognized as risk factor for later 
development of neurodegenerative disease56,57, numerous studies have sought to uncover the 
association between these events5,58'67. Although the epidemiological data are quite strong, 
very little is known about the mechanistic link between repeated mTBI and the development of 
either AD or CTE, and there are no published experimental models showing that multiple 
episodes of TBI induce specific neurodegenerative conditions. Although recently some research 
groups have produced animal models of mTBI1,61,68'71, studies on repetitive mTBI in laboratory 
models are few61'65-66'68'7^  anc| studies of chronic time points after single or repetitive mTBI are 
lacking altogether. Only two studies have reported tau involvement in an mTBI model1,68. In 
these studies, an increased amount of p-tau without evidence of tau aggregates was found in 
brain homogenates of wild-type (WT) mice after 14 days post single blast injury1, or 30 days 
post repetitive mTBI68 but not at 6 months post mTBI61. As the hallmark AD pathological 
features of amyloid plaques and NFTs have been reported in TBI patients, the use of transgenic 
models of AD and mutated tau have been proposed to investigate TBI pathogenesis. In this 
regard, Brody and colleagues showed that AD (3xTg-AD) and mutated Tau (P301L) mouse 
models demonstrate an acute increase in tau immunoreactivity and tau phosphorylation up to 
2 weeks after controlled cortical impact (CCI) injury64. However, the caveats of these models 
are that tau mutations are very rare in the general population, tau is not present at 
physiological levels in the mutant mice (p301L) and the models investigated thus far (e.g. WT, 
Tg44, p301L) do not express each human tau isoform. Consequently, we hypothesized that 
none of these models could adequately model the human response to TBI. Therefore for our
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investigation of the role of tau in TBI pathogenesis following our novel mTBI paradigm we 
decided to use hTau transgenic mice, which expresses 6 isoforms of human non-mutated tau on 
a null murine tau background72,73.
4.2. Materials and Methods:
4.2.1. Animals:
Male mice expressing human tau (hTau) on a C57BL/6 and null murine tau background72,73 
(aged 10-12 weeks, 20-24g, Jackson Laboratories, Bar Harbor ME) were housed singly under 
standard laboratory conditions (23°C ± 1°C, 50 ± 5% humidity, and 12-hour light/dark cycle) 
with free access to food and water throughout the study. These hTau mice were generated by 
crossing mice that express a tau transgene derived from a human PAC, H I haplotype, known as 
8c mice74, with tau knockout (KO) mice in which cDNAforthe enhanced green fluorescent 
protein (EGFP) was inserted into exon one of tau. The resulting hTau mice express all 6 human 
tau isoforms, but do not express mouse tau72. Of note, the physiological tau isoform ratio 
(3R/4R) in the hTau mice is not 1:1 as in human, rather it is 4:1 (Peter Davies, pers. comm.) but 
they are still closer to mimicking physiological occurrence of human tau than wild type mice 
(see Figure 4.3) or other tau transgenic models which express single isoforms of either mutated 
or wild type tau75. All procedures were carried out under Institutional Animal Care and Use 
Committee approval and in accordance with the National Institute of Health Guide for the Care 
and Use of Laboratory Animals.
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4.2.2. Injury groups and schedule:
For the behavioral analyses a total of 36 mice were randomly assigned to one of four 
treatment groups as described in Chapter 2, single injury, single sham, repetitive injury, 
repetitive sham. The behavior analysis began 24 h after the sole/last mTBI/anesthesia for each 
group. Behavior outcomes were assessed blinded to group assignment. In this study, less 
animals were assigned for each group than with the wild type studies (n=9/group as compared 
to 12/group for wild type mice) as we encountered difficulty in breeding these animals. On 
discussion with our colleagues and collaborators in the field, including the original creator of 
this mouse, Dr. Peter Davies, we find that this is a common problem. The breeding 
performance was mostly affected by a high rate of cannibalism by the mothers. Most of the 
litters comprised only 1 or 2 animals, and as we only used male transgenic animals it was very 
hard to generate groups of 6 to 12 animals with the matching ages for behavioral studies.
Following the acute time point of behavioral analyses, this cohort of mice was then allowed 
to survive for analyses at a later time point (see Chapter 5). Separately from this behavioral 
cohort, two other cohorts of hTau animals were assigned for pathological (n=12) and 
biochemical (n=12) examination. As before, the animals were randomly assigned to one of the 4 
treatment groups, with 3 mice per group for pathology and 3 mice per group for biochemistry. 
All mice for pathological and biochemical analyses were euthanized at 24 h post sole/last 
mTBI/anesthesia.
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4.2.3. Injury protocol:
The mTBI was administered to mice as previously described in Chapter 2. Mice were 
anesthetized with 1.5 L/min of oxygen and 3% isoflurane prior to anesthesia or mTBI. A 5 mm 
blunt metal impactor tip was retracted and positioned midway relative to the sagittal suture 
before each impact. The injury was triggered using the myNeuroLab controller at a strike 
velocity of 5m/s, strike depth of 1.0 mm, and dwell time of 200 ms. Sham injured animals 
underwent the same procedures and were exposed to anesthesia for the same length of time 
as the mTBI animals.
4.2.4. Assessment of motor function:
Assessment of motor function was evaluated by monitoring the time a mouse could remain 
on an accelerating rod using the rotarod apparatus (Ugo Basile, Varese, Italy) in the same 
manner we described previously in Chapter 2.
4.2.5. Assessment of Cognitive Function:
Learning and memory were evaluated by monitoring the distance and time taken to find an 
escape hole over a period of 6 training days (learning) and a final probe trial (memory) the 
same manner we described in Chapter 2.
4.2.6. Histology:
At 24 h after their last injury/anesthesia the mice assigned to histological studies were
anesthetized with isoflurane and perfused transcardially with phosphate-buffered saline (PBS),
pH 7.4 followed by PBS containing 4%  paraformaldehyde. After perfusion, the brains were post
fixed in a solution of 4% paraformaldehyde at 4°C for 48 h. The intact brains were then blocked
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and processed as previously described Chapter 2. Immunohistochemistry for GFAP, Ibal and 
APP was carried out as described in Chapter 2. Each slide was visualized with a bright field 
microscope (BX60), and digital images were visualized and acquired using an Olympus 
MagnaFire SP camera.
For Tau immunohistochemistry sections were stained with the following monoclonal 
antibodies at a 1:400 dilution: CP1373'76 [pS202]; PHF177'78 [pS396/404]; RZ379 [pT231] 
(Fig.4.5A). M CI is a conformation dependent antibody that reacts with both the N terminus 
(amino acids 7-9), and an amino acid sequence of tau in the third MTB (amino acids 313-322) 
that is necessary for in vitro formation of filamentous aggregates of tau similar to those seen in 
AD80 (Fig.4.5B). These Tau antibodies and protocols were generously provided by Dr. Peter 
Davies, The Feinstein Institute for Medical Research, Bronx, NY. A summary of antibodies used 
for these neuropathological analyses is showed in table 4.1.
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Figure.4.5: Tau phosphorylation sites for the antibodies used in this study (A)38.These phosphorylation 
sites are found both in normal brain and AD brains. MCI recognizes a very specific early pathological
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tau conformation produced by the intramolecular association between the extreme N-terminus (aa7-9) 
and the third microtubule repeat domain (aal313-322) of tau (B).
For terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, the 
in situ cell death detection kit (Roche Diagnostics, Indianapolis, IN) was used following the 
manufacturer's guidelines. Labeling was performed with DAB as the chromogen. To avoid bias, 
positive and negative controls were included to show nonspecific binding/reaction.
Protein Target Antibody Epitope Type Source
Amyloid Precursor Protein 22C11 aa66-81 Mouse mAb Millipore
Glial Fibrillary Acidic Protein GFAP GFAP Polyclonal Rabbit Dako
; Anti lba-1 lba-1 lba-1 Polyclonal Goat Abeam
Phospho-Tau CP-13 pS202/Pt205 Mouse mAb Dr. P. Davies
Phospho-Tau MC-1 C&NTerm i Mouse mAb Dr. P. Davies
Phospho-Tau PHF-1 pS396/404 Mouse mAb Dr. P. Davies
! Phospho-Tau RZ3 pT231 Mouse mAb Dr. P. Davies
Table.4.1: Summary of antibodies used in chapter 4.
4.2.7. Immunohistochemical quantification:
Immunoreactivity for cell markers was measured by quantitative optical segmentation as 
previously described in Chapter 2. Immunoreactivity for each cell marker was assessed within 
the superficial layer of the cortex, in the CA1 sub region of the hippocampus, and in the corpus 
callosum. For each animal, (n=3/group), sagittal sections were stained and analyzed blinded to 
the study grouping using ImageJ software (US National Institutes of Health, Bethesda, MD,
USA). Changes in CP13 and RZ3 immunoreactivity was calculated and expressed as a percentage 
of the field of view within the pyramidal cell layer of the CA1 and CA3 sub-regions of the 
hippocampus.
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4.2.8. Biochemical assessment of phosphorylated and total tau protein:
Mice were exsanguinated via aortic puncture using a wide-bore needle to prevent 
hemolysis of red blood cells. Immediately after cardiac puncture, mouse brains were perfused 
with chilled IX  PBS for 1 min to eliminate the confounding effects of blood proteins present in 
the brain vasculature. Brains were dissected at 4°C into hemispheres, then cortices, hippocampi 
and cerebella, and then snap frozen in liquid nitrogen.
Phosphorylated tau and total tau protein were analyzed in the hemisected hippocampi and 
cortices obtained from all groups (n=3/group). Snap-frozen hemisected cortices and 
hippocampi were sonicated in 0.5 ml and 0.3 ml of chilled M-PER buffer solution (Thermo Fisher 
Scientific, Waltham, MA) supplemented with protease inhibitor cocktail (Roche, Indianapolis,
IN). Biochemical analyses were carried out by our collaborators at the Feinstein Institute for 
Medical Research, Bronx, NY, to whom we sent coded tissue homogenates for quantitative 
assessments. Sample preparation for low-tau sandwich ELISA and quantitation of murine- 
specific tau protein was performed as previously described81. Total tau DA31, CP13, PHF1 and 
RZ3 were used as capture antibodies in the low-tau, Sandwich ELISA as described in Chapter 3. 
Data were expressed as pg tau/mg protein (tau and phosphorylated tau).
4.2.9. Statistics:
Behavioral data were analyzed using JMP 8.0 (SAS, Cary, NC) as previously detailed in
Chapter 2. Quantitative histologic parameters were analyzed with one-way ANOVA, with a
Tukey's post-hoc correction for multiple comparisons, unless indicated. ELISA data were
plotted and analyzed using Graph-Pad Prism (Prism 6.01, GraphPad Software Inc. La Jolla, CA).
One way ANOVA followed by Tukey's post-hoc test was used for comparison of soluble tau and
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A(34o levels between the four groups. Only p values < 0.05 were considered to be statistically 
significant and are indicated by an asterisk in the figures. Error bars represent the standard 
error of the mean (SEM).
4.3. Results:
4.3.1. Barnes maze : acquisition:
Acute acquisition deficits were only observed in the repetitively injured group relative to 
their sham controls (r-mTBI vs. r-sham, p < 0.05 repeated-measures ANOVA) (Fig.4.6A). The 
mean distance travelled over the 6 days acquisition period in the r-mTBI mice was 24% longer 
than the r-sham mice. There was no difference between the s-mTBI, s-sham and r-sham groups 
at any time point (p > 0.05 repeated-measures ANOVA).
The dataset for latency to escape was not normally distributed and thus did not satisfy 
the assumptions required for a repeated-measure ANOVA. The Wilcoxon signed rank test was 
used to test for the daily correlation between each group. No difference in escape latency 
performance was observed across all groups (p > 0.05) (Fig.4-6B). The average velocity was 
similar across all groups and all time points with a trend for the r-mTBI to be faster than the 
three other groups (p > 0.05; Fig.4.6C).
4.3.2. Barnes maze: probe:
The probe trial analyses determined the average time to reach either one of the three
holes of the target zone, (defined by the target escape hole and its adjacent north and south
holes). The analyses revealed that the r-mTBI mice performed the worst, requiring on average
21 sec to reach the target zone, followed by the r-sham (15 sec), the s-mTBI (12 sec), and the s-
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sham (9 sec) (Fig.4.6D). While there was a trend for both injured groups to perform worse than 
their respective sham groups, the time to reach the target or adjacent holes did not reach 
statistical significance (p > 0.05 for both injury groups; ANOVA). The mean velocity for the 
probe trial was similar across all groups (p > 0.05).
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Figure. 4.6: Evaluation of learning (acquisition) 
and spatial memory retention (probe) using the 
Barnes maze on days 8-14 after sole/ last mTBI. 
Mice were tested in the Barnes maze for their 
ability to locate a black box beneath the target 
hole. During the acquisition testing, the r-mTBI 
group traveled a greater distance before 
escaping to the target hole compared with their 
respective anesthesia controls,(*r-mTBI, p < 
0.05; r-mTBI) (A). The mean time to escape to 
the target hole (B) and the mean velocity (C) for 
acquisition phase was similar across all groups. 
For the probe trial (1 day following the 6 days of 
acquisition testing), the target box was removed 
and mice were placed in the middle of the table 
for a single, 60 sec trial. There was a trend for 
both mTBI groups to take longer to reach the 
target zone when compared to their respective 
control group (p > 0.05) (D). Data are presented 
as mean ± SEM.
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4.3.3. Rotarod:
Motor function was evaluated 24 h following the sole/last mTBI/ anesthesia. Overall, all 
animals exhibited increased rotarod performance when compared to their last day of pre­
training (Fig. 4.7). The performance of singly or repetitively injured animals was not different 
from that of their controls (p > 0.05; repeated measures ANOVA).
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Figure. 4.7: Effect of mild traumatic brain injury on rotarod performance. Values were recorded on 7 
separate days with three 5 min accelerating trials. Results are the mean ± SEM of the time animals 
remained on the rotarod before falling. There were no differences between injured and sham groups (p 
> 0.05) repeated measures ANOVA; (n = 9 per group).
4.3.4. Pathology of single and repetitive mild injury in hTau mice:
The brains of the hTau animals had no gross macroscopic differences when compared to the 
wild type animals. Macroscopic examination of fixed brains revealed evidence of focal 
microhemorrhage (<1 mm2) in the inferior surface of the cerebellum in all animals subjected to 
r-mTBI. Otherwise, there were no focal macroscopic lesions in any of the animals subjected to 
injury. Furthermore, as was intended with the original design of this paradigm, and
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demonstrated in the studies with wild type mice (Chapter 2), there were no skull fractures, 
cerebral hemorrhages, or contusions identified using this injury model in hTau mice.
4.3.5. Gial fib rilla ry  acidic protein immunostaining:
For mice subjected to r-mTBI, immunostaining for GFAP revealed evidence of a mild 
reactive astrogliosis in the corpus callosum (Fig.4.8A-D;l-L) and regions of the cortex underlying 
the impact site. In contrast, no gliosis was observed in the cortex at the impact site in sham 
animals or singly injured mice. In the CC, the r-mTBI group (Fig.4.8L) showed a notable increase 
in the area of GFAP immunoreactivity compared with r-sham, whereas no difference was 
observed between the s-mTBI and the s-sham (s-mTBI 3.0 ± 0.9% vs. s-sham 3.6% ± 0.45%; p > 
0.05; r-mTBI 11.2 ± 2.5% vs. r-sham 2.3 ± 0.4%; p < 0.05; Fig. 4.8M-N). In the CA1 region, there 
was no evidence of increased immunoreactivity across all groups (Fig.4.8E-H, N p > 0.05).
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Figure.4.8: Glial fibrillary acid protein (GFAP) immunohistochemistry of sagittal sections of hTau mouse 
brain at ~ 0.4 mm lateral to midline in the hippocampal region (A-L). Colored boxes indicate areas of 
interest, CA1 sub-region of the hippocampus (E-H) and corpus callosum (l-L) shown at higher 
magnification in the bottom two rows. There were no changes in the s-mTBI group (B) compared with 
their respective sham group (A). However, an increase in the area of GFAP staining was observed in the 
r-mTBI at 24 h after final injury in the corpus callosum (D, L). Quantitative analysis of GFAP staining in 
three 100 pm2 areas of the splenium of the corpus callosum at 24 h post last mTBI (r-mTBI 11.2 ± 2.5% 
vs. r-sham 2.3 ± 0.4%; p < 0.05) (M). Quantitative analysis of GFAP staining intensity in two 200 pm2 
areas of the CA1 region (p > 0.05) (N). Tissue sections were counterstained with hematoxylin. Data are 
presented as mean ± SEM, (*p < 0.05) (n=3 per group).
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4.3.6. Amyloid precursor protein immunostaining:
Numerous APP-immunoreactive axonal profiles were identified in sections from both injury 
groups (Fig.4.9B, D). These APP immunoreactive axonal profiles were observed as either 
granular or more elongated, fusiform swellings in the white matter of the parasagittal cortex, 
the CC, and the spinal trigeminal tracts of the brain stem (BS). APP-immunoreactive axonal 
profiles were observed 24 h post-injury in the CC of the s-mTBI (Fig.4.9B) and r-mTBI groups 
(Fig.4.9D) but not in their controls (Fig.4.9A, C). The numbers of APP-immunoreactive profiles 
in the CC of the s-mTBI was greater than in the r-mTBI group (s-mTBI group 18 ± 2.26 vs. r-mTBI 
14 ± 0.8 axonal profiles/100 pm2; p < 0.001; Fig. 9A). Overall, the APP immunohistochemistry 
observed in the hTau mice was similar to our initial study in WT mice (Chapter 2) in terms of 
number of immunoreactive axonal profiles per brain region (e.g. CC, BS). Axonal damage in the 
BS was minimal in the s-mTBI, whereas greater numbers of punctate immunoreactive swellings 
were present in the r-mTBI group. In the r-mTBI group, there was also evidence of cytoplasmic 
staining in neurons of the primary and secondary motor cortex.
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Figure.4.9: Amyloid precursor protein immunohistochemistry of sagittal sections of hTau mouse brain at 
24 h after sole/ last mTBI of sagittal sections of mouse brain at ~ 0.4 mm lateral to the midline. 
Immunoreactive axonal profiles were observed in the corpus callosum as either granular (arrow) or 
more elongated, fusiform (arrow head) swellings in both s-mTBI (B) and r-mTBI groups (D). Tissue 
staining from s-sham (A), and r-sham animals (C) was negative for APP immunostaining. Average counts 
of APP-immunoreactive axonal profiles per 100 pm2 in the corpus callosum (s-mTBI group 18.5 ± 1.8 vs. 
r-mTBI 14.1 ± 1.9 axonal profiles/ 100 pm2 (E). Data are presented as mean ± SEM (**p < 0.001) (n=3 per 
group).
4.3.7. Ionized calcium binding adaptor molecule 1 immunostaining:
As with the sham wild type animals previously reported in Chapter 2, we found no
evidence for inflammation with Iba l staining in the hTau sham animals (Fig.4.10A, C, E, G). In 
the singly injured animals, both resting and activated microglia (with a bushy morphology) were 
observed at 24h post injury in the CC (Fig4.10B) (s-mTBI 6.22 ± 0.9% vs. s-sham 3.22 ± 0.9%; p <
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0.05; Fig.4.101) and in the cortex (Fig4.10D) (s-mTBI 6.2 ± 0.9% vs. s-sham 4.01 ± 0.3%; p <
0.001; Fig.4.10J). For mice subjected to r-mTBI, immunostaining for anti-lba-1 revealed clusters 
of activated microglia in the CC (Fig.4.10D) (r-mTBI 13.7 ± 1.3% vs. r-sham 2.21 ± 0.6%; p < 
0.0001; s-mTBI 6.22 ± 0.9% vs. r-mTBI 13.7 ± 1.3%; p < 0.05; Fig.4.10H), and microglia w ith a 
bushy morphology in the region of the cortex underlying the impact site (r-mTBI 10.4 ± 1.3% vs. 
r-sham 2.01± 0.5%; p < 0.0001; s-mTBI 6.2 ± 0.9% vs. r-mTBI 10.4 ± 1.3%; p < 0.05; Fig.4.10J).
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Figure.4.10: Immunohistochemical labeling for microglia with anti-lbal at 24 h after sole/ last mTBI of 
sagittal sections of mouse brain at ~ 0.4 mm lateral to the midline. There was no microglial activation in 
the s-sham (A, E) and r-sham (C, G) groups. A mild increase in the area of lba-1 immunoreactivity was
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observed in the region of the corpus callosum (B), and with a bushy morphology (arrow) in the cortex (F) 
beneath the impact site at 24 h post s-mTBI. For mice subjected to r-mTBI, immunostaining for anti-lba- 
1 revealed clusters of activated microglia with hypertrophic and bushy morphology in the region of the 
corpus callosum and in the cortex underlying the impact site (H). Quantitative analysis of lba-1 staining 
intensity in three 100 urn2 areas of the corpus callosum (I) and in two 200 pm2 fields between layer III 
and V of the cortex (J) at 24h post sole/last mTBI. Data are presented as mean ± SEM, (*p<.05; **p<.005; 
***p<.0005) (n=3 per group).
4.3.8. Qualitative assessment of Tau immunohistochemistry:
To determine the intraneuronal distributions of tau immunostaining, when reviewing 
the tau immunohistochemistry we partitioned the stained neurons into three subcellular 
segments as represented in Fig.4.11.
DS
Figure.4.11: Subcellular partitioning of neuronal 
contours divided into three sub-regions: the 
somatic segment (SS), the dendritic segment 
(DS), and the membranous segment (MS).
MS
4.3.9. CP13 immunohistochemistry in the hippocampus:
Mouse brains exposed to single and repetitive mTBI exhibited enhanced 
somatodendritic phosphorylated tau CP13, a marker of the p-tau epitope at serine residue 202. 
CP13 is an early tau phosphorylation marker that also detects pretangles and late-stage NFT
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accumulation characteristic of several neurodegenerative diseases37,72,82. Within the CA1 
(Fig.4.12A-D) and CA3 (Fig.4.12E-H) sub-region of the hippocampus, but not in the dentate 
gyrus, robust CP13 immunostaining was observed in most of the single (Fig.4.12B, F) and 
repetitive mTBI groups (Fig.4.12D, H) compared to their respective shams (Fig.4.12A, E, C, G). 
Qualitatively, the magnitude of this increase was greater in the somatic and dendritic segment 
of the r-mTBI (Fig.4.12D, H) than in the s-mTBI (Fig.4.12B, F). CP13 was also evident in the 
membranous segment of the neurons of sham animals with increased CP13 staining observed 
in the r-sham (Fig.4.12C, G) group compared with the s-sham group (Fig.4.12A, E). 
Quantitatively, CP13 immunostaining in the CA1 of both injured groups was not different 
compared with their respective sham group (s-mTBI 12.5 ± 1.7% vs. s-sham 12.2 ± 1.6%; p > 
0.05; Fig.4.121). Within the CA3 sub-region, more CP13 immunoreactivity was evident in the r- 
mTBI compared to the r-sham group (r-mTBI 34.1.4 ± 4.8% vs. r-sham 18.9 ± 3.3%; p < 0.05) 
while only a small increase was observed between the s-sham and s-mTBI group (s-mTBI 25.5 ± 
3.2% vs. s-sham 23.9 ± 3.9%; p < 0.05; Fig.4.12J).
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Figure.4.12: Tau pathology using CP13 (p202) in the hippocampus of the hTau mice. There was 
enhanced phosphorylated tau immunoreactivity in the CA1 and CA3 of hTau mice at 24hrs after s-mTBI 
and r-mTBI compared with their respective sham controls (A-H). CP13 immunoreactivity revealed 
minimal staining in the membranous segment of the s-sham group (A) while a trend for an increase in 
immunoreactivity was observed in the r-sham (C). There was an intraneuronal progression of CP13 
immunoreactivity in the CA1 sub region of the hippocampus from the membranous segment as 
observed in s-mTBI (B) to the somatic segment in the r-mTBI (D). There was also an increase of CP13 
immunoreactivity in the CA3 sub region of all groups, again, with a trend for the r-sham (G) to have a 
stronger membranous segment staining than the s-sham (E). Both single and r-mTBI had amplified 
membranous and somatic staining (F, H).). Quantitative analysis of CP13 staining in the pyramidal cell 
layer of hippocampal regions CA1 (I) and CA3 (J) at 24h post sole/last mTBI (O). Tissue sections were 
counter-stained with hematoxylin, n =3/group respectively. Data are presented as mean ± SEM, (*p < 
0.05).
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4.3.10. RZ3 immunohistochemistry in the hippocampus:
Mouse brains exposed to single and repetitive mTBI also exhibited enhanced 
somatodendritic phosphorylated tau RZ3, a marker of the p-tau epitope at threonine residue 
231. This marker is used to detect phosphorylated tau protein accumulation in AD patients. 
Similar to CP13, a stronger RZ3 immunostaining was observed within the CA1 (Fig.4.13A-D) and 
CA3 (Fig.4.13E-H) sub-region of the hippocampus, but not in the dentate gyrus of the single 
(Fig.4.13B, F) and multiple mTBI groups (Fig.4.13D, H) when compared to their respective sham 
controls (Fig.4.13A, E, C, G). As with CP13, RZ3 immunostaining in the injured group was more 
pronounced in the r-mTBI (Fig.4.13D, H) than the s-mTBI group (Fig.4.13B, F). RZ3 in the r-sham 
(Fig.4.13C, G) animals was evident in the membranous and in a few somatic segments of the 
neurons while only the membranous segment was stained in the s-sham group (Fig.4.13A, E). 
RZ3 quantitation showed that immunoreactivity levels were significantly greater in the CA1 sub- 
region of the r-mTBI animals than in the other groups (r-mTBI 36.1 ± 2.8% vs. r-sham 17.9 ± 
4.6%; p < 0.001; s-mTBI 24.9 ± 3.7% vs. s-sham 17.7 ± 1.6%; p > 0.05; Fig.4.131). The RZ3 
immunoreactivity pattern in the CA3 was relatively similar in all groups (Fig.4.13), with a trend 
for a small increase in immunoreactivity observed in the injured groups (Fig.4.13J).
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Figure.4.13: Tau pathology using RZ3 (p231) in the hippocampus of the hTau mice. There was enhanced 
phosphorylated tau immunoreactivity in the CA1 and CA3 of hTau mice at 24hrs after s-mTBI and r-mTBI 
compared with their respective sham groups (A-H). RZ3 immunoreactivity revealed minimal staining in 
the membranous segment of the s-sham group (A) while a few neurons had strong membranous 
segment immunoreactivity in the r-sham (C). Membranous accumulation of RZ3 was observed in the s- 
mTBI (B) and with a stronger staining in the r-mTBI (D). RZ3 immunoreactivity is predominantly localized 
in the membranous segment of both s-sham and s-mTBI groups (E, F). The r-mTBI (H) show greater 
dendritic and membranous staining than the r-sham group (G). Quantitative analysis of RZ3 staining in 
the pyramidal cell layer of hippocampal regions CA1 (I) and CA3 (J) at 24h post sole/last mTBI (O). Tissue 
sections were counter-stained with hematoxylin, n =3/group respectively. Data are presented as mean ± 
SEM, (*p<0.05, * *p< 0.001).
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4.3.11. Qualitative analysis of PHF1 and M C I immunohistochemistry in the hippocampus:
To detect late-stage neurofibrillary-like pathology, we used two different antibodies: 
PHF1, which recognizes p-tau epitopes at both Serine 396 and Serine 404 and MCI, an AD 
conformation-specific antibody. The hippocampus was devoid of PHF1 and M CI 
immunoreactivity in both control and injured animals.
4.3.12. Tau immunohistochemistry in the cortex:
Abnormal phosphorylation and conformational changes of tau in the neocortex were 
evaluated with the same panel of monoclonal antibodies; CP13, RZ3, M CI and PHF1. For hTau 
mice subjected to single (Fig.4.14B, F) and repetitive mTBI (Fig.4.14D, H), immunostaining for 
CP13 and RZ3 revealed evidence of increase p-tau in the cell bodies and apical dendrites of 
cortical neurons underlying the impact site.
As expected given the lack of M CI immunostaining in the hippocampus, we did not 
observe noticeable changes across each group (Fig.4.14l-L). Similarly, the cortex was also 
devoid of PHF1 immunoreactivity in both sham and mTBI animals (Fig.4.14M, N, 0) with the 
exception of one mouse in the r-mTBI group that showed abnormal phosphorylated tau 
immunoreactivity in the membranous fragment of a few neurons in the neocortex (Fig.4.14P).
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Figure.4.14: Qualitative changes in tau phosphorylation in the neocortex. Tau pathology using CP13,
RZ3, MCI, PHF1 immunoreactivity in superficial layers of the cerebral cortex at 24h post sole/last 
mTBI/anesthesia. CP13 and RZ3 immunoreactivity were observed in the cell body and apical dendrites of 
cortical neurons of both injured groups (B, D, F, H). The immunoreactivity levels were greater than in 
both sham groups with hyperphosphorylated tau localized in the membranous segments of the neurons 
(A, C, E, G). There was no MCI immunostaining observed in any group (l-L). Sporadic PHF1 
immunostaining in the membranous segment of the r-mTBI (P) was observed at 24h post injury, while 
no cortical neurons were labeled in the s-mTBI both sham groups (M-O). Tissue sections (A-L) were 
counterstained with hematoxylin. (n=3 per group).
158
4.3.13. TUNEL:
Pyramidal neurons of the hippocampus, and neurons that stained positive for Tau in the 
cortex, were devoid of TUNEL positive staining, indicating that there was no apoptotic 
programmed cell death in either sham (Fig.4.15A, B) or injured animals (Fig.4.15C, D).
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Figure.4.15: There were no TUNEL positive neurons in any group in any brain region. TUNEL-positive 
neurons in the hippocampal CA1 sector in the r-sham (A, B) and the r-mTBI (C, D) at 24h post last 
anesthesia/injury. The black boxes in A and C (20x) indicate the regions of interest which are then shown 
at a higher magnification (40x) in panels B and D. The inset in the top right corner (D) represent an 
image of a control TUNEL-positive nuclei with condensed chromatin and apoptotic bodies. Tissue 
sections were counterstained with hematoxylin (n=3 per group).
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4.3.14. ELISA to detect low levels of mouse Tau:
To further confirm the histological findings, separate groups of injured and sham hTau 
mice were euthanized at 24 h post injury for biochemical analyses. Each brain region 
homogenate (cortices and hippocampi from one hemisphere) were subjected to low tau 
Sandwich ELISA coated with total tau DA31, p-tau CP13, PHF1, and RZ3.
We found no marked increases in the amount of soluble total tau DA31 or 
phosphorylated tau (CP13,RZ3,PH1) in injured compared with sham control groups for either 
the cortical (Fig.4.16) or hippocampal (Fig.4.17) brain sub-regions. However, a trend for an 
increase of total tau (DA31) was observed in the s-mTBI (+17%) and the r-mTBI group (+5%) 
when compared to their respective sham groups (s-sham 9.6 ± 1.2 pg tau/mg protein vs. s-mTBI 
11.1 ± 1.8%; r-sham 10.6 ± 1.6 pg tau/mg protein vs. r-mTBI 11.1 ± 1.1%; p > 0.05 p > 0.05; Fig. 
4.16A). A gradual trend, depending on the number of injuries or anesthesias, was also 
revealed when the amount of tau present in the brain region homogenates is quantified as a 
ratio of phosphorylated tau protein (CP13, PHF1 or RZ3) to total tau protein. There is a 17% 
increase of CP13 in the cortical homogenate between the s-sham and the s-mTBI and a 6% 
increase between the r-sham and the r-mTBI and a 39% increase of CP13 between the s-sham 
and r-mTBI group (Fig4.16E).
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Figure.4.16: Quantitative analysis of cortical homogenate from hTau mice at 24h post sole/last 
mTBI/anesthesia. Total Tau DA31 (A) p-tau CP13 (B), PHF-1 (C), and RZ3 (D) ELISAs. There was no 
difference in cortical soluble phosphorylated tau in injured hTau mice vs. sham animals. While not 
significant, there was always a trend for the injured groups to have a higher amount of phosphorylated- 
tau when compared to their respective shams. Quantitation of CP13, PHF-1, and RZ3 from cortical 
homogenates as a percentage of total tau protein (DA31) (E, F, G). Again, analyses revealed a non­
significant trend for an increase in the ratio of phospho to total tau in injured and r-sham groups 
compared to s-sham. Data are presented as mean ± SEM, (n=3/group), (p>.05; two-tailed Student's t 
test).
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Figure.4.17: Quantitative analysis of hippocampal homogenate of hTau mice at 24h post sole/last 
mTBI/anesthesia. Total Tau DA31 (A) phospho-tau CP13 (B), PHF1 (C), and RZ3 (D) ELISAs. There was no 
difference in hippocampal soluble phosphorylated tau in injured hTau mice vs. sham animals. 
Quantitation of CP13, PHF1, and RZ3 from hippocampal homogenates as a percentage of total tau 
protein (DA31) (E, F, G). There was no difference in the ratio of phosphorylated tau protein to total tau 
protein in injured vs. sham animals. Data are presented as mean ± SEM, (n=3 per group), (p>.05; two- 
tailed Student's t test).
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4.4. Discussion:
This chapter focused on the acute effects of single and r-mTBI in a transgenic mouse 
model expressing all 6 isoforms of human tau protein on a null murine background, in order to 
explore the potential role of tau pathobiology in TBI sequelae. Two major findings were 
revealed by this study. First we showed that single and r-mTBI induced a modest cortical 
increase in the soluble fraction of three different p-tau epitopes: CP13, PHF1 and RZ3.
Secondly, this increase was not associated with worse behavioral performance when compared 
to wild type animals. In all groups, there was no evidence of A(3 accumulation and/or M CI 
inmmunostaining, a distinct pathological conformation of the tau molecule in Alzheimer's 
disease. This study provides a direct connection between mTBI and tau pathology and indicates 
our model can mimic pathology observed in human brains, including neuroinflammation, 
diffuse axonal injury, behavioral impairments and an increase of tau phosphorylation1'5,67'68'83,84.
Recently there has been a surge of attention focusing on the neuropathological 
sequelae of TBI (especially repetitive concussive injury) amongst athletes engaged in contact 
sports and military personnel exposed to blast injury. Several studies have documented a 
distinct, slowly progressive tauopathy defined as CTE4'5,7. However, despite the growing 
evidence from postmortem analyses that seemingly link repeated mTBI with CTE, this causal 
relationship has not yet been firmly established, as autopsy confirmation is required and thus 
the precise incidence of CTE after repetitive head injury is still unknown67,85. The cases which 
have fueled the surge of interest in CTE, at least in the US, have been high profile cases3,86"88 
(celebrity athletes for example), who have died prematurely, and the incidence of CTE in
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individuals living for decades beyond the time of their TBIs remains to be explored. To explore 
the role and significance of tau in TBI it is therefore critical to utilize longitudinal studies in 
appropriate animal models that will adequately enable monitoring of the distinct biochemical 
and pathological changes that occur post-injury, and correlation with any behavioral 
dysfunction. We choose the hTau mouse model because it expresses all six isoforms of the 
human tau protein on a null murine background, and as such best recapitulates the relevant 
human tau background.
Very little is known about the mechanisms involved in the accumulation of tau proteins 
observed in human cases after TBI. Evidence from a recent animal model of TBI58 demonstrates 
rapid formation of neurotoxic oligomeric and p-tau aggregates that may be followed by a toxic 
gain of function. Whether the increase in soluble p-tau observed in our model at 24 h post 
injury is a transient, sustained or leads to aggregates remains to be determined. The increase 
of cellular p-tau may triggers a stepwise process that involves tau aggregation, gain of toxic 
function and conformational changes that eventually lead to paired helical filaments 
conformation, and the pathologic features of CTE and other tauopathies. However, while CP13 
(pS202) and RZ3 (pT231) are present both in normal and AD brains, in human AD, the increases 
of p-tau on the pS202 and pT321 motifs (as we observed in our model) could define early 
events that eventually disrupt tau MT function, precede tangle formation and 
neurodegeneration. Notably, pT231 phosphorylation has been shown to be the first phospho 
epitopes that appear during pretangle formation in AD36. Further work is required to address 
the time course and the presence if any, of other tau species such as soluble small oligomers, 
and insoluble tau species. However, the absence of M CI immunostaining suggests that mTBI
does not trigger the formation of toxic tau conformational species at 24h post single and r- 
mTBI. Therefore, this increase of p-tau could reflect various degree of brain neuroplasticity or 
the establishment of a series of events that may become toxic over time.
In the hTau mouse model of mTBI, injured at 3 months of age (comparable to young 
adult in humans) we observed key aspects of human mTBI pathology5,67, and intriguingly similar 
pathological outcome in many aspects when compared with WT mice at the acute time point84. 
First, consistent with our previous study in WT mice (Chapter 2), neurobehavioral impairments, 
neuroinflammation, and axonal injury in the absence of macroscopic tissue damage were 
observed in hTau animals. As anticipated, the major changes observed between the hTau mice 
and the WT animals were unveiled by the tau pathology and biochemistry. Notably cell body 
accumulation of CP13 and RZ3 hyperphosphorylated tau is evident at 3 months of age in the 
hTau mice while the WT were devoid of tau pathology. Since the hTau mice have an age 
dependent change in the localization and accumulation of tau hyperphosphorylation72, these 
features render this model ideally suited to assess whether a single or r-mTBI can accelerate 
pathological tau burden as seen in humans5,6,89. At 24 h post single/last injury an increase in p- 
tau (CP13, RZ3 and PHF1) was observed after immunohistochemical quantification. However 
the statistical analysis of the ELISAs reading revealed that this trend was not significant, perhaps 
owing to the small number of animals per group or due to the variance in levels of tau 
expression in these hTau mice. hTau mice were extremely difficult to breed compared to WT 
mice, and as such this precluded the analyses of a larger group for this study. Despite this 
limitation in sample size (i.e. low power and biological variation) increasing the number of 
animals per group will give a better representation of a general mouse cohort with a clearer
165
signal in potentially pathogenic changes to tau protein. For example, the post hoc power analysis 
on the ratio of CP13/DA31 from the cortical sample at an acute time point showed that the power was 
low (1%) as it is much lower than the generally accepted 80%. Therefore in order to detect significant 
changes with a mean difference of 5.5% between the s-sham and the r-mTBI group we should have used 
35 animals per group. Interestingly our findings are also seemingly in parallel with the only two 
relevant models of single or r-mTBI in the literature (in terms of age and injury severity). In this 
regards, Kane and colleagues reported an increase in p-tau at 30 days post repetitive mTBI 
injury68, while Goldstein et al (2012), demonstrate enhanced CP13 somatodendritic 
phosphorylated tau at two weeks post injury in the cerebral cortex of a single murine blast 
model1. In our recently published work on the effects of mTBI in aged hTau we investigated the 
effects of our various injury paradigms in 18-month-old hTau mice at 3 weeks post-injury90. At 
18 months, these mice already exhibit clear tau pathology, with tau hyperphosphorylation and 
inflammation. However, despite these age-related changes, in parallel with the pattern shown 
in this current study, we also observed augmented p-tau immunoreactivity along with an 
increase in astrocyte/microglia activation in the superficial layer of the motor/somatosensory 
cortex and in the corpus callosum. The comparison of these data (young vs. aged hTau mice) 
perhaps suggest that antecedent tau pathology, ageing and inflammation may be a significant 
factor involved in driving the pace of tau pathology in some human cases.
Although attempts have been made to define clinicopathological boundaries for the
diagnosis of CTE5'67'91, with some describing it as a distinct encompassing tauopathy5'7, it is
becoming evident that the presentation and incidence of CTE following repetitive mTBI is
complex in nature and involves additional contributory factors as discussed below, which must
166
be considered when developing mouse models of injury. These are factors that we plan to 
explore with this model.
In advanced ageing one of the most striking underlying features readily observed 
especially in the medial temporal limbic regions is tau pathology, as detected by AT8 
immunostaining at autopsy29. This universal feature of ageing has also been clearly 
demonstrated as early as 6-30 years of age, in select subcortical areas as AT8 (pS202) positive 
pretangles28. This presentation of abnormal tau material in humans may be considered to be 
intrinsic to the human brain and its initital appearance and/or propagation may arise as a result 
of several combinatory factors (such as; sub/concussive head injury, substance abuse in 
professional athletes, medication/drug history/steroids, ageing, inflammation, vascular 
damage, comorbid diseases, genetic background (ApoE; MAPT), environmental risk factors and 
much more). As such, if the staging of antecedent NFT-like pathology already exists in a subset 
of the young adult human population exposed to such risk factors mentioned above, this may 
possibly explain why certain individuals may be selectively susceptible to develop augmented 
CTE-like tauopathy following repetitive mTBI. This will continue to remain a challenge as it is 
currently impossible to detect or monitor changes in pathological tau profiles in humans before 
and after mild repetitive injury. Current advances to develop a specific tau biomarker for in 
vivo neuroimaging, such as has been developed for in vivo amyloid imaging with the (FDDNP) 
compound92, will be an invaluable tool to further help to shed some light on the role of tau 
pathobiology in disease. Such an advance with tau imaging would represent a major step 
forward to diagnose CTE in live patients. Another possibility will be to identify CSF or blood 
biomarkers of tau changes that correlate with tau pathobiology in the brain93,94. Total and p-
tau measurement in CSF is currently used as an AD diagnostic aid95'97, but we would suggest 
that markers for TBI or CTE will need to be of much greater scope (i.e. detecting multiple 
potentially pathological changes in tau) than what is currently available. Detailed mass- 
spectrometry characterization of tau in the brain and blood of our mouse models of TBI is 
currently ongoing in our laboratories, with the goal of providing such biomarker profiles for 
validation in human samples.
Another important factor that should be considered when developing animal models of 
injury that best recapitulate the human scenario is to use appropriate mouse models with the 
same human tau isoform background. In our model we used the hTau mice that expresses all 
six human tau isoforms on a null murine background. However unlike humans that express 
3R:4R tau isoform ratio at (50:50), they have been reported to express a higher ratio of 3R:4R 
tau isoform ratio at (4:1)72. Changes in the tau isoform ratio are associated with distinct 
tauopathies, for example, a shift toward an increase of 4R isoforms is observed in patients with 
PSP or AGD whereas a shift toward an increase of 3R is associated with FTDP1712. The effects of 
some of the FTDP-causing mutations in tau (for example; P310L, V337M and G272V) have been 
extensively studied in transgenic mice that develop widespread NFTs76,98, and these studies as 
well as in vitro cell culture models suggest that the 4R tau isoform is a potentially more 
favorable substrate for aberrant hyperphosphorylation, and also has the propensity to self­
aggregate into filaments more readily at a lower phosphorylation stoichiometry99. Therefore it 
is plausible that the significant imbalance in 3R:4R ratio in our hTau model may affect the 
outcome of tau pathology following injury as compared to humans and as such should be 
considered in the interpretation of our data.
Our qualitative immunohistochemical observations showed an increase in 
somatodendritic phosphorylated tau (CP13, PHF1, RZ3) in the superficial layer of the cortex of 
the injured group, as has been described many years after r-mTBI in CTE cases. Supporting 
these observations, ELISA of the cortical homogenate also revealed a trend toward an elevation 
of phosphorylated tau epitopes pS202 and pT231, all associated with early tau filament 
aggregation and pS396/404, a marker for late stage tau conformation such as NFTs37. The 
mechanisms for translation of mechanical forces into biochemical changes are likely to be 
complex and include a variety of signaling pathways and genes regulation. However, it is highly 
probable that the observed increase of soluble p-tau may be a part of a normal cell response 
caused by tearing the cell membrane and/or the subsequent influx of high calcium 
concentration into the cells. The resulting increase of calcium-dependent protease and other 
kinases and phosphatases may in turn, initiate abnormal p-tau on serine and threonine 
residues. Therefore if the level of phosphorylation is exceeded, the cell is more likely to 
experience increased cell death or abnormal function that may lead to neurodegenerative 
diseases. Whether specific phosphorylation sites contribute to the pathogenesis of r-mTBI as 
previously described in AD patients37 remain to be addressed.
In the hippocampus however, despite the subtle changes in p-tau levels as determined 
by ELISA, we observed a dramatic increase in p-tau immunoreactivity via immunohistochemical 
analysis, but this was localized in the subregions of the CA1 and CA3 hippocampal area.
Another notable observation between immunohistochemistry (IHC) and biochemical 
analysis surrounds the level of PHF1 immunostaining vs. PHF1 protein levels. Protein assays
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using ELISA showed the highest changes between injured and non-injured animals for the ratio 
of PHF1/DA31 (total tau). However IHC staining with the PHF1 antibody showed that the 
different brain regions were almost devoid of positive PHF1 immunostaining (this was in 
contrast to both CP13 and RZ3 antibodies which showed stronger immunostaining intensity). 
This difference could be attributed to the masking of the PHF1 epitope following fixation with 
paraformaldehyde, which forms strong cross-links made up of methylene bridges with primary 
amines of proteins in perfused tissue. The differences may also reflect mouse to mouse 
variation, which could be addressed as previously explained by increasing the numbers of mice 
in each group. Further analyses and quantification of both IHC and biochemical data may be 
needed to address this apparent discrepancy.
Based on these results, it remains unclear and to be determined if the acute increase of 
cortical tau phosphorylation originates from the endogenous pool of tau from formerly healthy 
axons damaged by the injury, or from tau newly synthesized as a response to the cytoskeletal 
damage. While further work is required to answer this question, TUNEL staining revealed no 
apoptotic neurons in the cortex or hippocampal regions in sham or injured animals. This 
suggests that neurons that show an enhanced somatodendritic phosphorylated tau staining are 
not apoptotic. These findings raise the question whether tau hyperphosphorylation is a 
permanent, progressive, or a reversible component after head injury. In other words, does it 
become completely resistant to autophagy and other endogenous cellular removal 
mechanisms? Is phosphorylated tau used to repair the damaged neuron's cytoskeleton? Is tau 
hyperphosphorylation fully reversible? Owing to its known involvement in AD pathogenesis, 
tau has been considered as a disease causing agent. However, the potential link between a
transient surge of tau hyperphosphorylation, as observed after TBI, and neurodegeneration has 
not yet been clearly defined. In fact, evidence suggests that tau phosphorylation at certain 
sites (e.g. KXGS motifs) may protect against tau aggregation100. In addition, Arendt and 
colleagues revealed that hyperphosphorylation of tau in hibernating animals reverses rapidly 
upon arousal from torpor53. Further works remain to be done, but similar to these observations 
from hibernating animals, tau hyperphosphorylation resulting from TBI might potentially 
involve an intrinsic response to protect the neurons from further damage through mechanisms 
that stabilize the cytoskeleton and synaptic structure101'102. These critical questions prompted 
our design and implementation of another study in order to evaluate the long term 
consequences of mTBI in hTau. A second cohort of hTau mice, exposed to the same four 
injury/sham paradigms, was euthanized at 12 months post injury (following behavioral 
characterization) and will shortly undergo pathological and biochemical analysis.
Other pathological features seen in human CTE cases, such as perivascular tau 
pathology, neuropil threads and astrocytic tangles that are occasionally observed from post­
mortem analysis at chronic time-points post r-mTBI5, were not observed in our mouse model of 
mTBI. Galiyas Silver stain, a traditional histopathological method used for the detection of 
neurofibrillary tangles will be performed to confirm these preliminary observations. It is 
possible that these differences between human CTE cases and our mouse model may be 
constrained by time-points of pathological assessment, differences in the severity and 
frequency of injury, interspecies differences; including the craniospinal angle, the significantly 
greater deformability of the murine skull, and the white to grey matter ratio in mice and 
humans. Overall, these data seem to suggest that tau hyperphosphorylation at acute time
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points post-injury may be a contributing factor to the mTBI pathology, however axonal injury 
and inflammation may be more important for TBI pathogenesis.
Moreover our findings herein also raise the question concerning the link between 
anesthesia exposure and increased tau phosphorylation, which have been reported on several 
occasions in the literature54,103,104. Indeed, a trend for lower spatial memory performance 
(Probe trial) was observed in the r-sham group. The pathological examination also revealed a 
tendency for an increase in tau phosphorylation in mice exposed to multiple anesthesias. This 
trend was not observed in our previous study in aged hTau mice. This could be explained by 
the transient increase of tau phosphorylation that resorbs within weeks post exposure105 or by 
the fact that aged tau mice have such high levels of phosphorylated tau that they supersede 
that which could be induced by anesthesia.
At the clinical level, repetitive mTBI/CTE can present with behavioral, cognitive, and/or 
motor-related symptoms. In the few months or years following injury the most common 
disturbances anecdotally recorded by patients or their relatives include behavioral changes, 
such as-impulsitvity, depression, aggression, mood swings and suicidality2,106,107. With regard 
to cognitive impairment, patients can exhibit impaired attention and/or concentration, 
executive function and memory problems as the disease progresses, possibly leading to 
dementia. Motor disturbances also appear several years after injury, represented as tremors 
(parkinsonian type), ataxia, dysarthria and impaired co-ordination5,108. To further characterize 
the early neurobehaviroal phenotype of our hTau mouse model post injury, we performed two 
different tests, Barnes maze (for spatial memory), and rotarod (motor cordination).
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When tested for behavioral performance in the Barnes maze, the r-mTBI group showed 
impaired learning consistent with our mTBI study in WT mice84. However, in contrast to our 
previous study, single injury failed to demonstrate any significant effect on the behavior of the 
hTau mice as they performed at the same level as their sham control counterparts (in term of 
escape latency and distance travelled). Alterations in genetic background of the animals could 
be the cause of such differences, because mice which have been genetically manipulated are 
known to perform differently for a given behavioral test. It is interesting to note that the overall 
performance of the hTau mice was superior to the WT groups as they were able to find the 
hidden box with the shortest distance and time travelled when compared to WT animals over 
the acquisition trial phase, although they performed worse on probe trial. Results from the 
rotarod suggest that neither injury nor anesthesia had an effect on the locomotor activity of 
these mice. There is currently no point of reference in the literature to compare motor related 
function in hTau mice, however, a direct comparison with our wild type mice suggest a motor 
coordination and balance deficit in these mice, as their score was 58% lower (overall) than their 
wild type counterparts at the same age and for the same experimental paradigm.
To date, numerous investigators have consistently reported a strong case for the 
development of tau pathology several years following repetitive mTBI5. However the majority 
of these studies have been from retrospective studies which have principally focused on biased 
samples of clinically symptomatic cases. The experimental data presented here suggest that 
tau pathophysiology along with inflammation and axonal injury (as seen in both wild-type and 
hTau models) all appears to play somewhat of a significant role in the early events preceding 
single or repetitive mTBI and strongly correlates with the (acute) behavioral changes post­
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injury. Additional longitudinal (prospective) studies in both humans and appropriate animal 
models that aim to characterize the distinctive pathological and biochemical profile of tau 
pathophysiology in the brain/CSF before and after injury will be required to evaluate the 
beneficial and/or detrimental role of tau in TBI sequelae.
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Chapter 5
5. General discussion
5.1. Overview of the current studies:
1. We developed a simple and reproducible mouse model of mTBI, which induces 
histopathological changes consistent with other animal models of brain trauma and 
learning/memory problems comparable to those observed in the human condition1'4.
2. Animals exposed to a s-mTBI had learning impairments without exhibiting spatial memory 
retention deficits when compared to their sham controls at 6 ,12 and 18 months post-injury.
3. Animals exposed to s-mTBI had transient behavioral impairment, diffuse astrogliosis, 
neuroinflammation, and axonal damage, whereas r-mTBI results in more significant 
behavioral deficits and pathological abnormalities.
4. Animals exposed to r-mTBI displayed persistent cognitive deficits, a slower rate of learning 
and progressive behavioral impairment over time. These deficits arise in parallel with a 
number of neuropathological abnormalities, including progressive neuroinflammation and 
continuing white matter degradation up to 12 months following repetitive injury.
5. Neither single nor r-mTBI was associated with elevated brain levels of amyloid beta or 
abnormal tau phosphorylation at 6 or 12 months post injury.
6. These data provide the first evidence that, whilst an s-mTBI produces neurobehavioral 
changes and pathology between acute and 6 months post injury, these changes appeared to 
be static for the 6 and 12 months period post injury.
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7. r-mTBI produces behavioral and pathological changes which continue to evolve many 
months post injury.
8. These findings recapitulate important aspects of human long term TBI sequelae, in 
particular persistent neuroinflammation, white matter injury, and axonal pathology in the 
corpus callosum3,5'9.
9. However, we did not observe the tau pathology which has been the focus of such debate in 
human TBI cases, particularly in the high profile chronic traumatic encephalpathy (CTE) 
cases which have been reported primarily in the US.
10. The hTau transgenic mice developed acute pathology (APP axonal profiles, microgliosis, 
astrogliosis) leading to neurocognitive impairments in a manner similar to our observations 
following mTBI in wild-type mice10.
5.2. Implications:
As mild brain injury or concussion does not typically result in death in humans, it is difficult 
to identify and study the pathological mechanisms of concussion at acute time points in 
humans. Thus, our current understanding of the consequences of mild brain injury comes 
almost exclusively from autopsied brains of individuals (typically athletes or military personnel) 
known to have a history of repeated head injuries. In many of these cases the clinical 
presentation included failing memory, depression and impulse control problems. In addition, 
the majority of these brains come from middle-aged patients and therefore the observed 
pathology does not as clearly represent the consequences of TBI as the effects of age can 
themselves be a confounding factor but can also present new variables such as genetic 
influences on long term outcome, the effects of other comorbid conditions, and/or chronic
189
effects of consumption of substances of abuse. Thus, the establishment of a representative 
animal model of mTBI in Chapter 2 holds important implications in studying acute 
histopathological sequelae after single and r-mTBI as human pathological samples are lacking at 
such short time points post injury.
Our results provided pathological and behavioral evidence that our model of mTBI is 
particularly suitable to study the effect of both single and multiple injuries as it reproduces 
traits of human mTBI. In this regard, our model is superior to models of mTBI that subject the 
animal to some degree of head surgery which results in various level of cranial disturbance11 
(e.g. CCI, FPI). In addition to allowing administration of more than two mTBI, the required time 
under anesthesia is minimal and thus clinically relevant. The EM coil-based device also delivers 
reproducible velocities without the need for frequent calibration while reducing the chance of a 
rebound that can occur with the weight drop head injury model11,12.
Therefore, we decided to us this model to examine the long-term sequelae following injury. 
Cause and effect relationships for the delayed sequelae of single and r-mTBI are not well 
understood, an animal model that translates to the human condition would improve our 
understanding of the evolution of mTBI pathology that occurs prior to the appearance of 
neurological and neuropathological dysfunction. The fact that our model of single and r-mTBI 
induced axonal injury within hours, inflammation and astrogliosis within days, and behavioral 
impairments within a week, supports evidence that single and multiple concussion can 
contribute to subsequent and immediate neurological disturbances.
The first study could be an important tool used for medical counseling of patients who have 
suffered concussions. This study concludes safety guidance should be issued for high risk
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groups such as children involved in sports, professional athletes and military personnel.
Because neurological disturbances can occur so rapidly, new rules regarding the period of 
recovery should be implemented, especially after sports injury. Athletes have a high risk for 
further exposure to trauma which most likely would result in exacerbated deficits as our r-mTBI 
data indicates. For example, students' academic performance depends largely on memory and 
processing speed; academic accommodation should be considered until the injured scholar is 
able to fully recover from the trauma.
The results in Chapter 3 present evidence that animals exposed to multiple injuries have 
sustained inflammation at 6 months post injury while the singly injured mice recover over the 
same period of time as s-mTBI mice have the same level of inflammation as their respective 
shams at 6 months post-injury. This may indicate that the individuals exposed to r-mTBI may 
have an elevated level of brain inflammation that does not subside with time, even if no 
additional trauma occurs. While no markers of inflammation were observed at 6 months post 
s-mTBI, at 12 months post injury, we observed a gradual increase in astrogliosis and 
inflammation in both the single and r-mTBI groups. While both injured groups had increased 
inflammation at 12 months post-injury, the r-mTBI group showed more intense pathology. This 
supports the current hypothesis that a history of mTBI could exacerbate the onset of brain 
inflammation that typically occurs with aging and is known to play a role in neurodegenerative 
disease. Further studies are clearly needed to confirm these observations, but this avenue 
could open the door for potential treatments targeting inflammation in the mTBI brain. The 
chronic inflammation observed over the many months following repetitive injury suggest that 
although early treatments for TBI patients (regardless of the injury severity) can minimize
further damage, our data suggests that a chronic treatment paradigm may also be needed to 
mitigate the longterm consequences of repetitive brain injury. Overall, our mouse model of 
head injury provides a platform for future studies that will have important implications in 
identifying molecular targets and testing therapeutic agents to alleviate the early and long term 
brain damage induced by mTBI.
In chapter 4 the short-term behavioral and pathological changes after a single and r- 
mTBI in hTau mice were consistent with those we observed in wild type mice. This may suggest 
that inflammation and axonal injury, rather than tau pathophysiology, play a significant role in 
the early events after single or r-mTBI and better correlate with the acute behavioral changes 
post-injury. The question of whether tau pathology may gradually appear over the days or 
months post injury remains to be addressed.
Taken together, the findings from these studies support the hypothesis that mTBI 
should be regarded as a chronic disease, not a one-time event. This concept holds important 
implications for the management and treatment of traumatic brain injury in humans as it often 
does not clinically present in the immediate aftermath of trauma, but rather months, or even
. • • 7,9,13-16years, post injury ' '
5.3. Ongoing work:
5.3.1. Characterization of our model of head injury at 24 months post injury:
The findings in Chapter 3 are key to understanding the evolution over time of a single and r- 
mTBI. However, the late life consequences of single and r-mTBI are still lacking as laboratory 
wild-type mice typically live only 2 to 3 years, and to our knowledge, this is the only study to
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examine such extended time points in an experimental model of head injury. As such, this 
study also provides an opportunity to evaluate mTBI coupled with the effects of aging as there 
is no information in animal or human autopsied brain on the impact of mTBI in the context of 
aging. Accordingly, the same cohort of mice in which we performed neurobehavioral testing at 
24h, 6 ,12 ,18  months post mTBI was tested for subsequent neurobehavioral impairments. 
When we designed this study we received skepticism over the fact that many mice might die 
before reaching this final time point for the study, but as expected based on the average life 
expectancy of mice in our vivarium, and the deliberately mild nature of the inflicted injury, only 
3 mice died (2 r-sham and 1 s-sham).
The remaining cohort of mice were thus tested for the 5th time in the Barnes Maze at 24 
months after injury/anesthesia, and were then euthanized for neuropathological and 
biochemical analyses (ongoing). The cohort was then separated for further ongoing 
pathological and biochemical analysis. Other parts of the central nervous system (spinal 
column, optic nerve) were also collected and fixed for further pathological examination. As 
observed at 18 months post injury the r-mTBI group had strong cognitive and learning 
impairment. In fact this last time point confirmed the trend observed at 18 months post injury 
where injured groups plateau and revealed the expected progressive decline in the sham group 
as they aged. Additionally, cerebral blood flow was also measured prior to euthanatization as 
the association of cerebral hypoperfusion and TBI is well established17,18. Cerebral blood flow 
analysis of this cohort (24 months post mTBI) illustrates a decrease of blood flow of about 10% 
in r-mTBI mice, however these results were not statistically significant, when compared to the
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r-sham. As this line of investigation is currently lacking in the field, examination of the blood 
brain barrier and the cerebrovasculature following brain trauma is necessary.
5.3.2. Chronic consequences of single and repetitive mTBI in hTau mice:
Although we do not intend to follow a cohort of hTau mice to the same extensive 
timepoints that we have for wild type mice, we have 36 male hTau mice which were subjected 
to the same injury/sham paradigms as the wild type mice (s-sham, s-mTBI, r-sham, r-mTBI, 
N=9/group) that have now been aged to 12 months post mTBI/anesthesia. As described in 
Chapter 4, sub-optimal breeding with the hTau mice has necessitated our use of smaller 
numbers of mice per study group. Preliminary analysis in the Barnes maze reveals age and time 
dependent spatial learning deficits in the r-mTBI group compared to r-sham animals.
Moreover, the hTau mice presented a trend for worse learning and spatial deficits when 
compared with the wild type cohort at 12 months post injury, as indicated by their impaired 
performance. While no pathological analyses have yet been carried out, the soluble fraction of 
the hTau brain homogenate is ongoing. Preliminary results revealed no changes overall in the 
soluble fraction, but a trend for an increase of tau aggregate in the injured group at 12 months 
post injury. Because of the high degree of variation of tau levels in these mice, further analyses 
are needed to fully interpret these data. We are currently characterizing and measuring the 
amount of total and phospho-tau in the insoluble fraction as well as its associated pathology. 
These preliminary data suggest that r-mTBI produce long term deficits in learning and cognitive 
function independent of tau accumulation in the soluble fraction of the brain homogenate.
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5.4. Future studies:
The findings described in this thesis will be extended to investigate the mechanisms driving 
other cognitive/behavioral alterations associated with TBI. For example, mTBI can increase the 
risk of post-traumatic stress disorder (PTSD), an anxiety disorder caused by a violent/traumatic 
event. PTSD and TBI often coexist because brain injuries are often sustained in traumatic 
experiences. To further understand and untangle the specific changes in PTSD's brain 
diagnosed patients, we are using our r-mTBI model to investigate how a stressful event at the 
time of injury could lead to PTSD.
Lipid metabolism and oxidation in TBI are of particular interest due their high concentration 
in the CNS and the chronic changes (inflammation, cell loss) observed in the major white matter 
tracks of the injured animals. We aim to use mass-spectrometry-based lipidomic platforms to 
identify and isolate a few lipid molecules out off hundreds lipid species as biomarkers for 
diagnosis of mTBI. Lipidomics has been demonstrated to be a useful tool in the study of
19 20 21mechanisms and biomarkers in many diseases such as cancer , atherosclerosis and obesity 
and thus could become a powerful tool to diagnose and scale the injury status of a patient.
Identification of an effective treatment for TBI is a major challenge for the neuroscience 
research community as all clinical trials evaluating potentially neuroprotective compounds have 
failed in demonstrating clinical efficacy. These disappointing results may be due to the fact that 
most therapeutic strategies target a single pathophysiological mechanism despite the fact that 
many mechanisms are involved in secondary injury after mTBI. Testing multifunctional 
therapies is now considered an important research direction in animal models of TBI. Previous
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studies in animals have provided a proof-of-principle for improvement of functional recovery at 
an acute time point after cortical injury but this effect failed to be translated clinically. We are 
currently tackling the problem with a different approach by focusing our treatment not only on 
the acute effect of mTBI but on a delayed neurorestorative treatment that would reduce the 
chronic inflammation cause by the injury observed in our mouse model. If correct, this 
approach could spark a new treatment strategy, one in which TBI patients must be treated not 
only for their primary injury but also for the long-term consequences that may last for years 
resulting from secondary injuries. The last major barrier of the translational gap between 
human and rodent model would be narrowed if the use of higher species with brains that are 
more anatomically and functionally closer to human were further developed. While we can't 
recapitulate all aspects of a human TBI in a mouse, we can identify and screen potentially 
relevant molecular mechanisms without the cost and ethical hurdles that comes with research 
using higher order species.
In addition, more research should explore different injury paradigms. As it is not unusual for 
athletes to experience more than five concussions in a career22'23, studies that incorporate a 
greater frequency of mTBI over longer period of time would better replicate the pathology 
observed in CTE patients. This area has, for the most part, been ignored by the research and 
medical communities until recently. There is no good way to assess when a brain is moderately 
injured, nor do we understand how the brain heals. Accordingly, further animal models should 
include additional variables such as the number, the severity and the frequency of mTBI to 
accomplish a better translation between animal experiments and the heterogeneity of human 
mTBI. The identification of common mechanisms of TBI sequelae across a wide range of
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laboratory models may represent our best hope of identifying therapeutics for broad 
application in the TBI patient population. Finally, further studies are needed to determine the 
relevance of mTBI to the future development of neurodegenerative disease.
5.5. Conclusions:
The work presented in this thesis has three key components: 1) the development and 
characterization of an animal model of mTBI, 2) the identification of sustained white matter 
inflammation and axonal damage after repeated mTBI, 3) tau hyperphosphorylation appears to 
have a contributory, but not primary role in the acute phase post-injury.
The results described in this thesis characterize both acute and long term (24 month) 
consequences of single and repetitive injury. This work represents a unique and critical 
contribution to the TBI research field, as until now, the majority of the TBI research has focused 
on the acute consequences of TBI, and until very recently neither mild nor repetitive injury was 
a focus. Major research and clinical efforts should emphasize the long term consequences of 
TBI and the development of reliable biomarkers for single and repetitive mTBI. TBI is not 
typically a single event from which we recover, but if untreated, can be the beginning of a series 
of events that we may have to deal with for years. In other words, this suggests that while early 
intervention (e.g. surgery, drug therapy) is the most desirable approach, there is a large 
therapeutic window in which interventions may prove efficacious. However, our data also 
suggest that the time post-injury may dictate the type of therapy that is needed for the greatest 
effect. As pointed out in this thesis, our results provide the first evidence that, whilst an s- 
mTBI produces transient neurobehavioral changes and pathology which remains static in the 
period following injury, r-mTBI produces behavioral and pathological changes which continue to
evolve many months post injury. These findings collectively recapitulate important aspects of 
human long term TBI sequelae, in particular persistent neuroinflammation, white matter injury, 
and axonal pathology in the corpus callosum7,16. The relationships between the history of 
mTBI(s) and the progressive neuroinflammation are likely to be complex and warrant further 
work to elucidate their association with neurodegenerative disease. Although tau is clearly a 
component of CTE, not everyone who has tau pathology has CTE24. Indeed, owing to the lack of 
large-scale controlled studies, there are also no compelling epidemiological data currently 
available to estimate the incidence or prevalence of CTE after r-mTBI. Long-term follow-up of 
multiple cohorts of individuals, such as American football players and soldiers, with 
consideration of the influence of risk factors such as mechanism, frequency and severity of 
injury, gender, life style and potential genetic predisposition is required to clearly define CTE as 
a disease entity both pathologically and clinically. Experimental TBI models like the one 
presented in this thesis should facilitate elucidation of the cellular and molecular changes 
underlying these phenomena. Translation from these preclinical studies to clinical application 
in human TBI populations will result in effective treatment for TBI and its chronic 
neurodegenerative sequelae.
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Appendix 1: Trace of Barnes maze performance in wild type animals.
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Appendix 2: Trace of Barnes maze performance in hTau animals.
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